Structural And Functional Analysis Of Engineered Cardiac Tissues In Response To Hypertrophic Growth Factors by Alvarez Lopez, Rosa Maria
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
2016
Structural And Functional Analysis Of Engineered
Cardiac Tissues In Response To Hypertrophic
Growth Factors
Rosa Maria Alvarez Lopez
University of Pennsylvania, rosaa@seas.upenn.edu
Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biomedical Commons
This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2163
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Alvarez Lopez, Rosa Maria, "Structural And Functional Analysis Of Engineered Cardiac Tissues In Response To Hypertrophic
Growth Factors" (2016). Publicly Accessible Penn Dissertations. 2163.
https://repository.upenn.edu/edissertations/2163
Structural And Functional Analysis Of Engineered Cardiac Tissues In
Response To Hypertrophic Growth Factors
Abstract
The development of myocardial hypertrophy and fibrosis are central pathological processes that are common
features resulting from many types of cardiac diseases. Moreover, a wide variety of inputs and interactions
contribute to pathological hypertrophy and fibrosis. For example, changes in biomechanical stress on the
myocardium, as occur during chronic pressure or volume overload, is a fundamental trigger for hypertrophy
and fibrosis. In addition, crosstalk between myocytes and fibroblasts contributes to the structural, mechanical,
and electrical remodeling in the pathogenesis of various heart conditions that lead to heart failure. During the
development of pathological hypertrophy and fibrosis, many agonists such as endothelin (ET)-1, angiotensin
(Ang) II, and transforming growth factor (TGF)-β are activated in parallel, obscuring attribution of their
individual, synergistic or subordinate effects. Finally, the development of hypertrophy and fibrosis themselves
contribute to load changes in the heart, further complicating mechanistic interpretation. One impediment to
further progress has been the lack of model systems that allow the experimental control required to draw
definitive mechanistic conclusions of each of its components, yet retain the essential features of the in vivo
environment.
Accordingly, a major focus of this thesis is to examine the ability of a myocardial tissue engineering platform
to decouple the effects of biochemical, mechanical and cell-specific inputs on microtissue auxotonic
contractility. The model employed is based on microfabricated polydimethylsiloxane (PDMS) templates that
generate arrays of 3D cardiac microtissues (CMT). Cantilevers within templates provide physiologically
relevant auxotonic loading to the CMTs, promote the appropriate 3D organization of neonatal rat cardiac
myocytes and fibroblasts, and report resting and twitch force generation in real time. Additionally, we
evaluated the correlation between sarcomere length and microtissue length, and developed twitch forces of
these microtissues in an auxotonic preparation.
While the role of known hypertrophic factors has been extensively studied using conventional cell culture and
integrated in vivo models, few studies have used engineered cardiac tissues to examine how key hypertrophic
agonists, alone or in combination, affect contractile parameters, including resting and twitch force as well as
rates of force generation and relaxation. We found that the pathological mediators, endothelin (ET)-1,
angiotensin (Ang) II, and transforming growth factor (TGF)-β, altered contractility with different
magnitudes. Differences in contractile responses led us to further investigate the length-tension relationship in
the microtissues. We further investigated how sarcomere length related to tissue length and contractile
properties. Interestingly, we identified differential sarcomere lengths upon stimulation with different
hypertrophic factors. ET-1 in particular, led to the largest changes in contractile properties. These results are
described in greater detail in Chapter 2.
Recognizing that biomechanical load acts in concert with pathological mediators in the development if
cardiac hypertrophy, we utilized this cardiac microtissue model to generate templates with cantilevers with
increased stiffness (Legant et al. 2009). The cantilever stiffness represent the resistance against which the
engineered CMTs needs to contract, and mimics increased afterload as might occur during hypertension. We
also studied the effect of increased afterload in combination with ET-1, Ang II, TGF-β upon force generation,
and cell and tissue morphology. Interestingly, our data shows that cell area is altered only in the presence of
increased afterload combined with hypertrophic factors, but not with the hypertrophic factors alone. These
results are described in greater detail in Chapter 3.
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/2163
While many studies have focused on the interactions of nonmyocytes and myocytes, few studies have looked
at the role of nonmyocytes in engineered tissue contractile function. Our studies focus on the role of
nonmyocytes in contractile function. Our results suggest that myocyte enrichment (nonmyocyte depletion)
leads to decreased contractile function, suggesting that nonmyocytes are required for proper contractile
function. We also evaluated how nonmyocytes within engineered tissues contribute to the ET-1-induced
changes in contractility. These results are described in greater detail in Chapter 4.
Collectively, these studies have provided insights as to how cardiac microtissues can be employed to both
isolate and integrate the biochemical and mechanical signals that contribute to changes in contractile function
in the context of myocardial hypertrophy and disease. Continued work and future directions is discussed in
Chapter 5.
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ABSTRACT 
 
STRUCTURAL AND FUNCTIONAL ANALYSIS OF ENGINEERED CARDIAC TISSUES 
IN RESPONSE TO HYPERTROPHIC GROWTH FACTORS 
Rosa M. Álvarez 
Kenneth B. Margulies 
 
 
The development of myocardial hypertrophy and fibrosis are central 
pathological processes that are common features resulting from many types of 
cardiac diseases. Moreover, a wide variety of inputs and interactions contribute 
to pathological hypertrophy and fibrosis. For example, changes in biomechanical 
stress on the myocardium, as occur during chronic pressure or volume overload, 
is a fundamental trigger for hypertrophy and fibrosis.  In addition, crosstalk 
between myocytes and fibroblasts contributes to the structural, mechanical, and 
electrical remodeling in the pathogenesis of various heart conditions that lead to 
heart failure. During the development of pathological hypertrophy and fibrosis, 
many agonists such as endothelin (ET)-1, angiotensin (Ang) II, and transforming 
growth factor (TGF)-β are activated in parallel, obscuring attribution of their 
individual, synergistic or subordinate effects. Finally, the development of 
hypertrophy and fibrosis themselves contribute to load changes in the heart, 
further complicating mechanistic interpretation. One impediment to further 
progress has been the lack of model systems that allow the experimental control 
required to draw definitive mechanistic conclusions of each of its components, 
yet retain the essential features of the in vivo environment.  
Accordingly, a major focus of this thesis is to examine the ability of a 
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myocardial tissue engineering platform to decouple the effects of biochemical, 
mechanical and cell-specific inputs on microtissue auxotonic contractility.  The 
model employed is based on microfabricated polydimethylsiloxane (PDMS) 
templates that generate arrays of 3D cardiac microtissues (CMT). Cantilevers 
within templates provide physiologically relevant auxotonic loading to the CMTs, 
promote the appropriate 3D organization of neonatal rat cardiac myocytes and 
fibroblasts, and report resting and twitch force generation in real 
time.  Additionally, we evaluated the correlation between sarcomere length and 
microtissue length, and developed twitch forces of these microtissues in an 
auxotonic preparation.  	
While the role of known hypertrophic factors has been extensively studied 
using conventional cell culture and integrated in vivo models, few studies have 
used engineered cardiac tissues to examine how key hypertrophic agonists, 
alone or in combination, affect contractile parameters, including resting and 
twitch force as well as rates of force generation and relaxation. We found that the 
pathological mediators, endothelin (ET)-1, angiotensin (Ang) II, and transforming 
growth factor (TGF)-β, altered contractility with different magnitudes. Differences 
in contractile responses led us to further investigate the length-tension 
relationship in the microtissues. We further investigated how sarcomere length 
related to tissue length and contractile properties. Interestingly, we identified 
differential sarcomere lengths upon stimulation with different hypertrophic factors. 
ET-1 in particular, led to the largest changes in contractile properties. These 
results are described in greater detail in Chapter 2. 
vi	
	
Recognizing that biomechanical load acts in concert with pathological 
mediators in the development if cardiac hypertrophy, we utilized this cardiac 
microtissue model to generate templates with cantilevers with increased stiffness 
(Legant et al. 2009). The cantilever stiffness represent the resistance against 
which the engineered CMTs needs to contract, and mimics increased afterload 
as might occur during hypertension. We also studied the effect of increased 
afterload in combination with ET-1, Ang II, TGF-β upon force generation, and cell 
and tissue morphology. Interestingly, our data shows that cell area is altered only 
in the presence of increased afterload combined with hypertrophic factors, but 
not with the hypertrophic factors alone. These results are described in greater 
detail in Chapter 3. 
While many studies have focused on the interactions of nonmyocytes and 
myocytes, few studies have looked at the role of nonmyocytes in engineered 
tissue contractile function.  Our studies focus on the role of nonmyocytes in 
contractile function. Our results suggest that myocyte enrichment (nonmyocyte 
depletion) leads to decreased contractile function, suggesting that nonmyocytes 
are required for proper contractile function. We also evaluated how nonmyocytes  
within engineered tissues contribute to the  ET-1-induced changes in contractility. 
These results are described in greater detail in Chapter 4.	
Collectively, these studies have provided insights as to how cardiac 
microtissues can be employed to both isolate and integrate the biochemical and 
mechanical signals that contribute to changes in contractile function in the 
context of myocardial hypertrophy and disease. Continued work and future 
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directions is discussed in Chapter 5. 
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CHAPTER 1: INTRODUCTION AND BACKGROUND 
 
1.1 Background 
1.1.1 Cardiac cycle and loading         
 The primary function of the heart is to pump blood through the circulation. In this 
chapter, cardiac function is discussed in the context of the mechanics of the ventricle, 
which is the most important component for the mechanical function of the heart and 
relevant to cardiac tissue engineering. The contraction cycle of the heart is typically 
presented as a pressure–volume loop with distinct phases of isotonic and isometric 
contraction during systole and relaxation during diastole. Briefly, the ventricles are 
relaxed during diastole, and blood fills them. Ventricular systole occurs in stages. First, 
an isometric contraction occurs, where the ventricle remains the same volume with the 
inflow and outflow valves closed. Once pressure rises sufficiently, the semilunar 
(outflow) valves open and the ventricles begin to eject the blood out and ventricular 
volume decreases. This interval ends when the ventricles begin to relax, and the 
semilunar valves close. It is important to note that while the cardiac cycle is described as 
a sequence of isotonic and isometric states, simultaneous and coupled changes in force 
and length occur. Therefore the contraction and relaxation of the heart is more precisely 
auxotonic.  
The mechanical forces acting on the heart are called preload and afterload. 
Preload is the initial distension of the ventricle by filling of the chamber with blood prior to 
contraction. The degree of filling modulates the force produced during contraction.   At 
the cellular level, increases in the length of rod-shaped cardiac myocytes and their 
sarcomeres are likewise a major factor regulating the force generation (ter keurs HE et 
al. 2008). The Frank-Starling law of the heart states that the larger the volume of blood, 
the further the ventricle is stretched (with larger sarcomere length), leading to stronger 
2	
forces of the contraction, and thus, larger quantity of blood that is pumped into the aorta 
during systole (Konhilas JP et al. 2002). The sarcomere itself is comprised of thick 
myofilaments that contain myosin and thin myofilaments that contain actin. As seen in 
Figure 1, the part of the sarcomere that contains Titin and thin myofilaments is called the 
I band, and the part that contains the overlap of thick and thin myofilaments is called the 
A band. The Z band attaches the thin myofilaments to each end of the sarcomere, while 
the thick filaments reside in the middle of the sarcomere. When a sarcomere 
contracts, myosin heads within the thick filament attach to actin to form cross-bridges. 
This step is called the power-stroke. Then, the thin filaments slide over the thick 
filaments as the heads pull the actin. When a new ATP binds with myosin, actin is 
released. Myosin then reaches forward again to bind actin in a new cycle with the high 
energy ADP + P configuration. This process is known as myosin-actin crossbridge 
cycling. During this cycling, the thick filaments composed of myosin do not change in 
length. It is the I band, which is rich in thin myofilaments and Titin that change length. By 
convention, the sarcomere length or the distance between two adjacent Z bands. The 
resulting sarcomere shortening leads to the generation of tension during the muscle 
contraction. Titin's primary functions are to stabilize the thick filament, center it between 
the thin filaments, prevent overstretching of the sarcomere, and to help the sarcomere 
re-establish baseline length, like a spring, after it is stretched. If a sarcomere is stretched 
too far, there will be insufficient overlap or cross-bridge of the myofilaments and the less 
force will be produced (Figure 1B). In contrast, if the muscle is over-contracted, the 
potential for further contraction is reduced, which in turn reduces the amount of force 
produced  (Figure 1C).  
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Figure 1.  Illustration of a sarcomere structure. An illustration of a sarcomere structure in 
resting state is depicted in A.  Thin filaments attached to Z discs are depicted in red. 
Interdigitating with the actin filaments are the thick filaments depicted in blue. The motor heads in 
the thick filaments can bind to the actin in the thin filament. Together with the titin molecules, 
which are represented as springs that go through the hollow thick filaments and attach to the Z-
discs, providing structural integrity to sarcomeres. When overstretched, the cross bridges 
between thin and thick filaments are reduced (B). Upon activation they move towards the thin 
filaments and contract the structure (C).  
 
Two key aspects of the regulation of myosin-actin cycling are the energy made 
available by the hydrolysis of ATP, and the calcium that makes the myosin-binding site 
available for myosin binding. Calcium is required by two proteins, troponin and 
tropomyosin, that regulate muscle contraction by blocking the binding of myosin to 
filamentous actin. In a resting sarcomere, tropomyosin covers the myosin binding sites 
of the actin molecules. Calcium ions need to bind with troponin-C molecules (within the 
tropomyosin protein) to alter the structure of the tropomyosin, forcing it to reveal the 
myosin-binding sites on the actin. 
A 
B 
C 
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Afterload, on the other hand, describes the end load or “resistance” against 
which the heart contracts to eject blood. Factors that affect afterload include the 
pressure within the vessels into which blood is ejected (e.g. this increases in 
hypertension), the elasticity of the vessels that receive blood ejected by the ventricles 
(e.g. this decreases with aging), and the chamber geometry of the ventricles themselves 
(chamber dilation and/or wall thinning increase wall tension in the ventricular 
myocardium).  
 
1.1.2 Pathological development of the heart 
Abnormal increases in afterload and neurohumoral regulatory systems are 
frequently observed contributors to the progression of ventricular dysfunction to clinical 
heart failure.  Upon initial increase in pressure or load, the heart responds with 
compensatory or adaptive responses by increasing force of contraction and increasing in 
mass (hypertrophy).  These adaptations initially augment the work capacity of the 
myocardium (Xu J et al. 2007, Souders CA et al. 2012, Emdad L et al. 2001, Bujak M 
and Frangogiannis NG 2007). However, over time, sustained activation and interaction 
between mechanical forces and pathology-associated mediators leads to cardiac 
dysfunction. There are numerous circulating factors that have been implicated in the 
development of pathologic hypertrophy of the heart, including endothelin 1 (ET-1), 
angiotensin II (Ang II), and transforming growth factor β (TGF-β), which regulate 
contractility, rates of contraction and relaxation, gene transcription, protein translation, 
and cellular metabolism during hypertrophic remodeling.  Prior studies have shown 
functional crosstalk between these factors (Gray MO et al. 1998, Rosenkranz S et al. 
2002, Iwanaga Y et al. 2001). For example, exogenous administration of Ang II results in 
the development of myocyte hypertrophy, coupled with the release of ET-1 and TGF-β in 
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vitro (Castanares C et al. 2007). However, it has been suggested that ET-1 plays a 
central role in mediating the actions of other hypertrophic factors (Weng X et al. 2015, 
Castanares C et al. 2007). Additionally, Ang II, ET-1, and their receptors (AT1 and ETA) 
compose a mutually reciprocal signal network in the myocardium (Piuhola J et al. 2003, 
Iwanaga Y et al. 2001, Drawnel FM et al. 2013). However, their redundancy is not 
complete, as the dual blockade of Ang II and ET-1 inhibition has resulted in enhanced 
anti-hypertensive benefits (Iwanaga Y et al. 2001). Furthermore, TGF-β has been shown 
to act downstream of Ang II and mediate Ang II-related hypertrophic and fibrotic changes 
(Schultz J et al. 2002). Further complexity arises because these hypertrophic factors are 
locally and systemically regulated, making it difficult to distinguish the effects from local 
activation and effects of mechanical loading. These local feedback loops and signal 
redundancy have made it difficult to isolate their individual and specific roles in 
pathological hypertrophy and the progression of heart failure  
 
1.1.3 Nonmyocytes in the development of cardiac hypertrophy 
Additionally, pathological myocardial hypertrophy involves at least two cell types 
undergoing distinct and interacting processes: cardiac myocyte (CM) enlargement or 
hypertrophy and cardiac fibroblast (CF) activation and proliferation. Approximately 70% 
of the cells in the human heart are nonmyocytes, primarily cardiac endothelial cells and 
cardiac fibroblasts, which is the predominant cell type (Chlopcíková S et al. 2001, Martin 
ML et al. 2012). The crosstalk between the two cell types contributes to the structural, 
mechanical and electrical remodeling involved in the pathogenesis of various conditions 
that lead to heart failure. A large body of research indicates that this crosstalk is 
mediated by paracrine signals and direct cell-cell interactions (Ottaviano FG et al. 2011, 
Ongstad et al. 2016, Zhang P et al. 2012). Studying CF-to-CM crosstalk in vivo and 
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determining how each cell type contributes to myocardial remodeling has proven difficult.  
One impediment to further progress is the lack of model systems that allow the 
experimental control required to draw definitive mechanistic conclusions, yet retain the 
essential features of the in vivo environment. In vivo, CFs are buried within densely 
packed CMs making a direct investigation of the function of each cell type in situ 
extremely difficult. For example, in a study using chimeric mice that had both angiotensin 
type 1a receptor null- and intact cells, infusion of Ang II induced hypertrophy and fibrosis 
(Rivard K et al. 2008). Because the majority of the proliferating fibroblasts were found to 
be surrounding CMs carrying the wild-type AT1aR gene, this report suggests that 
fibroblast activation by Ang II is CM-dependent. However, due to the small size of the 
fibroblasts and their location within densely packed CMs, the genetic background of the 
proliferating fibroblasts was not determined. To address the converse role of CF in 
modulating CM hypertrophy, one would want to selectively manipulate fibroblasts in vivo. 
Unfortunately, CF-specific promoters do not exist, so in vivo studies examining the CF-
dependence of CM hypertrophy are not currently possible. 
 
1.1.4 Gene expression associated with hypertrophy and fibrosis 
On a molecular level, cardiomyocyte hypertrophy is accompanied by re-activation 
of many genes ordinarily prominent during fetal development. The most characterized 
genes are β-myosin heavy chain (β-MHC), α-skeletal actin (α-SKA), α-smooth muscle 
actin (α-SMA), and atrial natriuretic factor (ANF) may be observed concomitant with a 
downregulation of α-myosin heavy chain and the Ca2+ pump of sarcoplasmic reticulum. 
In normal myocardium, α-SKA and α-SMA, are co-expressed and the amount of their 
transcripts has been shown to vary with species, developmental stage, aging, and during 
pathological situations (Suurmeijer AJH et al. 2003, Schwartz K et al. 1986), while 
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skeletal actin mRNA accumulation is observed during hemodynamic overload of rat 
hearts (Souders CA et al. 2012), passive stretch (Sadoshima J et al. 1993), and after 
administration of hypertrophic factors such as TGF-β or fibroblast growth factor 2 (FGF-
2), to cultured neonatal rat cardiomyocytes. Hypertrophic ventricular myocytes are also 
characterized by significant up-regulation of ANF (Izumo et al., 1988), which is scarcely 
expressed in normal adult ventricular myocytes. Myocardial hypertrophy leads to a 
replacement αMHC by the fetal βMHC isoform. It has been previously shown that 
predominance of the βMHC isoform tends to reduce cardiac power output compared to 
hearts in which the αMHC isoform predominates. Changes in gene expression related to 
myocyte hypertrophy occur alongside changes in gene expression related to fibroblast 
activation to the proliferative and secretory state that promotes fibrosis (scar formation). 
Furthermore, Ang II, ET-1 and TGF-β have been implicated in increased gene 
expression of collagen type I and type III, as well as expression of α-SMA  (Sadoshima J 
et al. 1993) by cardiac fibroblasts.  
 
1.1.5 Isolated muscle strip system in vitro model  
A commonly used model system to measure cardiac hypertrophic effects in 
contractility is papillary muscle or isolated muscle strip system. This model system has 
provided a way to study mature tissue contractile properties, however there are some 
limitations.  Only short-term experiments (few hours) can be done due to short-term 
survival of explanted macroscopic tissue. Moreover, cell type distribution in the tissue 
cannot be controlled, and different proportions of myocytes and fibroblasts can lead to 
differences in resting and twitch force.  Additionally, the experimental loading conditions 
of isolated tissue strip systems have mainly been limited to isometric (constant length) or 
isotonic (constant force) controls, whereas in physiological conditions cardiac muscle 
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contracts against auxotonic loads (simultaneous change in load and length). These 
differences in loading conditions can lead to differences in contractile responses.   Force 
generation as well as kinetics of myocardial tissues, are dependent on many factors 
including muscle length and associated sarcomere length, and myofilament calcium 
sensitivity, among others. Model system differences in the loading conditions, and 
associated differences in myofilament properties such as sarcomere length lead to 
varying inotropic (force-altering) responses (Palomeque J et al.  2006, Guccione JM et 
al. 1997, MacGowan GA and Koretsky AP 2000, ter Keurs HE et al. 2008, Li P et al. 
1994). In a pioneering study, Layland et al. demonstrated that cardiac troponin I (cTnI) 
has a pivotal role in the positive inotropic response of the murine heart to beta-
adrenergic stimulation (isoprenaline), however this effect is highly dependent on loading 
conditions, as dependence of cTnI in inotropic responses was most evident in the 
auxotonic, not the isotonic hearts nor in externally unloaded isolated cardiomyocytes. In 
another study, Li et al determined that the inotropic effects of Ang II are dependent on 
resting sarcomere length of the muscle tissue in an isometric preparation. While the 
untreated tissues exerted the maximal twitch force at the sarcomere length at the peak 
of the Frank Starling curve (~2.2um), the tissues treated with Ang II exhibited a different 
response. At the same maximal sarcomere length, Ang II exerted a negative inotropic 
response; while at shorter lengths, Ang II exhibited a positive inotropic response. 
Therefore, the inotropic actions of hypertrophic agonists such as ET-1, Ang II and TGF-β 
are dependent on the resting sarcomere length. While sarcomere length is usually set in 
isometric preparations, in auxotonic preparations tissues are allowed simultaneously 
change load and length, and thus, sarcomere length is not typically measured. 
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1.2.6  In vitro 2D models of cardiac hypertrophy  
In vitro 2D models of cardiac hypertrophy have allowed rigorous mechanistic 
studies of cardiac cell-specific responses (avoiding systemic effects) to hypertrophy, 
however, there are still some limitations.  Cardiac cells adapted to typical flat cell culture 
models lack 3-dimensional (3D) architecture and differ substantially from those of the 
intact heart. For example, in a rigid 2D culture substrate, cardiac myocyte hypertrophy is 
amplified due to the stiffness of the culture substrates, while fibroblasts expand and 
differentiate to myofibroblasts, the activated hypersecretory phenotype seen in 
pathological fibrosis (Rohr S. 2011, Wang J et al. 2003). In flat CF monocultures, it has 
been shown that Ang II directly stimulates CF proliferation, expression of collagens and 
other extracellular matrix proteins via AT1a receptors (Sadoshima J et al. 1993). Also, in 
vitro studies have shown that stimulation of CFs by Ang II induces the secretion of 
prohypertrophic and profibrotic factors such as TGF-β, ET-1, FGF-2, IL-6 and others, all 
of which function in an autocrine and paracrine manner (Fredj S et al. 2005, Fredj SP et 
al. 2005, Pedrotty DM et al. 2009). Thus, discerning between the effects of substrate 
stiffness and soluble factor-mediated responses is difficult to achieve. Culturing cells in 
silicon membranes that can be exposed to static stretch has overcome some of these 
limitations, however static stretch more closely mimics increase in preload rather than 
afterload, which is more relevant to the development of cardiac hypertrophy that occurs 
in many clinical conditions, such as hypertension and aortic stenosis.  
Therefore developing an in vitro culture method that recapitulates the 3D in vivo 
organization of the CMs, CFs, and extracellular matrix (ECM) is needed in order to 
identify mechanisms by which cell-cell interactions influence myocardial structure and 
function in vivo. 
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1.2.7 Engineered cardiac tissues as model systems to answer mechanistic questions in 
myocardial biology 
Engineered 3D tissues offer unique opportunities to study mechanistic questions 
in myocardial biology. A particularly desirable feature of an engineered tissue is the 
ability to control cell population and hence, cell-type specific gene expression while 
maintaining physiologically relevant tissue architecture. Despite recent progress, 
relatively few studies have used engineered cardiac tissue for mechanistic studies 
(Hinson JT et al. 2015).  A key feature of the 3D engineered tissues is that they are able 
to display more physiological characteristics of intact heart tissue than monolayer 
cultures. Cells in 3D tissues can make contact with surrounding cells in all directions in 
contrast to cells in a standard monolayer that sit on a rigid plastic surface and only make 
side-to-side contacts with other cells. These variations in the spatial distribution of 
adhesions has been shown to influence cell morphology, responses to soluble factors 
and forces generated (Baker BM and Chen CS 2012). The 3D microenvironment 
provides necessary cues to reconstitute the physiological phenotype of the isolated cells. 
Multiple studies have shown that the inclusion of nonmyocytes in engineered 
tissue constructs enhances neonatal rat cardiomyocyte survival and spreading (Naito H 
et al. 2006, Radisic M et al. 2008, Asnes et al. 2010). Narmoneva et al. showed that co-
culture of neonatal rat cardiomyocytes with nonmyocytes from the heart within a 
hydrogel promoted spreading and reorganization of neonatal cardiomyocytes 
contractions and enhanced expression of gap junction protein connexin-43. In contrast, 
cardiomyocytes cultured alone aggregated into sparse clusters and underwent 
significant apoptosis and necrosis. Naito et al. showed that collagen gels containing 
cardiomyocyte-enriched heart cell populations developed inferior contractile 
performance compared to Native heart cell population. Another group showed that 
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neonatal rat fibroblast and CMs co-cultured in agarose hydrogels resulted in prolonged 
action potential duration compared to cardiomyocyte cultures alone (Desroches et al., 
2012). Additionally, another group showed that spheroid microtissues derived from 
nonmyocytes showed remarkably enhanced contractile function, as well as enhanced 
response to inotropic drugs, which the authors suggest it is due a greater degree of 
cardiomyocyte maturity using a scaffold-free co-culture of myocytes and nonmyocytes 
express ECM and Ca2+-handling proteins, form functional cell-cell connections (as 
evidenced by spontaneous action potentials (APs), contractions, and connexin-43 
expression), and are amenable to cell type-selective gene transfer (Figure 2A). While the 
authors observed greater elongation of cells, sarcomere length was not measured, and 
could have impacted the force generation of these preparations.  
 
Figure 2: Cardiac tissue engineering methods to study physiological and pathological 
functionality of the heart. Scaffold-free engineered tissues composed of fibroblasts and 
myocytes is useful to study cell-cell interaction without cell-ECM interaction (Desroches BR et al. 
2012) (A). Muscular thin film 2D engineered tissue model allows cyclic stretch that leads to 
hypertrophic phenotype (McCain ML et al. 2013) (B) Increased afterload model achieved by 
changing the spring constant of the resisting material after tissues have been formed, resulting in 
cardiac dysfunction (Hirt MN et al. 2012) (C). 
 
 
 
1.2.8 Cardiac tissue engineering to study pathological remodeling 
A                  C B
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In one early application, engineered heart tissues derived from chicken 
embryonic cardiac cells were infected with adenovirus expressing β-adrenergic 
receptors to evaluate the effect on isometric force generation (Eschenhagen T et al. 
1997). Recently, de Lange WJ et al. developed engineered cardiac tissue fusing isolated 
neonatal mouse cardiac cells derived from both wild-type and myosin-binding protein C 
(cMyBP-C)-null mouse hearts. They were able to detect contractile abnormalities similar 
to those seen in intact hearts from cMyBP-C-/- mice. While these studies demonstrate 
the use of engineered cardiac tissue to model myocardial tissue function, the primary 
output was isometric force generation as opposed to a more relevant auxotonic 
contraction. Additionally, the relatively small numbers of cells that can be extracted from 
mouse hearts and concerns about species differences between mouse cells/hearts 
beating at 8-12 Hz vs. human cells/hearts beating at 1-3 Hz, represent additional 
shortcomings of this approach (de Lange et al. 2011). Moreover, the tissues had to be 
transferred from a culture dish to an intact fiber apparatus to perform mechanical and 
electrical measurements. Another group developed a 2D muscular thin film (MTF) model 
(Figure 2B) to recapitulate expression of genes associated with pathological cardiac 
hypertrophy as well as contractile impairment upon stimulation with cyclic stretch 
(McCain ML et al. 2013) and AngII (Horton et al. 2016). However, a key limitation to this 
study is the relative absence of biomechanical loading that is a critical factor regulating 
myocardial structure and function. Additionally, the sarcomere length of cell sheet has 
not been described, and this is an important shortcoming in the context of a negative 
inotropic response to Ang II.  A recent study modeled the increased afterload by creating 
3D millimeter-scale tissues tethered around silicone tubes with a low spring constant 
(Hirt MN et al. 2012). The addition of metal rods into the silicon tubes generated a 12x 
increase in afterload.  Interestingly, adding ET-1 and afterload increase resulted in 
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similar hypertrophic responses, including alterations in gene expression, and increased 
fibrosis and decreased contractile forces and relaxation velocities (Hirt MN et al. 2012). 
One of the limitations of this study was that the increase in afterload is not 
physiologically relevant. Also, the tissues engineered in these studies were large, which 
can lead to inadequate oxygen and nutrient diffusion, that is particular limiting under 
conditions associated with increased contractile demands. Interestingly, this group also 
published studies where addition of ET-1 resulted in a positive inotropic response in 
engineered tissues in an isometric preparation. Furthermore, the myocyte sarcomere 
length was not measured in these studies, so it is possible that differences in sarcomere 
length contributed to the differences in force generation observed in the two studies.  
 Developing engineered tissues to answer mechanistic questions requires the use 
of a smaller, more reproducible platform, organized and evenly distributed cells 
throughout the construct with the ability to directly measure functional outputs without 
having to transfer them to a different apparatus. 
 
1.2.9 Cardiac microtissue model utilized in the present studies 
In this work, we utilized an approach to generate cardiac microtissues (CMTs) 
that contract against flexible cantilevers and allow measurements of contractility in real 
time. Using photolithography, pairs of flexible cantilevers are molded into microwells 
(Figure 2A) where a cell-collagen mix is added. 
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Figure 3. Fabrication of microtissues. Process flow diagram for creating tissue arrays and 
tissue formation(A) Large arrays of microtissues are simultaneously generated on a substrate. (B) 
Cross section view of a single well (C). (adapted from (Legant WR et al. 2009)) 
 
This system also generates over 100 tissues in a micro scale (Figure 3B), 
allowing concentration gradients in microtissues (thickness ≈100 µm) to equilibrate 100 
times faster than those in bulk gels (thickness ≈1 mm), improving the ability of gradients 
to take full effect (Legant WR et al. 2009).  The cantilevers guide the contraction of the 
cell-matrix mix allowing the formation of CMTs (Figure 3B). After 3 days, the band of 
tissue draws the cantilevers closer together, and the syncytium of cardiac cells produces 
synchronized contractions (Figure 3C). Fluorescent beads embedded in the flexible 
cantilevers allow tracking of their deflection. Because the stiffness of cantilevers is 
calibrated, their deflection allows real-time measurement of force by taking advantage of 
the Euler-Bernoulli beam theory (Legant WR et al. 2009) to measure resting and twitch 
forces of tissues attached to the cantilevers. Generating tissues that are tethered to 
cantilevers allows for direct auxotonic (shortening) contractile measurements, as 
opposed to isometric contractions or cyclic stretch that are not reflective of in vivo 
myocardial biology. These cantilevers have measurable and customizable stiffness that 
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mimics the in vivo biomechanical load experienced by myocardium. Because the 
cantilevers represent the force or resistance that the cardiac tissue needs to surpass, 
the stiffness of the cantilever mimics afterload. Another advantage is the ability to 
change the stiffness of the cantilevers by a factor of (2.25x) by varying their geometry 
and material properties. The ability of changing the stiffness of the cantilevers allows us 
to decouple and combine the effect of load with other parameters. The CMTs provide a 
homogeneous, reproducible test bed for studies of myocardial biology. 
 
1.2.10 Cardiac microtissue function vs. other physiological models of cardiac contraction 
While great strides have been made in advancing cardiac engineered tissue 
models, there are differences between engineered and native cardiac tissues that must 
be kept in mind when extrapolating results from in vitro models to the clinical setting. A 
key design element of the µTUG engineered tissue system is the use of elastic 
cantilevers, which enhance the force development of cardiomyocytes within the tissue, 
resulting in higher tissue/cell tension, compacted extracellular matrix, increased 
alignment of the cells, and a better development of the sarcomeric structure. However, 
cardiac microtissues engineered with neonatal rat ventricular myocytes in this system 
generate twitch forces that range between 3µN and 5µN, if tethered to soft pillars or stiff 
pillars, respectively. Resting forces range between 10µN and 18µN depending on 
whether the tissues are tethered to soft or stiff pillars, respectively. These engineered 
tissues are on average between 0.2mm2 and 0.08 mm2 in cross sectional area, yielding 
stresses of 0.2 mN/mm2 to 0.3mN/mm2 for twitch cross-sectional stresses, and 
0.6mN/mm2 to 1.1mN/mm2 for resting cross-sectional stresses (depending if tethered to 
soft or stiff pillars).  Previous work using mouse trabeculae demonstrated force 
generation between 18mN/mm2 – 70mN/mm2 (under preload resulting in a sarcomere 
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length of 2.2um) depending on the cross sectional areas of the trabeculae, which ranged 
between 0.05mm and 0.3mm (Raman S et al. 2005). An even greater difference is 
observed when engineered cardiac tissues are compared to adult human cardiac cells. 
Intact human trabeculae in an organ bath usually develop between 16.7mN/mm2 (Freq = 
.5hz) - 30.3mN/mm2 (Freq = 2.5hz) (Rossman EI et al. 2003). 
Many things should be taken into consideration when studying functional 
differences between these muscle preparations. The loading system used to measure 
the force generated by the tissues can affect the force generated by the isolated tissues, 
as mentioned in section 1.2.4. While auxotonic preparations resemble more closely 
native cardiac loading, they do not allow preload adjustments to achieve maximal force 
generation. For example, increases in resting tissue tension, would tend to produce 
decreased in resting tissue length. These changes in resting tissue length can lead to 
potential differences in active force generation within the engineered tissues (as 
described in section 1.1.1). The use of more immature neonatal myocytes in engineered 
tissues likely also contributes to lower force development.  Another factor to consider is 
that the fraction of the engineered cardiac construct populated by cells and compact 
muscle strands is generally much smaller than in normal hearts. The rest of the 
engineered tissue is cell-free extracellular matrix, which can lead to inhomogeneous cell 
distribution decreases in force generation (Wang H et al. 20. Therefore, all these factors 
should be taken into consideration when interpreting results from engineered cardiac 
tissues.  
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CHAPTER 2: MEASUREMENT AND ANALYSIS OF FORCES IN RESPONSE 
TO HYPERTROPHIC AGONISTS 
2.1 Rationale 
Hypertrophic remodeling occurs in response to hemodynamic load and 
neurohormonal activation, leading to contractile dysfunction that progresses to heart 
failure, a common endpoint that carries a high mortality risk. Despite great progress in 
understanding key pathological processes, many fundamental questions remain 
unanswered. Numerous soluble substances are involved in cardiac function through 
their effects on cytoskeletal organization and contractility. There are numerous 
neurohormonal hypertrophic factors involved in the pathological development of the 
heart, such as endothelin (ET)-1, angiotensin (Ang) II, and transforming growth factor 
(TGF)-β, which regulate contractility, kinetics, gene transcription, protein translation, and 
cellular metabolism during hypertrophic remodeling.  Prior studies have shown functional 
crosstalk between these factors (Schultz et al. 2002, Rosenkranz S et al. 2002). For 
example, exogenous administration of Ang II results in the development of myocyte 
hypertrophy, coupled with the release of ET-1 and TGF-β in vitro (Sadoshima J et al. 
1993). However, it has been suggested that ET-1 plays a central role in mediating the 
actions of other hypertrophic factors (Wang X et al. 2015, Castanares C et al. 2007). 
Additionally, Ang II, ET-1, and their receptors (AT1 and ETA) compose a mutual 
reciprocal signal network in the myocardium (Piuhola J et al. 2003). However, their 
redundancy is not complete, as the dual blockade of Ang II and ET-1 inhibition has 
resulted in enhanced anti-hypertensive benefits (Iwanaga Y et al. 2001). These local 
feedback loops and signal redundancy have made their individual and specific roles in 
hypertrophy and the progression of heart failure difficult to isolate. 
A limitation of these studies has been the model systems utilized to parse 
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out the roles of different hypertrophic agonists. For example, in a rigid 2D culture 
substrate, cardiac myocyte hypertrophy is amplified due to the stiffness of the culture 
substrates, while fibroblasts expand, differentiate to myofibroblasts and release TGF-β, 
ET-1, and Ang II, all of which function in an autocrine and paracrine manner (8). Thus, 
discerning between the effects of substrate stiffness and soluble factor-mediated 
responses is difficult to achieve. Additionally, while 2D substrates allow for rigorous 
mechanistic studies, contractility measurements are hard to achieve. Another model 
system used to measure cardiac hypertrophic effects in contractility is papillary muscle 
or isolated muscle strip systems. This model system has provided a way to study mature 
tissue contractile properties, however there are some limitations.  Only short-term 
experiments (few hours) can be done due to short-term survival of explanted 
macroscopic tissue. Moreover, cell type distribution in the tissue cannot be controlled, 
and different proportions of myocytes and fibroblasts can lead to differences in resting 
and twitch force.  Additionally, the experimental loading conditions of isolated tissue strip 
systems have mainly been limited to isometric (constant length) or isotonic (constant 
force) controls, whereas in physiological conditions cardiac muscle contracts against 
auxotonic loads (simultaneous change in load and length). These differences in loading 
conditions can lead to differences in contractile responses.   A model system is needed 
that allows the experimental control necessary to draw definitive mechanistic 
conclusions and retains the essential in vivo features with the ability to measure 
contractile function. We describe the implementation of a microfluidic device that allows 
us measure auxotonic contractility in real-time after generating cardiac microtissues 
(CMTs) that contract against flexible cantilevers. We used the CMT model to measure 
the contractile effects hypertrophic factors and determine whether their co-application 
had a synergistic effect on contractility. Additionally, due to the evidence of ET-1 
19	
mediating the actions of other hypertrophic factors we hypothesized that ET-1 would 
result in an enhanced hypertrophic response, leading to greater changes in contractility. 
Force generation as well as kinetics of myocardial tissues, are dependent on 
many factors including muscle length and associated sarcomere length, myofilament 
calcium sensitivity, among others. Model system differences in the loading conditions, 
and associated differences in myofilament properties such as sarcomere length lead to 
varying inotropic (force-altering) responses (Palomenque J et al. 2006, Guccione JM et 
al. 1997, MacGowan JM et al. 1997, ter Keurs HE et al. 2008, Li P et al. 1994). In a 
pioneering study, Layland J et al. demonstrated that cardiac troponin I (cTnI) has a 
pivotal role in the positive inotropic response of the murine heart to beta-adrenergic 
stimulation (isoprenaline), however this effect is highly dependent on loading conditions, 
as dependence of cTnI in inotropic responses was most evident in the auxotonic, not the 
isovolumic hearts nor in externally unloaded isolated cardiomyocytes. In another study, 
Li et al determined that the inotropic effects of Ang II are dependent on resting 
sarcomere length of the muscle tissue in an isometric preparation. While the untreated 
tissues exerted the maximal twitch force at the sarcomere length at the peak of the 
Frank Starling curve (~2.2um), the tissues treated with Ang II exhibited a different 
response. At the same maximal sarcomere length, Ang II exerted a negative inotropic 
response; while at shorter lengths, Ang II exhibited a positive inotropic response. 
Therefore, the inotropic actions of hypertrophic agonists such as ET-1, Ang II and TGF-β 
are dependent on the resting sarcomere length. While sarcomere length is usually set in 
isometric preparations, in auxotonic preparations tissues are allowed simultaneously 
change load and length, and thus, sarcomere length is not typically measured. We 
aimed to determine the inotropic and kinetic effects of these hypertrophic agonists in 
auxotonic loading conditions and subsequently determine how the sarcomere length is 
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associated with these responses. 
2.2 Materials and Methods 
2.2.1 Neonatal Rat Ventricular Myocyte (NRVM) isolation 
Cardiomyocytes were isolated from 1 to 2-day old neonatal Sprague-Dawley rats 
using a trypsin-based dissociation method as previously described (Radisic M et al. 
2003).  The cells were pre-plated onto multiple T-75 flasks for 1 hour to allow fibroblasts 
to attach to the dishes. Cardiomyocytes still suspended in the media were retained and 
seeded onto a T-75 flask coated with fibronectin. Growth media was changed the next 
day. Three hours after media change, cells were dissociated with a 0.05% trypsin 
digestion for 3 minutes. The resulting cell population was subjected CMT generation. 
CMTs were cultured in high-glucose DMEM (Mediatech, Inc.) containing 10% horse 
serum (Invitrogen), 2% chick embryo extract (Charles River Laboratories International, 
Inc.), and Antibiotic-Antimycotic (Invitrogen). Cell culture medium was changed daily.  
 
2.2.2 Device fabrication and microtissue seeding 
Polydimethylsiloxane (PDMS) micro-fabricated tissue gauges (µTUG) were 
molded from the SU-8 masters as described previously (Legant et al. 2009). Fluorescent 
microbeads were embedded (Fluoresbrite 17147; Polysciences, Inc.) into the cantilevers 
to permit cantilever deflection tracking as previously described (Boudou T et al. 2012) 
PDMS molds were then cast onto the stamps to produce the final µTUG substrates. A 
PDMS to  cross-linker ratio of 1:20 was used, to yield nominal spring constants of 
0.20µN/µm. Cantilever spring constants were computed utilizing a capacitive MEMS 
force sensor mounted on a micromanipulator as described previously (Legant et al. 
2009). CMT substrates were treated with 0.02% Pluronic F127 for 30 minutes to 
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prevent cell-extracellular matrix interactions. 
A suspension of ~1.1x106 NRVMs within a reconstitution mixture, consisting of 
1mg/mL liquid neutralized collagen I (BD Biosciences) and 0.5mg/mL human fibrinogen 
(Sigma-Aldrich), was added to the substrate. The device was centrifuged to drive the 
cells into the micro-patterned wells. Cells contract around the cantilevers forming a 
synchronous tissue 2 days after seeding.  
 
2.2.3 Mechanical and kinetic measurements 
  Once the tissue is fully formed and synchronously beating, contractility 
measurements are taken. To quantify microtissue forces, brightfield and fluorescence 
images (Figure 2A) were taken at 30Hz using the EXi Blue Fluorescence Microscopy 
Camera (Q Imaging), and an Fl-Plan 10X objective on a Nikon Eclipse TE200-U (Nikon 
Instruments, Inc.) microscope, which was equipped with a live cell incubator. Only 
tissues that were uniformly anchored to the tips of the cantilevers were included in the 
analysis. Electrical field stimulation of biphasic square pulses of 1 ms was given by 
placing two carbon electrodes (1/4 in diameter; Ladd Research laboratories) separated 
by 2 cm on the sides of the samples connected through platinum wires to a stimulator 
(Radisic et al. 2008). 
To calculate resting force, brightfield images were used to calculated the 
difference in the position of the base of the cantilever and the deflected cantilever cap 
(Figure 4B) at that particular instance in time and force is calculated using F= kδ, Where 
F is the force generated by the microtissue, k is the bending stiffness of the post (0.20 
µN/µm), and δ is its deflection.  To measure twitch force, the displacement of fluorescent 
microbeads at the top of the cantilevers was then tracked using the SpotTracker plug-in 
in ImageJ (NIH) and the average peak force measured during each twitch event (Figure 
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4A) was recorded. The velocity of a cantilever at a given time point is calculated from 
Vi=δi+1−δi−1/ti+1−ti−1 where t represents the time elapsed from the start of the video. 
Values of maximum twitch velocity reported in this work were determined by comparing 
the maximum contraction and relaxation velocities measured at each post, and then 
averaging these values across multiple beats (Figure 4D). In turn, twitch force and twitch 
velocity at a given time point can be multiplied together to obtain the twitch power, 
Pi=FiVi (Figure 4E). 
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Figure 4. Measurement CMT twitch force, velocity, and power. Twitch force is calculated by 
measuring the displacement of fluorescent microbeads at the top of the cantilevers, which are 
tracked using a high-speed camera (Figure by Thomas Boudou) (A). To calculate resting force, 
brightfield images were used to calculate the difference in the position of the base of the 
cantilever and the deflected cantilever cap at that particular instance in time (B). The videos 
allows us to track the fluorescent beads over multiple twitch events at 1hz, which can be 
multiplied by the post stiffness to yield the twitch force (C). From this trace, the displacement data 
from the fluorescent beads can then be used to determine the twitch velocity (D) and power (E).  
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2.2.4 Hypertrophic agonist stimulation 
Hypertrophic factor treatment was started once the tissues formed a syncytium, 
generated synchronous twitches, which occurred 2 days after seeding the cells on the 
uTUG (3 days after cell isolation). Data were collected before hypertrophic factor 
addition and after 24 hours and 48 hours of growth factor stimulation (see Figure2 
below). To determine the optimal concentration for the hypertrophic factors, we treated 
tissues with increasing concentrations of factors until there was no further increase in 
resting or twitch force amplitude. The range of concentrations were chosen based on 
the previously reported concentration ranges that induced inotropic and other 
hypertrophy-related responses in NRVMs.  For each hypertrophic factor we tested the 
following concentrations (in 1ml of media): TGF-β (5 ng, 10 ng, 20 ng), Ang II (500 ng, 
750 ng, 1 µg, 2 µg), and ET-1 (250 ng, 375 ng, 500 ng, 1 µg) (Olson ER et al. 2008, 
Malhotra R et al. 1999, Schaub MC et al. 1997, Castanares C et al. 2007). 10 ng of 
TGF-β, 1 ug of AngII, and 500ng of ET-1 were chosen based on maximum resting and 
twitch force generation. To evaluate additive contractile responses to these growth 
factors, a cocktail using the final concentration of each factor was utilized.  
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Figure 5. Experimental Timeline. After the neonatal cardiac cell isolation, cells were pre-plated 
onto multiple T-75 flasks for 1 hour to allow fibroblasts to attach to the dishes. Cardiomyocytes 
still suspended in the media were retained and seeded onto a T-75 flask coated with fibronectin. 
Growth media was changed the next day to eliminate dead cells. Three hours after media 
changes cells are seeded into the microtissue array. After 2 days in culture (with media changes 
every day), tissues form and generate synchronous contractions, and videos and brighfield 
images are acquired for baseline measurements before beginning the hypertrophic agonist 
treatment. Measurements are acquired again after 24 and 48 hours of treatment.  
 
 
2.2.5 Sarcomere length measurements  
Microtissues were fixed with 4% paraformaldehyde in PBS for 15 minutes and 
permeabilized with 0.1% Triton X-100 in in 1xPBS+1%BSA+5% Goat serum. The 
tissues were incubated with antibodies against α-actinin (Abcam) in 
1xPBS+2%GS+1%BSA for 48 hours, and thereafter incubated with the secondary 
antibody in 1xPBS+2%GS+1%BSA overnight. Counterstaining was done with DAPI 
(Invitrogen). Images were processed by a custom routine in ImageJ (NIH) and MATLAB 
(Mathworks). The 2D Fourier transforms of images were determined as described 
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previously (AG Rodriguez et al. 2011) Only sarcomere length measurements with 
variance less 0.2 were included in the study, which excluded ~5-10% of the 
measurements per sample 
2.2.6 Statistics 
Results are expressed as mean ± standard error of the mean (SEM). Statistical 
significance was defined as a *p-value < 0.05 or **p-value < 0.005 for at least three 
independent experiments. Student’s t-test was performed with Microsoft Excel® for 
sarcomere length measurements.  A two-way ANOVA analysis with post hoc Tukey tests 
was performed with Stata (to determine statistical significance relative to control tissues 
for hypertrophic factor treatments).  
2.3 Results 
2.3.1 Effect of hypertrophic factors on auxotonic contractility of microtissues exposed to 
hypertrophic factors for 24 hours and 48 hours 
To determine early contractile responses of different hypertrophic agonists on 
engineered tissues, we treated tissues for 24 hours and 48 hours with 10ng TGF-β, 1µg 
AngII, and 500ng ET-1 in arrays of cantilevers with a nominal spring constant of k=0.20 
µN/µm. Additionally, we tested whether co-application of hypertrophic factors resulted in 
a synergistic effect on mechanical response.  Single hypertrophic factor treatment as 
well as the cocktail of hypertrophic factors induced increases in resting force (Figure 6A).  
We measured the change in force produced by each tissue, to correct for differences in 
baseline measurements. After 24 hours of treatment, change in resting force (Δ FR = FR 
d1- FR d0) for the ET-1 treatment resulted in 13-fold higher change in resting force than 
the Untreated (Untreated: Δ FR = 0.32±0.15 µN vs. ET-1 Δ FR = 4.26±0.36 µN), while 
Ang II and TGF-β resulted lower changes in resting force (Ang II: Δ FR= 
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2.48±0.47 µN, TGF-β: Δ FR= 0.76±0.08 µN) (Fig. 2B). Interestingly, the cocktail of the 3 
hypertrophic factors generated a change in resting force similar to ET-1 sample 
(Cocktail: Δ FR 4.71±0.28 µN). We also measured the change exerted by the tissues 
after the first day and the change from the day 1 to day 2, However, no statistically 
significant differences were observed for the changes from day 1 to day 2 of treatment. 
A one-way between subjects ANOVA was conducted to compare the effect of 
hypertrophic factor treatment on the contractility of CMTs in TGF-β, AngII, ET-1 and 
cocktail treatments. There were significant effects of hypertrophic factor treatment on 
CMT contractility at the p < 0.05 level for the 4 treatments [F(4,4) = 43.33, p <0.00005]. 
Post hoc comparisons using the Tukey HSD test indicated that the resting force mean 
for the ET-1 (FR day1 4.26±1.36 µN) was significantly different than the Untreated (FR day1 
0.32±0.15 µN). Ang II (FR day1 2.48±0.47 µN) demonstrated significant, but more 
moderate difference to the Untreated sample. Additionally AngII was statistically 
significantly different to each of the other groups, and the Untreated (FR day1 0.32±0.15 
µN) did not significantly differ from TGF-β (FR day1 0.76±0.08 µN), likewise ET-1 did not 
significantly differ from Cocktail treatment (FR day1 4.71±0.28 µN).  
Additionally we measured twitch force generated after 24 hours and 48 hours of 
hypertrophic factor treatment (Figure 6C).  Twitch force was recorded while microtissues 
were being electrically paced at 1hz using field electrodes. As was done for resting force 
measurements, we measured the change in force produced by each tissue, to correct for 
differences in baseline measurements. The cocktail of hypertrophic factors resulted in a 
23-fold increase in twitch force while ET-1 resulted in an 18-fold fold increase in twitch 
force compared to the Untreated sample. (Cocktail ΔFT=1.17±0.01 µN vs. ET-1: 
ΔFT=0.89±0.04 µN vs. Untreated: Δ FT =0.05±0.03 µN, p<0.001) (Figure 6D). TGF-β was 
the only hypertrophic factor that resulted in a decrease in twitch force (Δ FT =-0.21±0.06 
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µN, p<0.0001) (Figure 6D). AngII had a more moderate increase in twitch force (Δ FT 
=0.30±0.16 µN). While the co-application of hypertrophic factors resulted in higher 
resting and twitch force, it did not result in a synergistic effect in the contractility. Based 
on these results, we showed that ET-1 has a larger increase in both resting force and 
twitch force generation in microtissues A one-way between subjects ANOVA was 
conducted to compare the effect of hypertrophic factor treatment on contractility of CMTs 
in TGF-β, AngII, ET-1 and cocktail conditions. There was a significant effect of 
hypertrophic factor treatment on CMT contractility at the p<. 05 level for the 4 conditions 
[F(4, 4) = 41.53, p <0.00005]. Post hoc comparisons using the Tukey HSD test indicated 
that the mean twitch force for the ET-1 (FR day1 4.26±1.36 µN) was significantly different 
than the Untreated sample (FR day1 0.32±0.15 µN, p<0.001) and Ang II  (FR day1 0.30±0.16 
µN, p<0.001). However, the Untreated did not significantly differ from TGF-β (FR day1 
0.76±0.08 µN). Likewise, the Cocktail (FR day1 4.71±1.22 µN) did not significantly differ 
from ET-1. 
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Figure 6. Resting and Twitch force generation in CMTs after 24 and 48 hours of 
hypertrophic agonist treatment.  After CMTs were formed and synchronously beating, baseline 
force measurements at day 0 were acquired. Brightfield images were used to calculate the resting 
force (A). To account for baseline force differences, we computed the change in resting force per 
tissue after 24 and 48 hours of treatment, and the average across multiple tissues (N=25) is 
represented by the bar graph above (B). Using a high-speed camera, we collected data of the 
displacement of the cantilevers over multiple contractions. The bar graph above represents the 
average peak force for 3-5 contractions across multiple tissues (N=25) (C). Similarly to resting 
force, we computed the change in twitch force after 24 and 48 hours (D). 
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2.3.2 Correlation between microtissue length and twitch force generation after 24 hours 
of hypertrophic factor exposure 
The mechanical properties of isolated cardiac muscle in isometric preparations 
(constant length) have been widely studied.  Under isometric conditions, if the muscle is 
set at a short resting length, the resulting twitch force is relatively small, while if it is set 
at a longer resting length, the resulting twitch force is higher. However, the effect of 
resting length in an auxotonic preparation of engineered cardiac muscle is poorly 
understood. Because we observed the greatest magnitude of change in force in the first 
24 hours, we sought out to evaluate how the change in resting force affected the change 
in twitch force for individual tissues after 24 hours of treatment. Based on the previous 
work on isometric tissue experiments, we predicted that the larger the increase in resting 
force per tissue, the shorter the resting length, and consequently the lower the twitch 
force generated.  
However, our data showed that Ang II, ET-1 and the Cocktail treatment resulted 
in significant increases in resting force as well as twitch force as compared to the 
untreated sample, with ET-1 and the Cocktail exerting a larger increase than Ang II. 
Based on this data, we asked whether there was any relationship between the change in 
length from day 0 to day 1 to the change in twitch force on the same time span. 
Interestingly the change in resting force, which is directly related to, the decrease in 
microtissue length, did not correlate with the change in twitch force generated in 
untreated (Figure 7A) and treated samples (7B-E).  Consequently, we assessed how the 
length of the tissue at day 1, after 1 day of hypertrophic agonist treatment correlated with 
the twitch force on that same day. For individual growth factors, Ang II (Figure 8C), TGF-
β (Figure 8D), and ET-1 (Figure 8E), there was a statistically significant moderate 
negative correlation between resting length and generated twitch force (Ang II: R2=0.31 
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p=0.001, TGF-β R2=0.25 p=0.002, ET-1 R2=0.47 p=0.00001), however there was no 
significant correlation for the Untreated (Figure 8A) and Cocktail groups (Figure 8B).  
These data tells us that while the change in resting force does not affect the change in 
twitch force, the final resting length does moderately affects the final twitch force 
generated.  
 
 
Figure 7. Correlation of the change in tissue length and the change in twitch force 
after 24 hours of hypertrophic factor treatment. Change in twitch force was plotted 
against change in tissue length. A linear regression analysis and a correlation coefficient 
R2 were determined. All samples, Untreated (A), Cocktail (B), Ang II (C), TGF-β (D) and 
ET-1 (E), showed no correlation between the change in tissue length and the twitch 
force generated.  
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Figure 8. Correlation of the tissue length and twitch force at 1 day after hypertrophic 
agonist treatment. The twitch force and tissue length after 24 hours of hypertrophic agonist 
treatment were plotted against Each other. A linear regression analysis and a correlation 
coefficient R2 were determined. No correlation was identified in Untreated (A) and Cocktail (B). 
For AngII (C), TGF-β (D) and ET-1 (E), showed that 31%, 25% and 47% respectively of the 
variance in Twitch Force was related to the tissue length at day 1. 
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2.3.3 Tissue length and tissue breakage upon hypertrophic agonist treatment  
In addition to increases in resting force that paralleled increases in twitch force 
for ET-1 and the Cocktail, we observed that  those treatments also led to higher rate of 
tissue rupture occurred after hypertrophic factor stimulation. We observed the highest 
failure rate for the Cocktail group (61%), and ET-1 (54%), while  Ang II (43%), TGF-β 
(21%), and Untreated group (10%) had more moderate tissue breakage (Figure 9A). We 
evaluated whether the resting force (or tissue length) before hypertrophic factor 
treatment had an effect on the probability of breakage after hypertrophic treatment was 
added to the samples.  For the Cocktail, Ang II, and ET-1 groups, we found that higher 
resting forces before treatment led to a higher likelihood of tissue rupture in the first 24 
hours of hypertrophic factor treatment (Figure 9B). There was no significant difference 
between the twitch force before the addition of hypertrophic factor of tissues that 
ruptured and those that did not rupture (data not shown). Collectively, these findings 
indicate that, after 24 hours of hypertrophic growth factor stimulation, shorter tissue 
lengths, with higher resting forces, are associated with a higher probability of tissue 
breakage in our auxotonic microtissue model, primarily for ET-1, Ang II and the Cocktail.  
However, while hypertrophic factors are correlated with twitch force generated, twitch 
force itself is not correlated with rate of rupture.  
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Figure 9. Effect of resting force on tissue breakage. We measured the average 
percentage of tissue breakage for each for each of the hypertrophic agonist treatments 
(A). We evaluated differences in resting force from the tissues that broke and remained 
attached (B). Student’s t-test was used to compare between the agonist treatments and 
the Untreated, (A) and between Attached and Broken populations (B);  * denotes p<0.05 
and ** denotes p<0.005. 
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2.3.4 Characterization of resting sarcomere length and relationship to tissue length and 
twitch force generation after 24 hours of hypertrophic agonist treatment 
Sarcomere measurements have been traditionally done in isometric preparations 
where the sarcomeres are measured for a specific tissue length. Tissue length is 
typically positively correlated with sarcomere length. In other words, the longer the 
tissue, the longer the sarcomeres. The increased length of these sarcomeres may imply 
an elevated probability of actin-myosin cross-bridge formation, which contributes to 
higher actomyosin forces and leads to an enhanced force-generating capacity. To 
understand how sarcomere length correlated with microtissue length in our auxotonic 
preparation, we fixed the samples after 24 hours of stimulation and stained with α-actinin 
(ABCAM) (Figure10A). A line was drawn across the center of five or more consecutive 
sarcomeres, resulting in a Plot Profile function that reports the intensity profile along the 
line. The data from this plot was analyzed using MATLAB, the distance between the 
brightest points or peaks of the plot results in sarcomere length. We only included 
sarcomere lengths with variance less than 0.2 µm.   
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Figure 10. Resting sarcomere length in different hypertrophic agonist treatments. 
Immunofluorescent image shows Microtissues attached to cantilevers stained with a-actinin to 
detect sarcomeres (red).  A linescan (shown in yellow) is drawn across at least 5 sarcomeres, 
and the distance between the peaks is averaged to determine sarcomere length. Scale bar. 
Student’s t-test was used to compare between an agonist treatment and the Untreated sample;  * 
denotes p<0.05 and ** denotes p<0.005 
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Figure 11. Relationship between sarcomere length, tissue length and twitch force after 24-
hour hypertrophic factor treatment. Tissue length is plotted alongside sarcomere length to 
visualize the association with resting sarcomere length (A) to show that sarcomere length is 
inversely correlated to tissue length. Additionally, Twitch force generation after hypertrophic 
agonist treatment was plotted alongside sarcomere length to show that higher resting sarcomere 
length is associated with higher twitch force generation (B).  
 
 
 
We found that the Cocktail, and ET-1 treatments resulted in significant increases 
in resting sarcomere length 1.96 ± 0.02 µm, p<0.05 and 2.07 ± 0.02µm p<.0005 
respectively, compared to 1.89 ± 0.02 µm in the untreated sample. The TGF-β treatment 
resulted in a decrease in sarcomere length, resulting in sarcomere length of 1.70 ± 
0.02µm p <.005. Ang II did exhibit significant differences as compared to the Untreated 
(1.87 ± 0.02µm vs. 1.89 ± 0.02 µm). Interestingly, the sarcomere length was negatively 
correlated to tissue length (Fig. 11A), in other words, the longer the tissue length, or the 
lower the resting force, the shorter the sarcomere length.  
To further understand how this relationship affected twitch force generation, we 
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plotted sarcomere length against twitch force generation and found that the longer the 
sarcomere length of the tissue, the higher the twitch force generated after 24 hours of 
treatment (Fig. 11B). Myocardial length-dependent effects characterized in isometric 
preparations in twitch force generation have been well characterized. However, it is the 
first time that we observe a change in resting sarcomere length in an auxotonic 
preparation upon hypertrophic agonist stimulation.   
 
2.3.5 Characterization of contraction velocity and relaxation after 24 hours of 
hypertrophic agonist treatment 
While the strength contraction of cardiac tissue is important, the kinetics of the 
contraction and relaxation are also an essential determinant of cardiac performance. The 
regulation of myocardial contraction and relaxation kinetics is currently incompletely 
understood in auxotonic-loaded microtissues. From the start of the contraction phase, 
the contraction velocity of the CMT speeds up, reaches a maximum value, and then 
decreases back down to zero when the peak twitch force is reached. Here, the 
maximum value in the velocity is identified as Vmax Contraction and the average of the 
velocities up to the peak twitch force is identified as Vavg Contraction. Similarly, during 
relaxation, the CMT contraction speed starts at zero, decreases to some negative 
maximal value, and then returns to zero until the next twitch contraction commences. 
The greatest negative velocity reached during this phase is henceforth referred to as 
Vmax Relaxation and the average velocity, Vavg Relaxation. Because, the velocities are 
identified as Vmax Contraction vs. Vmax Relaxation, no negative values are used. 
As we observed the greater changes in force in the 24 hours of hypertrophic 
agonist treatment, we further evaluated the kinetic contractile profile in these first 24 
hours. We observed that the Vmax Contraction of the Ang II (Vmax day0= 58.18±2.51µm/s 
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vs. Vmaxday1= 76.992±3.68 µm/s, p<0.005), ET-1(Vmax day0= 60.21±4.38 µm/s vs. Vmax day1= 
86.21±8.11µm/s, p<0.005) and Cocktail (Vmax day0=  55.36±3.64µm/s  vs. Vmaxday1 = 
93.85±2.43µm/s, p<0.005) treatments were significantly increased after 24 hours (Figure 
10A). However, for the Untreated (Vmax day0 = 63.05±6.50 µm/s vs. Vmax day1= 48.72± 
8.12µm/s) and TGF-β (Vmaxday0 = 65.82±5.11µm/s vs. Vmaxday1= 42.76±3.32µm/s) the 
VmaxContraction decreased, but was not statistically significant (Figure 10A). Similarly, 
for Vmax Relaxtion of the Ang II (Vmax day0 54.01±2.58 µm/s vs. Vmax day1 = 71.29±3.56 µm/s 
p<0.005), ET-1 (Vmax day0 51.51±3.75 µm/s vs. Vmax day1 = 73.58±7.34 µm/s p<0.005), and 
Cocktail  (Vmax day0 54.83±3.48µm/s vs. Vmax day1 = 80.20±2.04 µm/s p<0.005) treatments 
were significantly increased, while Untreated (Vmax day0 49.03±5.02 µm/s vs. Vmaxday1 = 
40.30±6.58µm/s) and TGF-β (Vmaxday0 61.75±4.11µm/s vs. Vmax day1 = 60.92±2.99µm/s) 
did not show statistical significant differences when comparing to the values before 
hypertrophic agonist treatment.     
Moreover, we examined the ratio of VmaxRelaxation /Vmax Contraction. In a 
previous study using tissues in an isometric preparation of isolated muscle strip systems, 
the author showed that while the magnitudes of the velocities of contraction and 
relaxation can change vastly, the ratio of the Vmax of relaxation over Vmax of 
Contraction was not significantly different in 16 different conditions, which included 
different rodent strains, lengths, frequencies, isoproterenol concentrations, etc. Only 
when the tissues were not mechanically loaded, exposed not normal frequencies nor 
under physiological temperature this ration was out of balance (Janssen PML, 2010). In  
our studies we observed no statistically significant changes between the ratio of 
VmaxRelaxation /Vmax Contraction in the Untreated sample and in samples that were 
treated with hypertrophic agonists for 24 hours. Furthermore, the ratios of 
VmaxRelaxation /Vmax Contraction were similar across all samples. The ratios between all  
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Figure 12. Contractile kinetics profile in CMTs after 24 hours of hypertrophic agonist 
treatments. Using a high-speed camera, we tracked the displacement of fluorescent beads atop 
of CMTs, and calculated kinetics of contractility. Bars represent the average of individual tissues 
velocities over 3-5 twitches. Maximum velocity of contraction (Vmax Contraction) (A),Vmax 
Relaxation (B), Vavg Contraction (C), Vavg Relaxation (D), VmaxRelaxation /Vmax Contraction (E) 
were calculated from the data.  Student’s t-test was used to compare between day0 and day1;  * 
denotes p<0.05 and ** denotes p<0.005. 
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samples were fairly similar and ranged between 0.77-0.91.  
 
2.3.6 Contraction, peak force and 50% relaxation time measurements after 24 hours of 
hypertrophic agonist treatment 
In addition to the speed of contraction and relaxation we measured the time it 
took to reach peak force, 50% relaxation, and to complete a contraction. We observed 
that time to reach peak force, 50% relaxation, and complete a contraction was reduced 
for the untreated sample after 24 hours, but it was not statistically significant. Tissues 
exposed to TGF-β had decreased contraction and relaxation velocities upon treatment, 
and consequently had a longer time to reach peak force, 50% relaxation, and complete a 
contraction (Figure 13A-C). For the Cocktail, however, we observed an increase in 
speed of contraction and relaxation, but found that despite the increase in velocities, it 
took a longer time to reach peak force (increased force generation), 50% relaxation, and 
complete a contraction (Figure 13A-C). Moreover, ET-1 reached peak force at a shorter 
time, but took a longer time to reach 50% relaxation, and no statistically significant 
change in contraction time(Figure 13 A-C). On the hand, Ang II exhibited a statistically 
significant decrease in time to reach peak force, and a decrease in time to reach 50% 
relaxation and contraction, however these were not statistically significant(Figure A-C). 
Lastly, we looked at the ratio of time to peak and time to reach 50% relaxation. We did 
not observe any statistically significant change in this ratio, indicating, that the 
equilibrium between contraction and relaxation are maintained (Figure 11D).  
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Figure 13.  Contraction, peak force and 50% relaxation time measurements after 24 hours 
of hypertrophic agonist treatment. From the displacement data obtained from the fluorescent 
beads atop of CMTs, we calculated the time to reach peak force (A), time to reach 50% relaxation 
(B) and time to complete a contraction (C). Additionally, we measured the ratio of time to 50% 
relaxation over time to peak force. Bars represent average of maximum power over 3-5 twitches 
across multiple tissues. Student’s t-test was used to compare between day0 and day1;  * denotes 
p<0.05.  
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2.3.7 Power of contraction and relaxation measurements after 24 hours of hypertrophic 
agonist treatment 
Twitch power, which is the product of the instantaneous twitch force and twitch 
velocity, has a similar temporal trend as twitch velocity. Prior to contraction the power is 
zero. In the contraction phase, the twitch power reaches a maximum value, and then 
reduces back down to zero. A relaxation phase follows, during which the twitch power 
reaches a minimum (maximum negative) value of power, before it rises back up to zero. 
We found that maximum power was exerted after the time at which maximum velocity is 
reached, where force tends to be fairly low and before the time peak force is exerted, as 
at that point velocity equals 0 at that instant. We found that ET-1 [(Pmax day0 
=160.33±42.81 vs. Pmax day1 =363.48±84.32 p<0.005),( Pmax day0 =135.12±42.92 vs. Pmax 
day1 =313.60±77.80)] and the Cocktail [(Pmax day0 =152.05±30.90 vs. Pmax day1 
=429.30±21.04),( Pmax day0 =125.16±33.59 vs. Pmax day1 =433.98±46.35)]  had statistically 
significant increases in generation of power of contraction and power of relaxation 
(Figure 14A-B). However, for the other treatments we did not identify any statistically 
significant changes in power generation.  
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Figure 14. Power of contraction and relaxation after 24 hours of hypertrophic agonist 
treatment.  Using a high-speed camera, we tracked the displacement of fluorescent beads atop 
of CMTs, and calculated kinetics of contractility. Bars represent average of maximum power over 
3-5 twitches across multiple tissues. Measurements of maximum power of contraction (A),  
maximum power of relaxation (B) were obtained.  Student’s t-test was used to compare between 
day0 and day1;  * denotes p<0.05 and ** denotes p<0.005. 
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2.3.8 Relationship between forces, velocities and sarcomere length in individual tissues 
after ET-1 treatment for 24 hours  
To further evaluate the relationship amongst forces, velocities, and sarcomere 
length, we tracked the force generated per tissue in Untreated and ET-1 –treated arrays, 
and plotted against each tissue’s average resting sarcomere length (Figure 15A-B). We 
observed that sarcomere length was longer in tissues that generated higher twitch force, 
in both the Untreated and ET-1 samples. Additionally we found that longer sarcomere 
lengths seem to be associated with higher Vmax and Vavg values for both contraction and 
relaxation (Figure 15C-D).  Therefore, in our model of auxotonic contractility we observe 
a relationship between sarcomere length and twitch force generation as well as 
velocities of relaxation and contraction.  
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Figure 15. Paired force, velocity and sarcomere length measurements after 24 hours of   
ET-1 treatment. We repeated measurements for force velocity and sarcomere length as 
described above. In this experiment however, we plotted the average values on the left hand side 
and the paired values for each tissue’s force (A), kinetics (B) and sarcomere length (C) 
measurements to compare the relationship between these variables.  
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2.4 Discussion 
In this chapter, we demonstrate the ability of our system to identify contractile 
profiles in response to different agonists implicated in cardiac hypertrophy by 
simultaneously measuring the contractile force, velocity, and power produced by 
auxotonically-loaded CMTs.  Additionally, we examined how tissue length and 
sarcomere length are associated to these changes in contractility.   
Our results indicate that ET-1 elicits a larger positive inotropic effect in auxotonic 
twitch force and resting force generation as compared to Ang II and TGF-β.  While Ang 
II, TGF-β, and ET-1 are known to play important roles in the promotion of hypertrophic 
remodeling, the specific contributions of each factor have remained unclear. Much 
attention has been paid to Ang II as a potent modulator of cardiac hypertrophy 
(Sadoshima J et al. 1993, Dasgupta C et al. 2011, Gray MO et al. 1998). However, 
studies have shown that ET-1 acts downstream of AngII and TGF-β, and thus the effects 
of these factors are in part mediated by ET-1.  Given that ET-1 had the most significant 
effect in contractility, this could indicate that ET-1 may be a key player in mechanical 
remodeling in the heart. Nonetheless, model differences used in other studies should be 
taken into considerations (such as isometric vs. auxotonic preparations, flat culture vs. 
3D tissue preparations, in vitro vs. in vivo). Previous studies using engineered tissue 
models conflict on whether ET-1 has a positive or negative inotropic effect.  In the study 
that showed that ET-1 had a negative inotropic effect, ET-1 was added over 5 days in 
millimeter-length tissues, and in conjunction with thyroid hormone triiodothyronine (T3). 
T3 has been implicated in physiological hypertrophy, in increased release of TGF-β, and 
in significant increases in sarcomere lengths of cardiac cells (Yang X et al. 2014). In 
another study by the same group, using engineered tissues in an isometric preparation, 
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the authors identified that ET-1 treatment of engineered tissues, yielded positive 
inotropic response. However, sarcomere length was not discussed in these studies. 
Furthermore, the higher rates of tissue breakage in the AngII, ET-1 and Cocktail 
samples may lead to an underestimation of the maximum twitch force generated by the 
microtissues, as those with the highest resting force are the most likely to break. Further 
refinement of the model may allow the preservation  of tissues that produce higher twitch 
forces. 
 The sarcomere is the fundamental structural unit involved in force generation 
within cardiomyocytes. We measured resting sarcomere length after 24 hours of 
hypertrophic agonist treatment  and observed that upon treatment of microtissues with 
ET-1, resting sarcomere length increased. With TGF-β treatment, the resting sarcomere 
length decreased. Interestingly, we observed that decreases in tissue length (or 
increases in resting force), were in part correlated with increases in twitch force 
generation for ET-1 and the Cocktail of three factors.  Furthermore, increases in 
sarcomere length, were positively correlated with increased twitch force generation while 
negatively correlated to tissue length.  The discrepancy between tissue length and 
sarcomere length is counter-intuitive compared with purposeful stretching of isolated 
muscle, where increases in tissue length are positively correlated with sarcomere length 
and increased twitch force generation. However, we know that hypertrophic agonists 
lead to differentiation of fibroblasts to myofibroblasts, increasing the resting force 
generated by fibroblasts and myocardial tissue, in part by increased expression of alpha 
smooth muscle myosin as well as expression of extracellular proteins, which lead to 
increases in tissue stiffness. While the relationship of sarcomere length in myocytes and 
myofibroblast stiffness is not fully understood, previous studies have looked at the effect 
of stiffness on sarcomere length of myocytes. The authors found that with increasing 
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stiffness, myocyte sarcomere length increases (Rodriguez AG et al. 2011, Torre I et al. 
2014). Further evaluation of our system’s nonmyocyte effects in the tissue is needed to 
better understand this relationship. Moreover, upon treatment with Ang II, no significant 
changes in sarcomere length were observed. These results concur with a previous study 
using engineered multicellular constructs, which have revealed no change in sarcomere 
length upon Ang II treatment  (Horton RE et al. 2016). Additionally, these results could 
suggest that the resting sarcomere length increases upon hypertrophic factor exposure 
in vivo, and may potentially be related to a transition to pathophysiological changes in 
contractility of the heart. However, these changes are not observed when the length is 
controlled in isometric preparations. Further experiments evaluating dynamic sarcomere 
length changes in real time in response to these hypertrophic factors should be 
explored.  
To further our understanding of myocardial kinetics with force and sarcomere 
changes in auxotonically loaded microtissues, we measured maximum and average 
contraction and relaxation velocities, time to reach peak twitch force and 50% relaxation 
as well as maximum power of contraction and relaxation. We detected distinct kinetic 
responses among the different hypertrophic agonists. For example, microtissues treated 
with ET-1 reduced time to reach peak force, while the time to reach 50% relaxation 
increased. Despite the fact that the Cocktail treatment led to similar changes in resting 
and twitch force responses as ET-1, the kinetics were different. Cocktail treatment led to 
a shorter time to reach peak force as well as 50% relaxation, leading to an overall faster 
contraction.  
  To further understand the relationship between all of these parameters, we 
carried out paired experiments, where were able to trace a specific sarcomere length of 
cells in a tissue with the force and kinetics generated by the tissue. This study revealed 
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that sarcomere length was associated not only with higher twitch force generation, but 
also higher velocities of contraction and relaxation. While kinetic responses varied in for 
different treatments, we observed maintenance of the ratios of velocities of contraction 
and relaxation as well as the ratio of time to peak and time to reach 50% relaxation, a 
quality characteristic of myocardial tissue. Under physiological conditions, these effects 
on contractile function are likely to play an important role in adapting cardiac function to 
achieve optimal cardiac performance under the appropriate conditions of heart rate, 
loading and inotropic state (Janssen PML, 2010). A better understanding of the 
mechanisms of sarcomere length and contractility in health and disease may allow the 
development of novel therapeutic approaches for improving cardiac contractile function.  
 
2.5 Limitations 
Engineered heart tissue with auxotonic shortening, this technique has the 
potential to serve as a powerful tool to evaluate heart mechanics under different 
biochemical settings, and gained insights into the heterogeneity of microtissue 
contractile responses, that could not be captured by other methods. However, it is not 
without its limitations. To further examine the role of ET-1 in Ang II and TGF-β, co-
treatment of these factors with an ET-1 inhibitor could be performed.   Understanding the 
signals involved in transducing the hypertrophic actions of ET-1 to pathological 
mechanical remodeling in the heart will allow us to design selective therapies to prevent 
adverse cardiac remodeling. Another possible limitation is the fixation-related effects on 
sarcomere length. However, all samples were treated at the same time using the same 
fixation protocol. In its current configuration, this system does not allow for real-time 
measurements of sarcomere length. Sorting out the dynamic sarcomere changes that 
occur in vivo and in vitro (measuring changes live, for example with laser diffraction 
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techniques) could provide additional insight into these changes.  Additionally, 
because force is dependent on many factors such as calcium concentration, 
myofilament calcium sensitivity, etc., additional studies should evaluate additional 
factors that contribute to changes in force. Furthermore, refinements of our model 
should allow for comparisons of force and kinetics after agonist treatments under 
different loading condition. Finally, given that this technique relies upon optically 
tracking the location of posts over time, the temporal resolution of the 
measurements is limited by the speed of the camera used to acquire them. Therefore, 
future research efforts should focus on addressing these shortcomings. 
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CHAPTER 3: COMBINATORIAL SCREEN OF MECHANICAL AND 
SOLUBLE FACTORS 
 
3.1 Rationale 
 
Cardiac remodeling is defined as changes in the size, shape and function of the 
heart, caused most commonly by hypertension-induced left ventricular (LV) hypertrophy 
and myocardial infarction (MI). The classical model to study cardiac hypertrophy in vivo 
has been aortic banding (AOB) in which the afterload  of  hearts  is  increased  by  
banding  of the thoracic or the abdominal aorta. Previous studies have showed that rat 
hearts exposed to AOB leads to activation of cardiac Ang II and ET-1, which occurred 
differentially during the period of transition from left ventricular hypertrophy to congestive 
heart failure (Piuhola J et al. 2003, Iwanaga Y et al. 2001). However, the study was 
limited by the presence of renin-angiotensin, ET-1, and TGF-β systems, which are 
present in nearly all tissues of the body, making the distinguishing load-induced effects 
from local and systemic responses difficult. 
In vitro 2D models of cardiac hypertrophy have allowed rigorous mechanistic 
studies of cardiac cell-specific responses (avoiding systemic effects) to hypertrophy, 
however, there are still some limitations.  For example, in a rigid 2D culture substrate, 
cardiac myocyte hypertrophy is amplified due to the stiffness of the culture substrates, 
while fibroblasts expand, differentiate to myofibroblasts and release TGF-β, ET-1, and 
Ang II, all of which function in an autocrine and paracrine manner (Ottaciano FG et al. 
2011, Drwnel FM et al. 2015, ). Thus, discerning between the effects of substrate 
stiffness and soluble factor-mediated responses is difficult to achieve. Culturing cells in 
silicon membranes that can be exposed to static stretch has overcome some of these 
limitations, however static stretch more closely mimics increase in preload rather than 
afterload, which is more closely associated with the development of cardiac hypertrophy.  
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Tissue engineering provides an opportunity to study cardiac cells in 3D, which 
more closely mimics physiological conditions and allow the opportunity to stimulate cells 
with load that is more similar to physiological conditions. As mentioned above, our 
system has the ability to stimulate microtissues with varied levels of the auxotonic load, 
which mimics afterload, by changing the PDMS concentration. To evaluate the role of 
increased load, cells were seeded in devices with a 10:1 PDMS-to-curing base 
concentration that yielded cantilevers with spring constants of [k=0.45 N/m]. Additionally, 
we aimed to determine the inotropic and kinetic effects of these hypertrophic agonists in 
auxotonic loading conditions and subsequently determine how the sarcomere length is 
associated with these responses. Investigating how myocytes respond to different 
mechanical environments remains crucial for understanding both normal development 
and disease progression. We hypothesized that co-application of inotropic hypertrophic 
factors and mechanical load leads to a synergistic effect in mechanical response, tissue 
and cellular morphology, and downstream pathway activation.  
 
 
3.2 Materials and Methods  
 
3.2.1 Cell isolation and microtissue seeding 
Briefly, cardiac cells were isolated from 1 to 2 day neonatal Sprague-Dawley rats 
and seeded into the µTUGs as previously described in Section 2.2.1. The µTUG devices 
were made using a PDMS to cross-linker ratio of 10:1, which yields a stiffness of [k=0.45 
µN/ µm]. Cell culture medium was changed daily, and hypertrophic agent stimulation 
was provided with the same timeline as described in section 2.2.4. Mechanical and 
kinetic measurements, as well as sarcomere length measurements were performed as 
described in section 2.2.3 and 2.2.5, respectively.  
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3.2.1 Cell size measurements 
To measure the size of cells, the plasma membrane of cells within the 
microtissues was stained with Cell Mask Orange (Life Technologies) dye. According to 
the manufacturers recommendations, microtissues were washed with sterile 1X PBS 
and quickly submerged in a 1000X staining solution in cell culture media. Microtissues 
were quickly incubated for 7 minutes at 37 degrees. Microtissues were left intact in the 
microtissue device covered with PBS and a slide. Microtissues were imaged live 
immediately (within 20mins of staining). Fixation of microtissues was not possible, as the 
fixation caused disruption of the staining pattern in microtissues. Samples were imaged 
in a Leica TCS SP8 Confocal using a HC FLUOTAR L 25x/0.95 W VISIR, WD 2.50mm 
objective. 
 
3.2.2 Tissue volume estimation  
Tissue volume was calculated using the equation of an elliptical cylinder V = 
πWLH/4, where W is the long diameter of the cross-section of the ellipse at the center of 
the tissue, which is measured by taking a picture of the tissue at the middle; while H is 
the short diameter of the ellipse (or height of the tissue) which is acquired with a Z-stack 
acquired with a confocal microscope. Length of the tissue (L) was measured as the 
distance between the pillars. 
 
3.2.3 RNA isolation and RT-PCR  
Total RNA was extracted using the RNeasy micro kit (Qiagen), used in the high-
capacity cDNA reverse transcription kit (Applied Biosystems), and cDNA amplified using 
TaqMan gene expression assays in an ABI 7,300 system (Applied BioSystems). The 
RNA isolation protocol improvement included using stainless steel beads to improve 
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RNA yield, 1-Bromo-3-chloropropane (BCP) instead of chloroform, and an RNA buffer 
for elution instead of water yielded tight cycle threshold values within technical 
replicates.  
 
3.3 Results  
 
 
3.3.1 Effect of hypertrophic factors on auxotonic contractility of microtissues exposed to 
hypertrophic factors for 24 hours and 48 hours tethered to stiff cantilevers 
To determine early contractile responses of different hypertrophic agonists on 
engineered tissues, we treated tissues for 24 hours and 48 hours with 10ng TGF-β, 1µg 
AngII, or 500ng ET-1 in arrays of cantilevers with a spring constant of k=0.45 µN/µm. 
Additionally, we tested whether co-application of hypertrophic factors resulted in a 
synergistic effect on mechanical response.  Single hypertrophic factor treatment as well 
as the cocktail of the three hypertrophic factors induced increases in resting force.  A 
two-way multivariate analysis of variance was run to determine the effect of hypertrophic 
factors (Untreated, AngII, TGF-β and ET-1 and a Cocktail) on change in resting force in 
cardiac microtissues tethered to stiff pillars. Data are mean ± SEM (in µN) unless 
otherwise stated. Values of change in resting force were normally distributed, as 
assessed by Shapiro-Wilk's test (p > 0.05), and there were no outliers in the data, as 
assessed by Grubbs' test. The effect of the agonists on both resting force and developed 
force were assessed after 24 and 48 hours, as shown in Figure 14.  To correct for 
differences in baseline measurements, we measured the change in resting force 
produced by each tissue, After the first 24 hours of treatment, ET-1 (Δ FR 6.15±1.60 µN), 
Cocktail (Δ FR 4.17±1.03 µN), and AngII (Δ FR 4.01±1.09 µN) had the greatest change in 
resting force, while TGF-β (Δ FR 1.32±0.77 µN) exhibited a similar change in resting 
force as the Untreated sample (Δ FR 1.37±1.83 µN). In the second day of 
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hypertrophic factor treatment, the increase in resting force of all hypertrophic sample 
treatments (Cocktail: Δ FR 1.24±1.42 µN; TGF-β: Δ FR 0.87±1.76 µN; AngII: Δ FR 
1.30±3.11 µN; ET-1: Δ FR 1.46±2.26 µN) was similar to the Untreated (Δ FR 1.40±3.01 
µN) sample (Figure 14B). The differences between the hypertrophic factors on the 
change in resting force was statistically significant, F(8, 272) = 5.715, p < 0.001. Follow-
up univariate ANOVA shows that treatment after 24hours (F (8, 54) = 4.947, p = 0.011) 
was statistically significant between hypertrophic factors, but not after 48 hours (F (2, 54) 
= 2.115, p = 0.131). Statistical significance of a simple two-way interaction was accepted 
at a Bonferroni-adjusted alpha level of .025.  Games-Howell post-hoc tests showed that 
for 24hour treatment, microtissues from AngII, ET-1 and Cocktail had statistically 
significantly higher mean change in resting force than Untreated (p<0.05). AngII, ET-1 
and Cocktail were also statistically higher than TGF-β.  However, there was no statistical 
significant between Ang II, ET-1 and Cocktail.   
We measured twitch force generated after 24 and 48 hours of hypertrophic factor 
treatment (Figure 14C).  Twitch force was recorded while microtissues were being 
electrically paced at 1hz using field electrodes as described in Chapter 2. We measured 
the change in force produced by each tissue, as described for resting force. The twitch 
force generated by these tissues was much smaller than the resting force. AngII and the 
Cocktail  (Ang II: Δ FR 1.52±0.50 µN, Cocktail: Δ FR 1.81±0.46 µN) had the highest 
change in twitch force after 24hours of treatment for microtissues tethered to stiff pillars, 
while TGF-β had the lowest change (TGF-β: Δ FR -1.75±0.35 µN).  Tissues treated with 
ET-1, (Δ FR 1.05±0.86 µN) were similar to Untreated sample (Δ FR 1.01±0.49 µN). A 
second day of hypertrophic treatment, yielded a small change in twitch force among the 
samples compared to the first 24hours of treatment (Untreated: Δ FR 0.06±1.55 µN; 
Cocktail: Δ FR 0.16±0.57 µN; TGF-β: Δ FR 0.35±1.04 µN; AngII: Δ FR -0.20±2.02 µN; 
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ET-1: Δ FR 0.25±1.31 µN). A one-way univariate ANOVA was conducted to compare the 
effect of hypertrophic factor treatment on twitch force of CMTs in TGF-β, AngII, ET-1 and 
Cocktail conditions after 24 and 48 hours of treatments. There was a significant effect of 
hypertrophic factor treatment on CMT contractility (F (8, 224) = 7.618 p <0.0001,). 
Treatment after 24hours (F(4, 112) = 18.376, p <0.0005 ) was statistically significant 
between hypertrophic factors, but not after 48 hours (F(4, 112) = 0.499, p = 0.737). 
Statistical significance of a simple two-way interaction was accepted at a Bonferroni-
adjusted alpha level of p=0.025. Games-Howell post-hoc tests showed that for 24hour 
treatment, microtissues treated with Ang II (p=0.030) and Cocktail (p=0.022) had 
statistically significantly higher mean change in twitch force, while those treated with 
TGF-β (p=0.013) had statistically significant lower mean change in twitch force 
compared to the Untreated (p<0.05) samples. ET-1 treatment did not lead to significantly 
different twitch force changes compared to the Untreated (p=0.344), Ang II (p=0.483) 
and Cocktail (p=0.379).  
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Figure 16.  Resting and Twitch Force produced by CMTs after 24 and 48 hours of 
hypertrophic agonist treatment.  After CMTs were formed and synchronously beating, 
baseline force measurements at day 0 were acquired. Brightfield images were used to 
calculate the resting force (A). To account for baseline force differences, we computed 
the change in resting force per tissue after 24 and 48 hours of treatment, and the 
average across multiple tissues (N=25) is represented by the bar graph above (B). Using 
a high-speed camera, we collected data of the displacement of the cantilevers over 
multiple contractions. The bar graph above represents the average peak twitch force for 
3-5 contractions across multiple tissues (N=25) (C). Similarly to resting force, we 
computed the change in twitch force after 24 and 48 hours (D). 
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We performed a multivariate analysis to determine whether there was an 
interaction effect in the contractile response of cardiac microtissues to hypertrophic 
factors (AngII, TGF-β, ET-1, Cocktail) x Stiffness (0.20 µN/µm, 0.45 µN/µm) x length of 
treatment (24hours, 48hrs). We used the contractility data described in Chapter 2 on 
microtissues cultured in soft pillars. To calculate the expected additive response of load 
and hypertrophic factor for each condition, we used the difference between Untreated 
samples in soft and stiff  (ΔFstiff –soft) as the value of contribution of load.  We calculated 
the contribution of hypertrophic factor as the values of Force generated by the addition 
of a hypertrophic factor minus the baseline (force generated by the Untreated sample). 
We then added the effect of adding a hypertrophic factor from soft pillars to the “load 
factor”. We performed a three-way mixed ANOVA to determine if there was an 
interaction effect among stiffness x hypertrophic factor x time in the resulting change in 
resting and twitch force (Data shown in Appendix 1A). Post-hoc pairwise comparisons 
revealed that stiff pillars in addition to the of the ET-1 (p<0.0001) and AngII (p=0.003) 
treatments resulted in a statistically significant response in change in resting force after 
the first 24 hours, but not after 48 hours of treatment as compared to the soft pillars.  
Furthermore our analysis revealed that addition of TGF-β (p<0.0001) or AngII (p=0.007) 
resulted in a synergistic response in the change in twitch force after the first 24 hours 
compared to soft pillars.   (Further details are presented in Appendix 1A). 
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Figure 17. Calculation of expected additive response of load and hypertrophic 
factor effects. We estimated the expected additive response of hypertrophic factor 
treatment in change in resting (A) and twitch force (B), by first calculating the 
contribution of load (Untreated samples : load contribution = ΔFstiff –soft). We calculated 
the contribution of hypertrophic factor as the values of Force generated by the addition 
of a hypertrophic factor minus the baseline (force generated by the Untreated sample). 
We added these two factors to get to the expected additive response (C). 
 
 
 
 
 
 
 
Expected Δ Force  = Contribution of hypertrophic factor response (as measured in soft pillars)  
     + Contribution from increased auxotonic load  
= (ΔF hypertrophic factor response in soft pillars – Δ F Untreated samples in soft  
 pillars  + (ΔF in untreated samples in stiff pillars - Δ F in untreated samples in soft    
 pillars)   
C 
A B 
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3.3.2 Effects of ET-1, TGF-β, Ang II alone and in combination, in contractile kinetics  
While the strength contraction of cardiac tissue is important, the kinetics of the 
contraction and relaxation are also an essential determinant of cardiac performance. As 
described in Section 2.3.5 we looked at the following metrics: Vmax Contraction Vmax 
Relaxation, and ratio of VmaxRelaxation /Vmax Contraction. As we observed the greater 
changes in force in the 24 hours of hypertrophic agonist treatment, we further evaluated 
the kinetic contractile profile in these first 24 hours. We observed that the Vmax 
Contraction of the Ang II (Vmaxday0= 48.66 ±7.89µm/s vs. Vmaxday1= 58.16±8.88 µm/s, 
p<0.005), ET-1(Vmax day0= 47.95±4.38 µm/s vs. Vmax day1= 68.41±5.68.11µm/s, p<0.005) 
and Cocktail (Vmaxday0 = 44.55±1.55µm/s  vs. Vmaxday1 = 57.74±1.52µm/s, p<0.005) 
treatments were significantly increased after 24 hours (Figure 16A). However, for the 
Untreated (Vmax day0 = 49.20±7.62 µm/s vs. Vmax day1= 44.56± 7.62µm/s) and TGF-β 
(Vmaxday0 = 46.82±3.29µm/s vs. Vmaxday1= 32.44±2.14µm/s) the Vmax Contraction 
decreased, but was not statistically significant (Figure 18A).  
Similarly, for Vmax Relaxation of the Ang II (Vmax day0 35.77±8.46 µm/s vs. Vmax day1 
= 42.12±3.56 µm/s p<0.005), ET-1 (Vmax day0 32.52±1.75 µm/s vs. Vmax day1 = 44.96± 3.81 
µm/s p<0.005), and Cocktail  (Vmax day0 35.29±1.43µm/s vs. Vmax day1 = 48.45±1.44 µm/s 
p<0.005) treatments were significantly increased, while Untreated (Vmax day0 34.90±4.85 
µm/s vs. Vmaxday1 = 31.26±4.83µm/s) and TGF-β (Vmaxday0 32.43±3.37µm/s vs. Vmax day1 = 
23.48±1.49µm/s) did not show statistical significant differences when comparing to the 
values before hypertrophic agonist treatment.    
Similar to the results in the soft pillars that we discussed in the Chapter 2, we 
observed no statistically significant changes between the ratio of VmaxRelaxation /Vmax 
Contraction in the Untreated sample and in samples that were treated with hypertrophic 
agonists for 24 hours. Furthermore, the ratios of VmaxRelaxation /Vmax Contraction were  
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similar across all samples. We did not observe any statistically significant change in this 
ratio, indicating, that the equilibrium between contraction and relaxation is maintained. 
Further statistical analysis is provided in Appendix 1.  
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Figure 18. Contractile kinetics profile in CMTs after 24 hours of hypertrophic agonist 
treatments. Using a high-speed camera, we tracked the displacement of fluorescent beads atop 
of CMTs, and calculated kinetics of contractility. Bars represent the average of individual tissues 
velocities over 3-5 twitches. Maximum velocity of contraction (Vmax Contraction) (A),  Vmax 
Relaxation (B), Vavg Contraction (C), Vavg Relaxation (D), VmaxRelaxation /Vmax Contraction (E) 
were calculated from the data.  ANOVA was used to determine differences between groups at 
day 0 and at day 1;  * denotes p<0.05.  
 
 
 
 
E 
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3.3.3 Power of contraction and relaxation measurements after 24 hours of hypertrophic 
agonist treatment 
Twitch power is calculated as previously described in Chapter 2. Briefly, we refer 
to Pmax of Contraction as the maximum value of the twitch power in the contraction 
phase, before it reduces back down to zero. Pmax of Relaxation is the twitch power 
reaches a minimum (maximum negative) value of power, before it rises back up to zero. 
We found that maximum power was exerted after the time at which maximum velocity is 
reached, where force tends to be fairly low and before the time peak force is exerted, as 
at that point velocity equals 0 at that instant. As shown in Figure 19A, we found that the 
tissues in the Untreated sample generated Pmax day0 =183.95 vs. Pmax day1 =166.82 
however, tissues treated with ET-1 generated statistically significant increases in power 
after 24 hours of treatment (Pmax day0 =201.74±42.81 vs. Pmax day1 =431.19±84.32, 
p<0.005). Cocktail,(Pmax day0 =192.13±30.90 vs. Pmax day1 =269.40±21.04, p=0.023), and 
Ang II ((Pmax day0 =203.76±33.59 vs. Pmax day1 =238.26±46.35, p=0.048) had more 
moderate, but still significant increases in power after 24 hours of treatment. TGF-β on 
the other hand, caused a decrease in power generation in microtissues after 24 hours of 
treatment (Pmax day0 =197.19±42.92 vs. Pmax day1 =61.64±77.80).  
Furthermore, we measured the generation of power of relaxation upon 
hypertrophic treatments (Figure 19B). The Untreated samples  generated a moderate, 
but not significant increase in power generation (Pmax day0 =76.61 vs.  Pmax day1 =82.90) 
while ET-1(Pmax day0 77.52  vs. Pmax day1 =246.67, p<0.0001) generated the largest and 
statistically significant increase in power generation. Ang-II (Pmax day0 76.41 vs. Pmax day1 
=106.82, p=0.040) and the Cocktail  (Pmax day0 82.96 vs.  Pmax day1 =134.97, p=0.033) 
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generated more moderate increases in power of relaxation after 24 hours of treatment. 
Similarly, to the generation of power of contraction, treatment of TGF-β (Pmax day0 77.08 
vs. Pmax day1 =26.96) also led to a decrease in power of relaxation.  
 
 
 
 
Figure 19. Power of contraction and relaxation after 24 hours of hypertrophic agonist 
treatment.  Using a high-speed camera, we tracked the displacement of fluorescent beads atop 
of CMTs, and calculated kinetics of contractility. Bars represent average of maximum power over 
3-5 twitches across multiple tissues. Measurements of maximum power of contraction (A),  
maximum power of relaxation (B) were obtained.  Student’s t-test was used to compare between 
day0 and day1;  * denotes p<0.05 and ** denotes p<0.005. 
 
 
3.3.4 Effects of AngII, ET-1 and TGF-β alone and in combination, in sarcomere length 
 
 To understand how sarcomere length correlated with microtissue force and 
velocity in our auxotonic preparation, we fixed the samples after 24 hours of stimulation 
and stained with α-actinin (ABCAM) as described in Section 2.2.8. We only included 
sarcomere lengths with variance less than 0.2µm.  As shown in Figure 20, we found that 
the resting length of the sarcomere for the ET-1 and AngII treatments after 24 hours 
resulted in significant differences in sarcomere length 1.85 ± 0.03µm p<0.05 and 1.86 ± 
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0.03µm (p<0.0001) respectively, compared to 1.74 ± 0.02µm in the Untreated sample. 
The TGF-β treatment resulted in a decrease in sarcomere length, resulting in sarcomere 
length of 1.69 ± 0.02µm p<0.05. The Cocktail treatment however, did not exhibit 
significant differences as compared to the Untreated (1.79 ± 0.02µm vs. 1.74 ± 0.02µm).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Resting sarcomere length in microtissues tethered to stiff pillars. 
Immunofluorescent images of microtissues attached to cantilevers stained with a-actinin were 
used to detect sarcomeres and measure sarcomere length (as described in 2.3.4). Our results 
show that sarcomere length is lower in stiff pillars than in soft pillars. Microtissues treated with 
AngII and ET-1 had statistically significant increases in sarcomere length, while those treated with 
TGF-β had statistically significant reduction in sarcomere length. Student’s t-test was used to 
compare between an agonist treatment and the Untreated sample;  * denotes p<0.05 and ** 
denotes p<0.005  
3.3.5 Effects of AngII, ET-1 and TGF-β alone and in combination, in cell and tissue size 
Hypertrophic remodeling in the heart is characterized by morphological changes 
including cell and tissue enlargement. To examine the effects of hypertrophic agonists 
on cell size within the microtissues, we compared the effect of both hypertrophic growth 
factor and afterload enhancement (microtissues tethered to stiff pillars) on cell size.  We 
stained the plasma membrane of cells and measurements were performed as described 
in Figure 21A-B. For microtissues tethered to soft cantilevers, post -hoc 
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analysis using Games-Howell revealed that there were no statistically significant 
changes (Figure 21C) in cell size with hypertrophic factors (Cocktail: AC20= 194.94± 
11.93µm2, p=0.152; Ang II: AA20= 189.82 ± 8.32µm2,p=0.102; TGF-β: AT20=175.46 ± 
15.02µm2, p=0.894; ET-1; AE20=181.34 ±13.55µm2), p=0.097) compared with the 
Untreated sample (Untreated: AU20=177.67 ± 12.62µm2). For microtissues tethered to 
stiff cantilevers, AngII, Cocktail and ET-1 (AC10=226.67± 7.53µm2, p=0.020; 
AA10=245.22± 9.55µm2, p<0.0001; AE10=231.95± 8.94µm2, p=0.020) each significantly 
increased cell size compared the  Untreated microtissues (A10T=214.47± 14.54µm2).  
TGF-β had no statistically significant change in cell size compared to the, Untreated 
microtissues p=0.250). However, we carried out a Two-Way ANOVA and found no 
synergistic interaction between factor and stiffness. 
 
 
 
Figure 21. Cell membrane staining in situ, and assessment of average cardiomyocyte size 
in CMTs.  Flourescent image of cell membrane staining with (Cell Mask Orange) (A). Deliniation 
of cell membrane to calculate areas of cells embedded in the microtissues (B).  Assessment of 
cross-sectional areas of cells within CMTs after hypertrophic interventions in soft and stiff pillars 
(C). Scale bar indicates 50 µm.  
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Additionally, we measured tissue volume by estimating it to be a cylindrical 
ellipse using the equation V = πW*L*H/4 (Figure 21 A-C). We measured the cross-
sectional area of each tissue and multiplied by the length of the tissue (Figure 21 D).  In 
soft pillars, We observed 2.45x increase in volume in the microtissues treated with the 
Cocktail (VC20= 1.20 ±0.36 x10-3 mm3, p= p<0.0001) (Figure 21E), 2x smaller with AngII,  
(VA20= -0.83±0.63 x10-3 mm3, p=0.004), with TGF-β, 4x smaller (VT20= -1.98±0.22 x10-3 
mm3, p=0.001 ), 1.5x increase (VE20= 0.72 ±0.34x10-3 mm3, p<0.0001) compared to the 
Untreated (VU20= -0.49±0.24 x10-3 mm3). In the stiff pillars, AngII treatment resulted in 
0.20x larger (VA10=-0.64± 0.21 x10-3 mm3, p=0.043); TGF-β , 3.4x smaller (VT10=-
2.67±0.27 x10-3 mm3, p<0.001), ET-1, .25x larger (VE10=-0.59±0.54 x10-3 mm3, p=0.001), 
the Cocktail,  3.42x larger (VC10=1.11±0.46 x 10-3 mm3, p=0.028) compared to the 
Untreated (VU10=-0.78±0.30x10-3 mm3).  
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Figure 22. Microtissue volume after 24 hours of hypertrophic factors treatment in 
microtissue tethered in soft and stiff pillars. Data table shows an example of the 
measurements and calculations of microtissue volume (A) for a microtissue treated with the 
Cocktail treatment, as shown in (B).  Diagram shows model used to estimate microtissue volume 
from Brightfield images (C).  Baseline and 24 hour treatment measurements of microtissue 
volume (D). Change in microtissue volume after 24 hours of hypertrophic factor treatment (E). 
Scale bar indicates 50µm.  
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3.3.6 Effects of AngII, ET-1 and TGF-β alone and in combination, in gene expression 
 
The changes in contractility upon hypertrophic factor stimulation led us to 
investigate gene expression associated with cardiac remodeling.  Fibrosis is a hallmark 
of pathological cardiac remodeling. Fibrosis signals including collagen-1, collagen-3 
expression in fibroblasts are augmented during pathological cardiac remodeling. In 
CMTs, transcript concentration of the collagen-1 was increased by all treatments 
compared to the Untreated samples (referred to as ‘20N’ in the graph below) in soft 
cantilevers (our control), but particularly by ET-1 (20E: 2.6x) and Cocktail (20C: 2.5x). 
For collagen-3, the Untreated  (10N: 3x) and Ang II (10A: 2.25x) samples of microtissues 
tethered to stiff cantilevers resulted in the highest fold change.  Additionally, α-Smooth 
Muscle (α-SMA) is a characteristic marker of fibroblasts-to-myofibroblast transition in the 
fibrotic heart.  We see increases in α-SMA expression for all treatments compared to the 
Untreated sample tethered to soft pillars (20N). In particular the (3.5x) Cocktail (20C) 
and (3.1x) ET-1 treatment (20E) in the soft cantilevers as well as the Ang II and Cocktail 
in stiff cantilevers, result in large increases in α-SMA. Furthermore, in myocardial 
hypertrophy, the re-expression of fetal actin isoforms, including the sarcomeric skeletal 
actin (SKA). Increased SKA expression represents a well-accepted marker for cardiac 
hypertrophy in different animal species and humans, during hemodynamic overload, 
passive stretch and TGF-β stimulation (Schaub et al., 1997; van Bilsen and Chien, 1993, 
Eppenberger-Eberhardt et al., 1990).. Our results show that SKA is upregulated upon 
treatment of hypertrophic factors, particularly when the microtissues are tethered to stiff 
cantilevers (10N: 1.71x , 10C: 1.89x, 10T: 1.37x, 10A:1.74x,  10E:1.66x) compared to 
our control.  
 
We measured βMHC and αMHC expression, and the ratio of the two. We 
observed an increase in power generated by microtisssues. A higher 
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ratio of αMHC to βMHC, which correlates with what is observed in initial adaptive 
responses to hypertrophic factors, where the α-MHC (fast isoform) is actually higher than 
the β-MHC (slow isoform) isoform. In terms of mechanical power, which is a product of 
the developed force and the velocity of shortening, it has been previously shown that 
higher expression of α-MHC correlated to higher power produced by microtissues 
(Gupta MP 2007, Herron TJ and McDonald KS 2002). Our results show (Figure 19A-B) 
that all of our treatments were correlated with higher α-MHC expression than  β-MHC 
leading to a higher α-MHC /β-MHC ratio. However, the highest ratio of α-MHC /β-MHC 
was observed in samples were microtissues tethered to soft pillars were treated with ET-
1 (2.70x).  
Lastly, we measured the expression of atrial natriuretic protein (ANP) gene, a 
classical marker of hypertrophy. Similar to above, all of our samples resulted in 
increases of ANP expression, however, Ang II (20A: 3.25x) in soft pillars as well as the 
Cocktail (10C:3.75x) and ET-1 (10E: 4x) in stiff pillars, resulted in the highest expression 
of ANP.  
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Figure 23. Gene expression responses to hypertrophic factors relative to the Untreated sample 
in soft cantilevers. In the graphs above, treatments are denotes as the following: Cocktail as ‘C’, 
TGF-β as ‘T’, AngII ‘A’ and ET-1 as ‘E’, stiffness is denoted by PDMS concentration, namely ‘20’ for 
soft pillars made with 20-1 PDMS-to-curing base concentration, and ‘10’ for stiff cantilevers made with 
10-1 PDMS-to-curing base concentration. collagen 1 (A), collagen 3 (B), alpha smooth muscle actin 
(αSMA) (C), skeletal actin (D) ANP (E), and ratio of α-MHC to β-MHC (F), expression were measured 
in all microtissue samples. * denotes p<0.05 and ** denotes p<0.005 
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3.4 Discussion 
 
This study provides a multivariate assessment of the effects of hypertrophic 
agonists AngII, TGF-β, and ET-1 alone and in combination, with length of treatment and 
stiffness on forcefulness and kinetics of contractility, sarcomere length, cell size, tissue 
width, and hypertrophic gene expression in engineered cardiac microtissues. Our 
studies revealed that the stiffness, hypertrophic factor stimulation and length of exposure 
has an effect in both resting and twitch force, as well as on kinetic parameters, such as 
Vmax contraction, Vmax relaxation, Time to peak and Time to reach 50% relaxation. 
Additionally, hypertrophic treatment led to structural changes in microtissues. Lastly, 
gene expression associated with hypertrophy and fibrosis was increased upon 
stimulation of hypertrophic factors.   
 Further analysis into the effect between stiffness, hypertrophic factor stimulation 
and length of exposure in resting force revealed a statistically significant effect of ET-1, 
AngII and Cocktail treatments after 24 hours. Multivariate analysis revealed that AngII 
and TGF-β, in particular, have a statistically significant interaction with stiffness on their 
effect on twitch force generation. Previous work revealed a relationship between AngII 
and stiffness in the form of stretch in in vitro studies and pressure overload models in in 
vivo studies. However, it wasn’t clear if stiffness could provide a synergistic response. 
The increase in contractility could potentially be related to load-mediated activation of 
angiotensin type 1a receptor (AT1aR), which consequently leads to an enhanced AngII 
effect upon addition of this hypertrophic factor (Horton RE et al. 2016). Further 
investigation of AT1aR expression in our tissue model could provide additional insights 
into the mechanism of this synergy in our model system. Additionally, AngII resulted in a 
statistically significant increase in forcefulness of contraction, which is a characteristic of 
the initial adaptive response in load-mediated hypertrophy models (Emdad L et al. 
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2001). Further work could identify mechanical effectors downstream of this synergistic 
response and provide insights into the mechanisms of this response on the synergistic 
effect in forcefulness of contraction, which could prove useful for therapeutic studies.  
We also observed diminished contractile kinetics, in particular reduced Vmax of 
Contraction and Relaxation. While inherent variation of isolated neonatal rat ventricular 
myocytes could lead to variations in kinetic parameters, we carried out paired contractile 
analysis in stiff and soft arrays of tissues engineered from cells from the same isolation.  
A slower velocity generation has been characterized in tissues that are able to produce a 
larger force to pull on the stiffer pillars in previous studies (Edmund Sonnenblick 1982 ). 
Other work in single cells has shown that the rate of contraction is largest in the absence 
of any applied stress, monotonically decreases with increasing tensile stress, and 
eventually vanishes when the applied stress equals the stall stress. This was recently 
observed in cardiac microtissues, where microtissues contracted with smaller speeds 
when subject to increasing force (Wang H et al. 2013).  
Furthermore, we studied the interaction of hypertrophic factor and increased 
afterload in sarcomere length. Sarcomere lengths of myocytes in microtissues tethered 
to stiff pillars were lower than in the sarcomere lengths of myocytes in softer pillars. 
Shorter sarcomere lengths have been associated with increased afterload in response to 
increased sarcomereogenesis. A recent study demonstrated that sarcomerogenesis is 
upregulated in myocytes cultured on stiff gels (McCain ML et al. 2014). However other 
reports have suggested that sarcomere structures are optimized on gels with 
physiological elasticity (Jacot JG 2008). Another factor to consider is the fibroblast 
effects on sarcomere length myocyte. Mechanical load has been known to be associated 
with fibroblast proliferation and differentiation to myofibroblasts. It is possible that upon 
increased load stimulation, myofibroblast population increases and leads to a 
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diminishing effect on contractility. Further work, looking at myofibroblast quantitation and 
increased matrix levels as well as matrix stiffness could provide insights into the effect of 
these factors on contractility. Further studies looking at sarcomereogenesis and 
fibroblast number and interaction with myocytes in microtissues exposed to higher 
afterloads would provide insights to further understand changes in sarcomere length. 
Morphological changes after hypertrophic treatment of AngII, Cocktail and ET-1 
demonstrated statistically significant increases in cell size in stiff pillars, but not in soft 
pillars.  Studies performed in vitro in 2D cell culture systems have previously shown that 
myocytes increase in size in response to these factors, irrespective of mechanical load 
(static stretch). One challenge with these cell culture substrates is that cells are exposed 
to the stiffness of the plate, and thus makes it harder to distinguish between the load-
mediated effects and the hypertrophic factor effects. A recent study using engineered 
tissues that were not exposed to load reported no cell size or tissue thickness difference 
in response to Ang II (Horton RE et al. 2016), while observing changes in contractility. 
Therefore it is possible that cell area changes observed in 2D culture systems are due to 
the increased load. Auxotonically-loaded engineered tissues model overcomes 
challenges related to dimensionality and culture substrate stiffness that confound 
traditional cell culture systems.  
Interestingly, while cells in microtissues resulted in increased cell area, 
microtissue changes in volume were reduced in microtissues exposed to increased 
afterloads. In a recent report (Wang H et al. 2013) looking at microtissue morphology 
when exposed to higher loads, it was reported that increased load led to increased 
remodeling and compaction of the matrix by the cells and a steady reduction of construct 
size (Wang H et al. 2013). Therefore it is possible that while we do not observe larger 
changes in tissue width as in soft pillars, AngII, ET-1 and the Cocktail leads to a 
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reduction of the inherent thinning that is observed in microtissues tethered to stiff pillars. 
Additionally, the authors report that thinning occurs as part of an elastic deformation that 
is volume-conserving. In other words, while changes in length, height and width of 
microtissues occur result in a null change in volume. On the other hand, our results 
suggest that  hypertrophic growth factor could lead to inelastic volume deformations in 
our microtissues. A limitation of these comparisons is that Wang et al. estimated volume 
changes using a dumbbell model to estimate tissue volume, and report that when the 
tissue gets thinner in the middle while areas around the posts get larger (hence forming 
a dumbbell shape). Furthermore, it is possible that there is a cell dropout that contributes 
to larger cell size without increasing tissue volume.	Our results, as we can see in Figure 
19B, did not lead to enlargement of tissues around the areas of the posts. Further 
studies with direct volume measurements should provide insights on whether changes in 
microtissue volume that we are elastic or inelastic.  
In addition to contractile and morphological changes in response to load and 
hypertrophic factors, we observed increased expression of genes associated with 
cardiac remodeling, such as ANP, Collagens 1 and 3, skeletal actin and alpha smooth 
muscle actin. Afterload enhancement in our microtissues results in increased expression 
of skeletal actin and alpha smooth muscle actin. Interestingly, we did not observe the 
myosin heavy chain switching that is typically observed upon exposure to hypertrophic 
stimulants, such as load and hypertrophic factors. It has been reported that early after 
hypertrophic stimulation, an initial adaptive enhancement of contractile function is 
observed, and upon persistent activation of hypertrophic factors decrease in cardiac 
contractility ensues (Mann DL et al. 2005). Because we focus on the first 24 hours of 
treatment, we may be observing this enhanced contractile output, which is related to 
higher αMHC levels than βMHC. Higher αMHC values and lower βMHC values 
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are correlated with higher power generation by cardiac tissue (Gupta MP 2007, Herron 
TJ and McDonald KS 2002), which we observed in our model. Further studies evaluating 
longer exposures to hypertrophic factor treatment as well as increased afterload, could 
provide more information regarding whether our tissue can undergo that isoform switch 
that occurs in hypertrophic models in vivo as well as in passive stretch 2D models in 
vitro.  
Changes in mechanical load lead to structural and functional phenotype changes 
in our microtissue model. Our results demonstrate that engineered cardiac constructs 
could provide a platform for studying in vitro effects of complex stimuli, including 
biochemical and load enhancement, that occur in vivo. Our data shows that we are able 
to de-couple and couple biochemical, in other words, hypertrophic factor stimulation and 
increased auxotonic load.  We observed an increase in cell size occurred only in the 
presence of load and hypertrophic factor. In standard 2D flat culture in plastic substrates, 
the hypertrophic factor-mediated effects are hard to distinguish from the load-mediated 
effects.  . Further refinements to our model should include the ability to increase load 
post tissue formation, as well as evaluated a graded effect of loading.  These constructs 
can serve as a model system to improve our basic understanding of cardiac mechanical 
remodeling and identify underlying mechanisms that can potentially be exploited to 
improve mechanical remodeling in the heart. 
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3.5 Limitations 
A limitation of this study was that the sarcomere measurements of myocytes in 
tissues tethered to soft and stiff cantilevers were not done in parallel, though the same 
procedure and reagents were used in both analyses. Furthermore, paired 
measurements of microtissue contractility and sarcomere length were not performed. 
Further work should be conducted in parallel to avoid potential confounders of 
experimental variability. 
Additionally, we did not observe large enhancement on twitch force with the 
addition of load to the stimulation with different hypertrophic factors. Further work should 
explore whether large resting forces affect the twitch force generation. Incrementally 
dosing the load would also be valuable to determine if there is a graded effect in loading, 
going beyond the maximum value of load added in our experiments.  
Furthermore, it is possible that enhanced load leads to activation of other factors 
in the sample, complicating the interpretation of the effects of each factor. It is also 
possible that some factors are more sensitive to load than others. Studies are needed 
that neutralize the effects of the factors not being studied, such as with neutralizing 
antibodies for the receptors of the hypertrophic factors, to isolate the effects of each 
factor being studied. Increased load effects can also be better studied this way. 
 While our studies focused on short-term responses of hypertrophic factors and 
load, it is possible that the effects of load take a longer time to manifest themselves. 
Longer studies may provide additional insights on the effects of hypertrophic factors long 
term, which are difficult to extrapolate from our data.  AngII resulted in a statistically 
significant increase in forcefulness of contraction, which is a characteristic of the initial 
adaptive response in load-mediated hypertrophy models (Sadoshima J et al. 1993). 
However, TGF-β led to a diminished contractile response. Previous studies have shown 
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that TGF-β mediates the AngII transition (Schultz J et al. 2002) from adaptive enhanced 
to a subsequent caontractile dysfunction step in cardiac hypertrophic remodeling. 
However, our experiments were performed over 48 hours, therefore longer experiments 
are needed to determine if these changes are also reflective of the pathophysiological 
changes that occur weeks, months, or years down the road. Previous work 
demonstrated that TGF-β, (1) acts downstream of AngII, and (2) mediates AngII 
hypertrophic effects. Further work could identify mechanical effectors downstream of this 
synergistic response and provide insights into the mechanisms of this response on the 
synergistic effect in forcefulness of contraction, which could prove useful for therapeutic 
studies.  
Additionally we measured tissue volume indirectly, by measuring the center of 
the tissue. Future studies should consider measuring volume directly by measuring 
widths throughout the length of the tissue.  Cell dropout, which contributes to larger cell 
size without correspondingly greater tissue volume (Anversa P et al. 1986), also needs 
to be evaluated.  This phenomenon could also explain disproportionate increases in 
resting force compared with twitch force. 
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CHAPTER 4: CELL-SPECIFIC CONTRIBUTIONS TO AUXOTONIC 
CONTRACTILITY IN CMTS  
 
4.1 Rationale  
Engineered cardiac microtissues (CMTs) provide a model for mechanistic studies with 
the potential to better understand of the interplay of cardiac cells in cardiac remodeling. 
Determining how nonmyocytes contribute to myocardial mechanical responses has 
proven difficult. In vivo, fibroblasts (CF) are buried within densely packed myocytes 
(CMs) making a direct investigation and quantification in situ extremely difficult. As the 
associated clinical picture of fibrosis represents a serious challenge in medical 
treatment, garnering a deeper understanding of the interplay between nonmyocytes and 
cardiomyocytes is pivotal to improve therapeutic methods for patients with myocardial 
infarction. Previous studies have demonstrated that engineered tissues made with a 
native heart cell population compared to myocyte-enriched (or nonmyocyte depleted) 
cell populations generated improved resting (diastolic) and twitch (systolic) force. (Nichol 
JW et al. 2012). Assessment of native neonatal heart cell populations has revealed that 
myocytes usually account for 45-55% of the cells while nonmyocytes account for 50-
65% (Chlopcíková S et al.2011). Of the nonmyocyte population, studies have shown that 
more ~70% of the nonmyocyte population is made up of fibroblasts (Chlopcíková S et 
al.2011) While the native heart population may display higher contractile forces than the 
myocyte-enriched tissues, the ability to create tissues with different cell populations 
offers an opportunity to determine cell-specific responses in engineered tissues.  
Our previous work using the native heart cell mix demonstrated that ET-1 
resulted in increased twitch force, increased resting force (shorter tissue length) and 
longer resting sarcomere lengths compared to other hypertrophic factors such as TGF-β 
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and Ang II (Chapter 2). Interestingly, the sarcomere length of myocytes in shorter tissues 
with higher twitch force was longer than in longer, less active tissues. In other words, 
there was the expected positive correlation between sarcomere length and twitch force 
generation irrespective of the overall length of the engineered tissue. This led us to 
speculate that the resting force and thus, length of microtissues, is regulated by 
nonmyocytes in auxotonically-loaded microtissues engineered with a native heart cell 
population.   We hypothesized that depleting nonmyocytes from microtissues to create 
myocyte-enriched microtissues, would produce lower resting force and increased tissue 
length. We first sought to understand the role of nonmyocytes in contractile responses, 
including resting and twitch force generation, kinetics and sarcomere length. We 
generated tissues with the native heart mix population (Chapter 2) ~50%CMs:50%CFs, 
tissues with intermediate ,myocyte enrichment with ~83%CM:17%CF, and tissues that 
contained mostly myocytes 93%CM:7%CF. Furthermore we investigated how myocyte-
enriched tissues responded to ET-1 treatment. Building microtissues with varying 
proportions of cardiac cells is critical to understanding the role of myocytes and 
nonmyocytes in the contractility profile, including resting force and twitch forces, kinetics 
and sarcomere length, length-tension relationship, of CMTs in 3D. 
  
4.2 Materials and Methods 
4.2.1 Cell isolation and contractility measurements 
Briefly, neonatal rat ventricular cells (NVRC) were isolated from 1 to 2 day-old 
neonatal Sprague-Dawley rats as previously described in Section 2.1. The µTUG 
devices were made using a PDMS to cross-linker ratio of 20:1, which yields a stiffness of 
[0.20µN/µm]. Cell culture medium was changed daily. Mechanical and kinetic 
measurements, as well as sarcomere length measurements were performed as 
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described in section 2.2.3 and 2.2.5, respectively.  
 
4.2.2 Flow Cytometry methods for sorting cardiac cells 
 The cells were pre-plated onto multiple T-75 flasks for 1 hour to allow fibroblasts 
to attach to the dishes. Cardiomyocytes still suspended in the media were retained and 
seeded onto a T-75 flask coated with fibronectin. Cells were washed using 1x PBS and 
growth media was changed the next day at least three hours prior to the staining 
protocol.  After cells were incubated for at least 3 hours with fresh media, 500ng/ml of 
Tetramethylrhodamine methyl ester perchlorate (TMRM) (ThermoFisher) in DMEM 3:1 
M199, 1%HEPES, 1%Glutamax, 1%insulin, 1%Antibiotic-antimycotic was added and 
incubated at 37°C for 30 minutes. After incubation, cells were washed with 1X PBS and 
dissociated with a 500ng/ml TMRM in 0.05% trypsin solution for 3 minutes. Trypsin was 
deactivated with DTI and cells were spun down for 5 minutes at 1000 rpm. The cells 
were re-suspended in 1%BSA DMEM and DAPI to get 5-8x106 cells/ml. Cell solution 
was filtered (40µm filter) and added to a tube with 5 ml of media. Cells were sorted using 
the BD FACS Aria II SORP.  
After excluding cell fragments and aggregates (Figure 24A) along with dead cells 
(DAPI+) (Figure 24B) gating was based on TMRM fluorescence (Figure 24C), employed 
to identify the myocyte enriched population based on mitochondrial size as previously 
described (Hattori F et al. 2010, Nguyen PD et al. 2012, Rachel Truitt, unpublished 
data). The TMRM- population was considered to be mostly nonmyocytes. Myocyte 
number in the TMRM+ population was confirmed with Troponin staining, which yielded 
93% ± 3% Troponin+ cells (Figure 24D). The viability of the cells was assessed using 
Trypan blue dye that revealed 93% viability in the TMRM+ population (Figure 24D). 
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Figure 24. Serial Gating to sort viable TMRM+ myocytes from an NVRC isolation. The 
sample was serially gated to isolate the population of viable myocytes. Large aggregates were 
excluded (A).   DAPI+ cells were excluded as dead (B). TMRM positivity was used to isolate 
myocytes from the native neonatal heart population. Further antibodies staining revealed a high 
myocyte purity and viability in the TMRM+ sample. Data from a representative native heart cell 
population is shown in this figure. 
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4.2.3 Microtissue seeding of sorted cells 
Three different cell populations were created with the same number of cells. The 
native heart cell population, which we call Native (~50%CM: 50%CF) was generated as 
described previously in section 2.2.1. Tissues were made with intermediate number of 
fibroblasts, which we call CM+ samples (~83%CM: 17%NM). Basically, 10% of the cell 
population was added from the TMRM-1 (sorted as described above in 4.2.2), and 90% 
of the TMRM+ CM++ population (93%CM: 7%NM). Lastly, we created a myocyte-
enriched population, which we call CM++ that contained the TMRM+ population that we 
sorted as described above in 4.2.2. (93%CM:7%CF). All of the experiments were 
performed paired, with cardiac cells from the same cell isolation to account for potential 
variations in contractility between isolations.  
Contractile measurements on the tissues were performed on the same day for all 
arrays. However, because different proportions of fibroblasts lead to different length of 
time of tissue formation (i.e. the higher the fibroblast concentration the faster the tissue 
formed), we adjusted the surfactant (Pluronic 127) (Legant et al. 2009) concentration 
with which we coated the PDMS surface of the microtissue arrays to provide more 
surfactant with less sticking to the PDMS substrates for slower-forming tissues. For 
example, arrays used for the CM++ population were coated with 1% Pluronic F127 
overnight (without spinning down). The arrays for the CM+ cell population were treated 
with 0.1% and Native population 0.01%..  In all cases, the Pluronic 127 is spun down the 
next day and left for 30 minutes to prevent PDMS and cell-extracellular matrix  
interactions. Two washes with 1X PBS were made to remove the excess Pluronic F127. 
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4.3 Results  
4.3.1 Characterization of resting and twitch force generation with different concentration 
of fibroblasts 
To determine contractile responses of different concentration of fibroblasts on 
engineered tissues, we used flow cytometry to separate nonmyocytes and CMs from the 
neonatal rat hearts and engineer tissues with different concentrations in arrays of 
cantilevers with a spring constant of [k=0.20 µN/µm]. The samples were prepared as 
described in 4.2.3. We carried out a one-way multivariate analysis of variance to 
determine the effect of hypertrophic factors on change in resting force in cardiac 
microtissues tethered.  Data are mean ± SEM unless otherwise stated. Values of change 
in resting force (Figure 22) were normally distributed, as assessed by Shapiro-Wilk's test 
(p > .05), and there were no outliers in the data, as assessed by Grubbs' test. There 
were statistical significant differences in resting force between tissue types. At day 0, the 
resting force of the Native tissues was Fday0 = 9.95±3.00 which is 21% higher than CM+ 
tissues (Fday0 = 8.24±0.78, p<0.01) and 119% larger than in the CM++ tissues (Fday0 = 
4.55±1.89, p<0.0001). The resting force in the CM+ tissues was 81% higher than in the 
CM++ tissues (p<0.001). Within each group of tissues, there was no statistically 
significant difference in the change in resting force between day 0 and day 1 (Native: 
Fday0= 9.95±3.00 vs. Fday1 = 11.8 ± 3.24; CM+: Fday0 = 8.24±0.78 vs. Fday1 = 7.72 ± 1.50; 
CM++:  Fday0 = 4.55±1.89 vs. Fday1=3.9±1.53), though time-dependent increases tended 
to occur in the Native tissues while time-dependent decreases were observed in the 
CM+ and CM++ tissues.  As a result, the intergroup differences in resting force were 
even more pronounced at day 1. 
 
We also measured the twitch force generated by the microtissues with different 
proportions of nonmyocytes. At day 0, the twitch force of the Native tissues was 
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Fday0 = Fday0 = 3.23±0.48, which is 13% higher than CM+( Fday0 = 2.85 ±0.59, p=0.05) and 
48% larger than in the CM++ sample (Fday0 = 2.18±0.56, p=0.005). Similar to resting 
tension, within each group of tissues, there was no statistically significant difference 
between the twitch force produced from day 0 and day 1 ( Native: Fday0 = 3.23±0.48 vs. 
Fday1 = 2.60±0.64; CM+: Fday0 = 2.85 ±0.59 vs. Fday1 = 2.88±0.43; CM++: Fday0 = 
2.18±0.56 vs. Fday1 = 2.09 ±0.77). Pairwise analysis revealed statistically significant 
differences across samples. At day 1, the twitch force developed by microtissues with 
the Native population of cells (Fday1 = 2.60±0.64) was 10% less than that of CM+ (Fday1 = 
2.88±0.43, p=0.045) and 24% greater than that of CM++ (Fday1 = 2.09 ±0.77, p=0.011). 
At day 1, the twitch force for CM+ tissues was 38% greater than in CM++ tissues 
(p<0.01). Therefore, an increasing proportion of fibroblasts has significant, but 
quantitatively smaller, effects on twitch force than on resting force. 
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Figure 25. Resting and Twitch force generation in CMTs engineered with different number 
of fibroblasts. After CMTs were formed and synchronously beating, baseline force 
measurements at day 0 were acquired. Brightfield images were used to calculate the resting force 
(A). Using a high-speed camera, we collected data of the displacement of the cantilevers over 
multiple contractions (B). We observed that depletion of fibroblasts leads to lower resting forces 
and tends to lower twitch forces.  The bar graph above represents the average peak force for 3-5 
contractions across multiple tissues (n=15) (B). 
 
 
 
4.3.2 Contractile kinetics profile in CMTs after 24 hours of hypertrophic agonist 
treatments 
We also explored how contractile kinetics would respond to different amounts of 
fibroblasts. There was no difference in change in Vmax from day 0 and day 1 for  all of 
the samples, however, there were differences among the different groups. At day 0 and 
day1, the maximal velocity of contraction increased was highest for the Native (VmaxC 
day0 = 85.47 ±5.51 vs. VmaxC day1 = 86.63 ±2.70) than the maximal velocity for CM+ 
(VmaxC day0 = 70.49 ±4.11 vs. VmaxC day1 = 74.20 ±3.73) and the CM++ CMTs (CM++: 
VmaxC day0 = 52.35 ±3.64 vs. VmaxC day1 = 60.59 ±2.43). To determine differences of 
maxima velocity, we performed a One-way ANOVA, to compare values of maximal 
velocity at day 1. There was a statistically significant difference between the Native and 
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CM+ (p=0.004) as well as CM++ (p<0.001). There was also a statistically significant 
difference betweem CM++ and the CM+ microtissues (p=0.003). 
For maximal relaxation velocity , There was no difference in change in Vmax 
from day 0 and day 1 for  all of the samples, however, there were differences among the 
different groups. At day 0 and day1, the maximal velocity of contraction increased was 
highest for the Native (VmaxR day0 = 75.37 ±5.03 vs. VmaxR day1 = 78.72±7.73), as 
compared to CM+ (VmaxR day0 = 55.47±4.38 vs. VmaxR day1 = 61.10 ±8.11) and the CM++ 
(VmaxR day0 = 44.92±6.80 vs. VmaxR day1 = 49.96 ±6.85). There was a statistically 
significant difference between the Native and CM+ (p<0.001) as well as CM++ 
(p<0.001). There was also a statistically significant difference betweem CM++ and the 
CM+ microtissues (p=0.02).  
Similar to the results with native heart cell population described in the Chapter 2, 
we observed no statistically significant changes between the ratio of VmaxRelaxation 
/Vmax Contraction in the Untreated sample and ET-1 treated with hypertrophic agonists 
for 24 hours. Furthermore, the ratios of VmaxRelaxation /Vmax Contraction were similar 
across all samples. We did not observe any statistically significant change in this ratio, 
indicating, that the equilibrium between contraction and relaxation are maintained. 
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Figure 26. Contractile kinetics profile in CMTs with different number of fibroblasts. Using a 
high-speed camera, we tracked the displacement of fluorescent beads atop of CMTs, and 
calculated kinetics of contractility. Bars represent the average of individual tissues velocities over 
3-5 twitches. Vmax Contraction (A),Vmax Relaxation (B), VmaxRelaxation /Vmax Contraction (C), were 
calculated from the data. Our results show that increasing the number of fibroblasts leads to 
increases in maximal velocities of contraction and relaxation.  Student’s t-test was used to 
compare between day0 and day1;  * denotes p<0.05 and ** denotes p<0.005. 
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4.3.3 Resting sarcomere length in microtissues engineered with different number of 
nonmyocytes 
To determine the effect of nonmyocytes in sarcomere length, we measured 
sarcomere length by fixing the samples as described in 2.2.5. As presented in Figure 24, 
At day 1, the resting sarcomere length by microtissues with the native population of cells  
(SL=1.76±0.02) was statistically significantly longer than that of CM+ (SL =1.71±0.02, 
p=0.057) and CM++ (SL = 1.66±0.01, p<0.0001). CM+ samples difference with CM++ 
was p=0.045.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Resting sarcomere length in microtissues engineered with different number of 
fibroblasts. Immunofluorescent images of microtissues attached to cantilevers stained with a-
actinin were used to detect sarcomeres and measure sarcomere length (as described in 2.3.4). 
Our results show that increasing fibroblast number in the tissues leads to increases in sarcomere 
length. Student’s t-test was used to compare between an agonist treatment and the Untreated 
sample;  * denotes p<0.05 and ** denotes p<0.005  
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4.3.4 ET-1 response in myocyte-enriched tissues  
 
 
As described in Chapter 2, ET-1 induced the greatest resting and twitch forces in 
microtissues compared to other hypertrophic growth factors. We also observed and 
increase in sarcomere length that corresponded to the ET-1 treatment. By performing 
these experiments in myocyte-enriched preparations, we sought to investigate the role of 
fibroblasts in the responses observed during ET-1 exposure. In myocyte-enriched 
tissues, we observed negligible changes in resting force after ET-1 treatment compared 
to untreated tissues (Fig. 28A). However, we observed significant changes in twitch 
force after ET-1 addition (Fig. 28B). Interestingly, this ET-1 induced increase in twitch 
force was associated with a substantial increase in sarcomere length (Fig. 28C).  This 
change in sarcomere length after ET-1 exposure in myocyte-enriched tissues was 
quantitatively greater than that observed after exposure to ET-1 in native tissues (Native: 
SLUntreated =1.89 ± 0.03 and SL ET-1 =2.02 ± 0.07 vs. CM-enriched: SLUntreated =1.64 ± 0.03 
and SLET-1=1.91± 0.11, p-value for intergroup difference in the change with ET-1 p= 
0.001). 
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Figure 28. Resting and twitch force, and Sarcomere length measurements after 24 hours of 
ET-1 treatment in myocyte-enriched tissues (CM++). As described previously, baseline force 
measurements at day 0 were acquired after all tissues were synchronously beating. Brightfield 
images were used to calculate the resting force (A). Using a high-speed camera, we collected 
data of the displacement of the cantilevers over multiple contractions (B). Our data shows that 
ET-1 does not lead to a statistically significant effect in resting force (A), however it does lead to a 
statistically significant effect in twitch force in myocyte enriched tissues (CM++). Sarcomere 
length was increased upon stimulation of ET-1 for 24 hours.  
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 4.3.4 Length-tension relationship in CM-enriched microtissues  
 
 
We next evaluated how the resting length of the tissue correlated with twitch 
force generation in ET-1-treated and Untreated myocyte-enriched microtissues.  The 
Untreated tissues exhibited a weak but positive length-tension relationship R2=0.30 
p=0.012, the longer the tissue the higher the twitch force generated (Figure 29A). On the 
other hand, the ET-1 treated samples exhibited a negative length-tension relationship, 
with longer tissues having lower twitch force R2=0.74, p=0.001 (Figure 29B). These data 
indicate that while ET-1 treatment does not induce a significant change in average 
resting force (Figure 29A), the final resting length observed in individual microtissues is 
strongly and inversely correlated with the twitch force generated, such that the shortest 
tissues generate the highest twitch forces in myocyte enriched preparations. 
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Figure 29. Correlation of the tissue length and twitch force at 1 day after ET-1 treatment in 
myocyte-enriched tissues (CM++). The twitch force and tissue length after 24 hours of ET-1 
were plotted against each other. A linear regression analysis and a correlation coefficient R2 were 
determined. In the Untreated sample (N=20), 30% of the variance in twitch force generation was 
related to the tissue length at day 1. In the ET-1 sample (N=20) we observed that 74% of the 
variance in twitch force generation was related to the tissue length at day 1.  
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4.3.5 Kinetics of ET-1 treated myocyte enriched microtissues 
 
We also assessed how contractile kinetics were impacted by the addition of ET-1 
over 24 hours, as illustrated in Figure 27. The Untreated sample started at VmaxC day0 = 
77.53±3.0, changed minimally the following 24 hours, reaching VmaxC day1 = 72.73±2.49, 
which was not statistically significant. Meanwhile, while ET-1 VmaxC day0 = 78.87±6.04, 
the maximal velocity of contraction increased by twofold upon the addition of ET-1 over 
24 hours to  VmaxC day1 = 144.38±7.65 (p<0.0001) 
Relaxation Velocity also increased significantly upon the application of ET-1 over 
24 hours.  There wasn’t a statistically significant difference in the baseline relaxation 
Vmax at day 0 across samples (Untreated: VmaxR day0 = 60.72±2.11 vs ET-1: VmaxR day0 
= 65.79±6.44). The Untreated sample did not change significantly in the next 24 hours 
(VmaxR day1 = 50.77±2.22), while the exposure of ET-1 for 24 hours increased the 
relaxation velocity by 91% (ET-1: VmaxR day1 = 115.91±5.78, p<0.001). 
Similar to the results with native heart cell population described in the Chapter 2, 
we observed no statistically significant changes between the ratio of VmaxRelaxation 
/Vmax Contraction in the Untreated sample and ET-1 treated with hypertrophic agonists 
for 24 hours. Furthermore, the ratios of VmaxRelaxation /Vmax Contraction were similar 
across all samples. We did not observe any statistically significant change in this ratio, 
indicating, that the equilibrium between contraction and relaxation are maintained.  
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Figure 30. Contractile kinetics profile in CMTs after 24 hours of hypertrophic agonist 
treatments. Using a high-speed camera, we tracked the displacement of fluorescent beads atop 
of CMTs, and calculated kinetics of contractility. Bars represent the average of individual tissues 
velocities over 3-5 twitches. Maximum velocity of contraction (Vmax Contraction) (A),Vmax 
Relaxation (B), Vavg Contraction (C), Vavg Relaxation (D), VmaxRelaxation /Vmax Contraction (E) 
were calculated from the data.  Our results show a statistically significant increase in maximal 
velocities of contraction and relaxation after ET-1 treatment.  Student’s t-test was used to 
compare between day0 and day1;  * denotes p<0.05 and ** denotes p<0.005. 
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4.4 Discussion 
 
 
In this chapter, we examined the impact of differences in the proportions of 
cardiac myocytes on the contractility of engineered auxotonically-loaded 
CMTs.  Additionally, we examined the effect of ET-1 in myocyte-enriched tissues and 
determined how tissue length and sarcomere length are associated to these changes in 
contractility.   
Our results indicate that microtissues engineered with the native heart cell 
population with roughly 50% cardiac myocytes have enhanced contractile properties with 
higher tissue compliance than the microtissues engineered with moderately reduced 
fibroblast content (CM+) and highly myocyte-enriched (CM++) cell populations. The 
enhanced contractile performance of the tissues was determined by higher resting and 
twitch force generation as well as longer sarcomere lengths. Our results concur with 
previous studies that have described a superior contractile profile for engineered tissues 
generated from the native heart cell population (Radisic M et al. 2008, Asnes CF et al.  
2006). The microtissues created with an intermediate fibroblast concentration, revealed 
contractile performance that was in between the native heart cell population and the 
myocyte-enriched population, indicating that there is a an association between 
increasing number of nonmyocytes and increasing resting and twitch force, as well as 
maximal contraction and relaxation velocities. Similarly, the sarcomere length 
measurements indicate that increasing the number of nonmyocytes in the microtissues 
leads to longer resting sarcomere lengths. These results underscore the importance of 
quantifying nonmyocytes in cardiac tissues, particularly when measuring forces in 
auxotonically loaded engineered tissues.  
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Our understanding of the length-tension relationships in heart tissue has been 
limited by the inability to control the cell content in the tissue, and understand how 
nonmyocytes contribute to contractile responses. The experimental loading conditions of 
isolated tissue strip systems have mainly been limited to isotonic (constant force), and 
isometric (constant length) setups, where the tissue length or sarcomere length are set 
to a specific value. Under the isometric conditions typically utilized (often at the tissue 
length associated with maximal twitch force, Lmax) the potential impact of how the 
nonmyocyte population dynamically affects the resting sarcomere length of myocytes, 
and thus their contractility, is not taken into consideration. Our previous work (Chapter 2) 
revealed a negative length - twitch force response in microtissues engineered with the 
native heart cell population, a relationship that was further exacerbated by the treatment 
of hypertrophic factors (Figure 5). These results led us to believe that the shorter resting 
length (or higher resting force) was possibly governed by activated nonmyocytes. In this 
chapter, we demonstrate that depleting nonmyocytes in microtissues (myocyte-enriched 
microtissues), yields a statistically significant positive length-tension relationship in 
Untreated samples. While the overall compliance of the tissue is reduced with the 
depletion of nonmyocytes, this experimental setup allow us to discern myocyte-governed 
contractile responses in auxotonically-loaded tissues, where longer lengths are 
correlated with higher twitch force generation. Consequently, auxotonic loading 
conditions in microtissues, which characterize cardiac tissue behavior in physiological 
conditions, reveals an interesting nonmyocyte governed behavior of tissue length – 
sarcomere length – twitch force generation.  
Interestingly, after treating the microtissues with ET-1, we see a negative length 
–tension relationship. While our enrichment methods yields higher myocyte purities than 
previously described for pre-plating methods, (75%-90% purity, Chlopcíková S et 
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al.2011 , Brown MA et al. 2009) the nonmyocyte depletion is not absolute.  This leads us 
to consider the possibility that ET-1 activates the nominal nonmyocyte population in the 
myocyte-enriched tissues. While this effect does not yield statistically significant changes 
in resting force, it does reveal that nominal differences in tissue length among the 
different microtissues in the array, that strongly influence twitch force generation. Based 
on previous work we know that ET-1 activation in nonmyocytes leads to proliferation and 
myofibroblast differentiation (Rodriguez-Pascual F et al.  2014), a cell population that is 
characterized by having muscle-like properties, including higher force-generating 
capabilities compared to inactivated fibroblasts. This contractile “phenotype” of the 
fibroblasts leads to more elongation of the myocytes as previously described (Nichol et 
al. JW 2008), and thus, as we observe here, a longer sarcomere length. Previous 
studies have suggested that the fibroblast can affect on myocytes contractility by direct 
interaction with  myocytes as well as by the release of paracrine factors (Nichol et al. JW 
2008, Pedrotty DM et al. 2009). Additionally, we also observed a low R2 value in the 
length-tension relationship in the Untreated sample in the myocyte-enriched 
microtissues. Given that fibroblasts govern the resting force, it is possible that small 
differences in number of fibroblasts as well as levels of activation (due to the forces 
applied during isolation and sheer stress during flow cytometry) lead to variations in 
tissue length and thus a lower R2 value in the positive length-tension relationship. 
Further work looking at the mechanism of the fibroblast effects on myoctes should be 
considered. 
  It is also possible that ET-1 affects cytoskeletal organization and myofilament 
properties directly. A Kruger at al. showed that Angiotensin II triggers a transition of titin 
isoform switch from N2A to the stiffer isoform N2B (expected to cause smaller 
sarcomere lengths) (Kruger M et al. 2008). Interestingly, ET-1 does not promote the 
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transition to the stiffer N2B isoform, and may potentially block the isoform switch.  This 
would suggest that ET-1 might favor the more distensible N2BA isoform, and hence 
produce longer sarcomere lengths in our model.  
Further work, using auxotonically-loaded single cells or an entirely pure myocyte 
engineered tissue, could reveal additional insights into the direct effect on ET-1 on 
myocyte cytoskeletal properties.  
Based on our knowledge of fibrosis and pathological cardiac remodeling that lead 
to cardiac dysfunction, it is possible that the positive effect of nonmyocyte number on 
sarcomere length reaches a plateau, and becomes negative in the presence of a high 
nonmyocyte population.  
 In summary, this study reveals novel insights regarding the effect of 
nonmyocytes in the contractile profile of auxotonically-loaded microtissues. Our work 
reveals an interesting relationship between decreasing number of nonmyocytes and 
resulting decreases in resting force, twitch force, maximal contraction and relaxation 
velocities as well as sarcomere length. Particularly, it provides data demonstrating 
potential distinctions between sarcomere length and overall tissue length in 
auxotonically-loaded microtissues engineered with varying proportions of heart cell 
subtypes. These studies also highlight how differences in cell proportions can alter 
agonist-mediated responses in engineered hearts tissues. Further studies generating 
microtissues with different proportions of myocytes to nonmyocytes should reveal 
interesting insights about the effects of the different cells in the contractility of cardiac 
tissue and reveal new insights about the mechanisms associated with different cell-type 
contributions.   
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4.5 Limitations 
It is important to highlight some limitations of these studies. Firstly,  paired 
measurement of sarcomere length and contractile parameters, was not performed in 
these studies. Future studies should be performed such that each tissue’s contractile 
properties are paired with its myocytes’ sarcomere length. Additionally, it is important to 
note that sarcomere length was measured in fixed tissues, therefore it is possible that 
the fixation may have altered the absolute sarcomere length. However, the differences 
between groups should be consistent, as we performed sarcomere length 
measurements in parallel, and using the same fixation reagents and protocols.  
Additionally, it is possible that there are variations in the number of nonmyocytes 
in each tissue sample, and variations in the level of fibroblast-to-myofibroblast 
differentiation. Further assessments of the nonmyocyte population in the tissues should 
reveal interesting insights about the effects of the different cells in the contractility of 
cardiac tissue and reveal new insights about the mechanisms associated with different 
cell-type contributions.   
Moreover, the cells from native heart mix population were not exposed to the 
effects of sorting. While previous work in our lab revealed little damage to cells after 
exposure to cytometry sorting, this damage can be assessed by creating tissues with a 
50:50 proportion of myocytes to nonmyocytes reconstituted the same way as the 
isolated cells. Furthermore, engineering tissues that have a larger nonmyocyte 
population than the myocyte population (myocyte depletion) resembling a fibrotic heart 
tissue, would provide novel insights as to the effect of number of nonmyocytes in 
contractility and sarcomere length.  
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CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Conclusions 
 
The purpose of these investigations was to evaluate the differential effects of 
hypertrophic factor stimulation on cardiac contractility using an in vitro culture method 
that recapitulates the 3D in vivo organization of the myocytes and nonmyocytes to 
identify mechanisms by which these factors influence myocardial structure and function 
in vivo. We demonstrated the ability of our system to dissect differential contractile 
profiles in response to agents implicated in cardiac hypertrophy, namely, Ang II, ET-1, 
and TGF-β, as well as increased load by simultaneously measuring the contractile force, 
velocity, and power produced by auxotonically-loaded CMTs. Additionally, we examined 
how tissue length and sarcomere length are associated with these changes in 
contractility.  
While the effects of these hypertrophic factors have been studied in in vivo 
(Souders CA et al. 2012, Bujak M and Frangogiannis NG 2007) and in vitro models, both 
in flat culture (Schaub MC et al. 1997, Sadoshima J et al. 1993) and in 3D culture 
(Horton RE et al. 2016, McCain ML et al. 2013, Hirt MN et al.  2012) less is known about 
how engineered tissues in auxotonic preparations can recapitulate these changes in 
contractility. Furthermore, we realized that little is known about how sarcomere length 
and length-tension relationships play a role in contractile performance in cardiac 
engineered tissue studies using auxotonic preparations. Yet, the sarcomere is the 
fundamental structural unit involved in force generation within cardiomyocytes, and 
resting sarcomere length is major determinant of both resting and twitch force in cardiac 
myocytes and the intact myocardium. Accordingly, assessment of sarcomere 
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length is essential for determining how pro-hypertrophic factors are affecting contractile 
performance. For example one group, published a positive inotropic response in 
engineered tissues in an isometric preparation, and a negative inotropic response for 
millimeter-length tissues in an auxotonic preparation.  However, there were key 
differences in the culture conditions. For example, in the second study, thyroid hormone 
triiodothyronine (T3), a physiological hypertrophic factor implicated in increases in 
sarcomere lengths of cardiac cells (Rodriguez AG et al. 2011, Yang X et al. 2011), was 
used to substitute for serum in the culture conditions, and could have contributed to the 
differences in inotropic responses. However, the myocyte sarcomere length was not 
noted. Our results indicate that for microtissues engineered with a native heart cell mix, 
ET-1 elicits a larger positive inotropic effect in auxotonic twitch force and resting force 
generation compared to Ang II. TGF-β, in contrast, produced a negative inotropic 
response. In other words, ET-1 produced the largest change in force, while AngII 
produced a moderate increase and TGF-β resulted in a decrease in twitch force 
generation. Interestingly, we observed that the sarcomere length of myocytes in tissues 
treated with ET-1 was longer than those in the Untreated, Ang II and TGF-β (shorter 
than in the Untreated), suggesting that at least some of the effects on contractility could 
be attributed to changes in sarcomere length induced by the hypertrophic factor. 
Furthermore, while the correlation of sarcomere length and twitch force generation goes 
hand in hand with what is expected from the Frank-Starling relationship (Konhilas JP et 
al. 2002), we observed a counter-intuitive correlation between sarcomere length and 
tissue length. The longer the sarcomere length, the shorter the tissue, and the higher the 
resting force. Sarcomere length and tissue length are usually positively controlled 
variables in isolated muscle preparations obtained from mature hearts. Changes in 
sarcomere length in myocytes within relatively immature engineered heart tissues had 
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not been previously noted.   
The finding that myocytes exhibiting longer sarcomere length while the overall 
tissue length was shorter led us to speculate that the tissue length, or resting force, 
could be regulated by nonmyocytes in our auxotonically-loaded engineered microtissues 
system.  The importance of nonmyocyte in engineering cardiac tissues has been 
previously noted (Radisic M et al. 2008, Nichol JW et al. 2008). Nonmyocytes have been 
shown to enhance resting and twitch force generation in engineered cardiac tissues 
(Asnes CF et al. 2006), elongated cells (Nichol JW et al. 2008 ), greater inotropic 
response (Naito H et al. 2008). However, how the number of nonmyocytes plays a role in 
sarcomere length in myocytes has not been previously studied. We developed 
engineered tissues with increasing number of myocytes (and decreasing number of 
nonmyocytes). Namely we engineered three types of tissues: Native heart cell mix (CM: 
50% - NM: 50%), Cm+ (CM:83% - NM:17%), and CM++ (CM:93% - NM:7%).  Our 
results suggest that microtissues engineered with the native heart cell population with 
roughly 50% cardiac myocytes have enhanced contractile properties than the 
microtissues engineered with moderately reduced fibroblast content (CM+) and highly 
myocyte-enriched (CM++) cell populations. The enhanced contractile performance of the 
tissues was determined by higher resting and twitch force generation in association with 
longer sarcomere length.  
Moreover, we observed a moderate positive length-tension response in 
Untreated microtissues composed of mostly myocytes (CM++), but upon stimulation of 
ET-1, we observed a small and non-statistically significant increase in resting force in 
tissues treated with ET-1. However, when we looked at each tissue individually, we 
observed that small differences in length correlated with differences in twitch force 
generated. In particular, we observed that the shorter the tissue, the higher the twitch 
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force generated. It is possible that the small amount of  (~7% nonmyocytes) 
nonmyocytes present in the tissue were enough contribute to the resting force and tissue 
length–tension relationship. However, this does not preclude whether other unidentified 
direct effects on myocytes are also involved (discussed below, in Future Directions 
section).  
To further understand the contractilility of microtissues in response of 
hypertrophic effectors, we evaluated the effect of increased auxotonic load or afterload 
of the cantilevers by 2.25x.  Increasing mechanical load led to structural and functional 
phenotype changes in our microtissue model, demonstrating the potential of engineered 
cardiac constructs as a platform for studying in vitro effects of complex stimuli, including 
the combination of biochemical and load enhancement, that occur in vivo. Treatment 
with AngII, ET-1 and the cocktail of hypertrophic factors induced significant increases in 
cell size in stiff pillars, but not in soft pillars.  Studies performed in vitro in 2D cell culture 
systems have previously shown that myocytes increase in size in response to these 
hypertrophic factors, irrespective of mechanical load (static stretch) (Sadoshima J et al. 
1993). One challenge with these flat cell culture substrates is that cells are exposed to 
the stiffness of the plate, making it harder to distinguish between the load-mediated 
effects and the hypertrophic factor effects. 
Taken together, these studies have provided insights into the mechanisms by 
which hypertrophic effectors modulate contractility in auxotonically-loaded engineered 
tissues.  
 
 
5.2 Future Directions   
 
Future experiments will extend our understanding of how mechanical, soluble 
and cell interaction cues regulate myocyte contractility. Particularly, 
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further studies should focus on the mechanisms by which nonmyocytes, and 
hypertrophic factors affect the sarcomere length of tissues. Further refinements of the 
model, such as inhibitor studies, enhancements in loading conditions as well as live 
sarcomere imaging could prove useful for future studies.  
 
5.2.1 Nonmyocyte effect on auxotonic contractility and sarcomere length 
In our study, increasing fibroblast number in microtissues increased contractility 
and sarcomere length, so we suspect that nonmyocytes mediate the changes in 
sarcomere length in Untreated and ET-1 treated tissues.  While previous studies showed 
that increased stiffness led to increased sarcomere length of myocytes (Rodriguez AG et 
al. 2011, Torre I  et al. 2014), the basis for this relationship is not clear.  It is possible that 
the presence of fibroblasts  increase the stiffness of the tissue and thus affect sarcomere 
length via ECM modulation or higher resting force. Measuring stiffness of the tissue 
using a nanoindentator and over a series of tissue lengths could reveal whether the 
presence of nonmyocytes affects the overall stiffness of the tissue. Furthermore, 
fibroblasts induce ECM changes, such as increases in collagen and fibronectin in 
response to hypertrophic factors, such as Ang II (Gray MO et al. 1998, Sadoshima J et 
al. 1993, Sarkar S et al. 2004).  These changes in ECM can induce changes in 
myocytes, as myocytes cultured on collagen display enhanced physical association 
between cytoskeletal components, for example myocyte surface integrins interact with to 
mediate cellular hypertrophy (Lal H et al. 2007, Lal H et al. 2009).  
It is also possible that nonmycytes regulate sarcomere length in myocytes 
directly via cell-cell interactions, and thus may be pulling on and deforming the 
myocytes. Mechanical adherens junctions (cadherin) and electrical gap junctions 
(connexin) are heterocellular junctions that have been well studied in myocyte and  
107	
fibroblast interactions.  For example, connexin 43 has been shown to dorm 
heterocellular junctions between nonmyocytes and myocytes. We could test the 
importance of these junctions in our system, by. Inhibiting these junctions using              
β-glycyrrhetinic acid (BGA). Additionally, previous studies showed that stimulating 
fibroblasts with TGF-β to induce a myofibroblast phenotype, leads to increase 
expression of N-cadherin junctions and a decrease in expression of connexin 43 
junctions (Thompson SA et al. 2011), decreasing electrophysiological function, and 
induces an arrythmogenic effect. Using live cell imaging, they showed that 
myofibroblasts were capable of pulling on and deforming the myocyte cell membrane. 
This mechanical deformation is key to the cell aspect ratio of myocytes, which plays an 
important role in the contractility of myocytes (Bray MA et al. 2008). Furthermore, pre-
treatment with blebbistatin or by using double knowckdown Rho fibroblasts to inhibit the 
contractility of nonmyocytes restored electrophysiological function. While this group did 
not see Cadherin 11 (OB-Cadherin) in heterocellular junctions, other groups have 
demonstrated the importance of Cadherin 11 to be the predominant cadherin in 
myofibroblasts alone or in combination myocytes both in vitro and in vivo (Bowen CJ et 
al. 2015,  Borg TK and Baudino TA). Furthermore, investigating other possible junctions, 
such as integrins, other connexins, intercalating disks, desmosomes , tight junction 
proteins (Bowers SL 2012, Kakkar R and Lee RT 2010), which are mechanically 
anchored to the actin cytoskeleton could provide insights into whether these interactions 
can affect sarcomere length. The hypothesis that heterocellular junctions mediate the 
stretch of myocytes, as well increases in sarcomere length, can be addressed by 
blocking these heterocellular junctions with neutralizing antibodies or inhibiting the 
contractile properties of the nonmyocyte population. Therefore, further investigating the 
type of heterocellular junction that predominate in engineered tissues, and inhibiting 
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these interactions could lead to better understanding of how fibroblasts affect myocytes 
and sarcomere length in our tissues.  
Other possible contributors to our findings are paracrine interactions. As we 
discussed in Chapter 1, there is intercellular paracrine communication that occurs upon 
stimulation of AngII, ET-1 and TGF-β in myocytes and nonmyocytes. Many factors are 
part of this autocrine/paracrine interaction, such as LIF, CT-1, MMP, TIMPs, etc. For 
example, a previous study showed that engineered cardiac tissues co-cultured with 
nonmyocytes led to myocyte elongation coupled with the expression of active MMP-2 
protein (not present in CM-enriched constructs), increased pro-MMP-2, and reduced pro-
MMP-9 expression (Nichol JW et al. 2008). Additionally, they showed that nonmyocytes 
led to a decrease in myocyte apoptosis, further confirming the importance of 
nonmyocytes in cardiac tissue. Interestingly, MMP inhibition studies suggested that 
MMP-1 is required for the cell elongation observed in the co-culture of nonmyocyte with 
myocytes in engineered tissues (Nichol JW et al. 2008). Furthermore, Radisic M et al. 
showed that pre-treating polymer scaffolds with cardiac fibroblasts before myocyte 
seeding, led to greater tissue contractility and myocyte alignment suggesting a paracrine 
effect from fibroblasts (Radisic M et al. 2008). 
Further evaluation of our system’s nonmyocyte effects in the tissue is needed to 
better understand the relationship of nonmyocyte number with sarcomere length and 
contractility. Better understanding of the interaction between myocytes and nonmyocytes 
in physiology and how they change in pathophysiology could provide novel insights of 
the importance of nonmyocytes in cardiac contractility.  
 
5.2.2 ET-1 effect on sarcomere length 
Our studies showed that ET-1 came out to be the largest modulator of 
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contractility and samples treated with ET-1 had the largest increases in sarcomere 
length.  However, endothelin receptor antagonists have failed in clinical trials (Ertl G and 
Bauersachs J, 2004). Understanding the signals involved in transducing the hypertrophic 
actions of ET-1 to pathological mechanical remodeling in the heart will allow us to design 
selective therapies to prevent adverse cardiac remodeling. 
ET-1 could also have a direct effect on myocytes that induces changes in 
sarcomere length and contractility rather than simply a main effect on fibroblasts. A 
previous study showed that AngII induced a transition from the isoform of titin to the 
stiffer N2B isoform of titin, with shorter sarcomere length in neonatal rat ventricular 
myocytes. However, ET-1 did not promote the transition to N2B, leading to longer 
sarcomere lengths. If this were observed in our microtissues, then ET-1 might favor the 
more distensible N2BA isoform and induce longer sarcomere lengths in our model.  
Therefore, follow up studies to examining N2B and N2A levels after ET-1 administration 
or manipulating N2B/N2A levels independent of ET-1 would help inform this speculation 
(Kruger M et al. 2008). Furthermore, results from another study suggested titin, and not 
ECM, is primarily responsible for the  passive force (resting force) and sarcomere length 
in Lanfendorff perfused hearts. The role of titin in resting  force was determined by 
degrading titin without affecting the ECM, using a relaxing solution that incorporated 
dithiothreitol (DTT). DTT however, has also been associated with inhibition of fibroblast 
spreading (Grinnell F and Feld MK, 1980 ). Therefore, further work is warranted to parse 
out role of titin, which modulates passive force in myocytes,  and fibroblasts in resting 
force and myocyte sarcomere length in cardiac tissue. Interestingly, a recent study using 
microtissues engineered with iPS cells with Titin mutations, the authors did not observe 
any change in the tissue’s resting force, while in vivo, titin mutations and isoforms have 
been linked to differences in resting force (passive/diastolic force) (Hinson JT et al. 
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2015). It is possible that the contributions of titin and nonmyocytes to the resting force of 
cardiac tissue  vary from native tissue to engineered tissue. Understanding the signals 
involved in transducing the hypertrophic actions of ET-1 to pathological mechanical 
remodeling in the heart might allow design therapies to mitigate adverse cardiac 
remodeling. 
 
5.2.3 Mechanisms of contractile changes and inhibitor studies 
A limitation of this study is that the hypertrophic agonists have been known to 
affect each other. Ang II has been shown to increase the expression of ET-1 (Drawnel 
FM et al. 2013). Additionally, Ang II’s hypertrophic effects have been previously 
attributed to the actions of TGF-β. These effects have been shown in a longer time 
scale. However, because of the nature of the micro-scale of our system where diffusion 
can occur within minutes, it is likely that these effects would occur in a shorter timescale. 
Future studies could address the potential of the hypertrophic factors inducing one 
another using selective antagonists and/or genetic manipulations of particular agonists 
or receptors. Additionally, extending our experiments beyond 48 hours could provide 
other insights of longer-term effects of these factors on the resting and twitch force 
changes.  
 
5.2.4 Effect of loading conditions on contractility and sarcomere length 
We observed that increased load led to shorter sarcomere lengths as well as a 
slower velocity generation described previous studies (Edmund Sonnenblick 1962). A 
limitation of our studies is that we only tested two loads. Further studies should consider 
a range of loads to parse out load dependent effects in contractility and sarcomere 
length. Additionally, given that the stiff arrays are already made at the time we add the 
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cells, the increased load not only affects the cells after the tissue is formed, but also 
during its formation. Further model refinements should consider utilizing materials that 
allow us to selectively modify load after tissue formation.  
Moreover, different loading conditions (isometric, isovolumetric and auxotonic), 
have led to differences in inotropic responses (Layland J et al. 2004), therefore looking 
at how different conditions lead to changes in contractile responses would be valuable. 
While auxotonic load more closely resembles contractility of the heart in vivo, most 
studies in isolated papillary muscles have been done in isotonic and isometric 
preparations. Better understanding of how results of auxotonically-loaded tissues 
compare to previous studies is difficult with our current mode. Further refinements of our 
model should allow for comparisons of force and kinetics after agonist treatments 
under different loading conditions. 
 
5.2.5 Live sarcomere length measurements 
In its current configuration, this system does not allow for real-time measurements of 
sarcomere length in live tissues. Sorting out the dynamic sarcomere changes that occur 
in vivo and in vitro (measuring changes live, for example, with laser diffraction 
techniques) could provide additional insight into the sarcomere changes that we 
observed.  Additionally, force is dependent sarcomere length-dependent changes in 
myofilament calcium sensitivity, as well as calcium concentration, additional studies 
should evaluate additional factors that contribute to changes in force.  
These data reinforce the ability of engineered tissues to decouple different 
factors that contribute to cardiac remodeling. Future studies in this field will better 
describe how multiple factors, including mechanical, biochemical and cell-specific effects 
interact to produce a coordinated contractile output.  Additionally, we highlight the 
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importance of sarcomere length, when determining inotropic contractile responses of 
cardiac tissue. Furthermore, our results suggest that nonmyocytes are required to 
engineer highly functional cardiac tissue their communication with neighboring myocytes 
are important to in the study of cardiac contractility and remodeling.  
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APPENDIX  
 
STATISTICAL ANALYSIS 
Variable Labels: 
 
Stffness  Factor 
0 
(k=0.20uN/um) 
Untreated 0 
Cocktail 1 
TGF-B 2 
Ang II 3 
ET-1 4 
  
1 
(k=0.45uN/um) 
Untreated 0 
Cocktail 1 
TGF-B 2 
Ang II 3 
ET-1 4 
 
 
A1.1 RESTING FORCE 
 
Univariate Analysis of Variance 
 
Between-Subjects Factors 
 N 
Stiffness 0 147 
1 141 
Factor 0 63 
1 57 
2 63 
3 60 
4 55 
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Tests of Between-Subjects Effects 
Dependent Variable:   Delta1 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 1148.372a 9 127.597 23.269 .000 
Intercept 2659.370 1 2659.370 484.979 .000 
Stiffness 70.462 1 70.462 12.850 .000 
Factor 834.540 4 208.635 38.048 .000 
Stiffness * Factor 67.147 4 16.787 3.061 .017 
Error 1853.414 338 5.483   
Total 5542.352 348    
Corrected Total 3001.786 347    
 
a. R Squared = .383 (Adjusted R Squared = .366) 
 
 
Estimated Marginal Means 
 
1. Stiffness * Factor 
 
Estimates 
Dependent Variable:   Delta1 
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .603 .295 .023 1.183 
1 4.670 .375 3.933 5.408 
2 .808 .361 .097 1.518 
3 2.534 .396 1.756 3.313 
4 3.699 .443 2.828 4.569 
1 0 1.368 .428 .527 2.209 
1 4.172 .552 3.086 5.258 
2 1.322 .511 .317 2.327 
3 4.088 .349 3.401 4.775 
4 6.152 .451 5.266 7.039 
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Pairwise Comparisons 
Dependent Variable:   Delta1 
Fact
or 
(I) 
Stiffness 
(J) 
Stiffness 
Mean 
Difference (I-
J) Std. Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
0 0 1 -.765 .519 .142 -1.787 .257 
1 0 .765 .519 .142 -.257 1.787 
1 0 1 .498 .667 .456 -.814 1.811 
1 0 -.498 .667 .456 -1.811 .814 
2 0 1 -.514 .626 .412 -1.745 .717 
1 0 .514 .626 .412 -.717 1.745 
3 0 1 -1.554* .528 .003 -2.592 -.516 
1 0 1.554* .528 .003 .516 2.592 
4 0 1 -2.453* .632 .000 -3.696 -1.211 
1 0 2.453* .632 .000 1.211 3.696 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
Univariate Tests 
Dependent Variable:   Delta1 
Factor Sum of Squares df Mean Square F Sig. 
0 Contrast 11.893 1 11.893 2.169 .142 
Error 1853.414 338 5.483   
1 Contrast 3.059 1 3.059 .558 .456 
Error 1853.414 338 5.483   
2 Contrast 3.703 1 3.703 .675 .412 
Error 1853.414 338 5.483   
3 Contrast 47.535 1 47.535 8.669 .003 
Error 1853.414 338 5.483   
4 Contrast 82.742 1 82.742 15.089 .000 
Error 1853.414 338 5.483   
 
Each F tests the simple effects of Stiffness within each level combination of the other effects shown. 
These tests are based on the linearly independent pairwise comparisons among the estimated 
marginal means. 
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2. Stiffness * Factor 
 
Estimates 
Dependent Variable:   Delta1 
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .603 .295 .023 1.183 
1 4.670 .375 3.933 5.408 
2 .808 .361 .097 1.518 
3 2.534 .396 1.756 3.313 
4 3.699 .443 2.828 4.569 
1 0 1.368 .428 .527 2.209 
1 4.172 .552 3.086 5.258 
2 1.322 .511 .317 2.327 
3 4.088 .349 3.401 4.775 
4 6.152 .451 5.266 7.039 
Pairwise Comparisons 
Dependent Variable:   Delta1 
Stiffne
ss 
(I) 
Factor 
(J) 
Factor 
Mean 
Differe
nce (I-
J) 
Std. 
Error Sig.b 
95% Confidence 
Interval for 
Differenceb 
Lower 
Bound 
Upper 
Bound 
0 0 1 -4.068* .477 .000 -5.416 -2.719 
2 -.205 .466 1.000 -1.523 1.113 
3 -1.931* .494 .001 -3.326 -.536 
4 -3.096* .532 .000 -4.599 -1.593 
1 0 4.068* .477 .000 2.719 5.416 
2 3.863* .521 .000 2.391 5.334 
3 2.136* .545 .001 .596 3.677 
4 .972 .580 .948 -.667 2.611 
2 0 .205 .466 1.000 -1.113 1.523 
1 -3.863* .521 .000 -5.334 -2.391 
3 -1.727* .536 .014 -3.241 -.212 
4 -2.891* .571 .000 -4.505 -1.277 
3 0 1.931* .494 .001 .536 3.326 
1 -2.136* .545 .001 -3.677 -.596 
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2 1.727* .536 .014 .212 3.241 
4 -1.165 .594 .506 -2.842 .513 
4 0 3.096* .532 .000 1.593 4.599 
1 -.972 .580 .948 -2.611 .667 
2 2.891* .571 .000 1.277 4.505 
3 1.165 .594 .506 -.513 2.842 
1 0 1 -2.804* .698 .001 -4.777 -.831 
2 .046 .666 1.000 -1.837 1.929 
3 -2.720* .552 .000 -4.280 -1.161 
4 -4.784* .621 .000 -6.539 -3.029 
1 
0 2.804* .698 .001 .831 4.777 
2 2.850* .752 .002 .725 4.976 
3 .084 .653 1.000 -1.761 1.929 
4 -1.980 .713 .058 -3.993 .033 
2 
0 -.046 .666 1.000 -1.929 1.837 
1 -2.850* .752 .002 -4.976 -.725 
3 -2.766* .619 .000 -4.515 -1.018 
4 -4.830* .681 .000 -6.755 -2.905 
3 
0 2.720* .552 .000 1.161 4.280 
1 -.084 .653 1.000 -1.929 1.761 
2 2.766* .619 .000 1.018 4.515 
4 -2.064* .570 .003 -3.675 -.453 
4 
0 4.784* .621 .000 3.029 6.539 
1 1.980 .713 .058 -.033 3.993 
2 4.830* .681 .000 2.905 6.755 
3 2.064* .570 .003 .453 3.675 
 
 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Dependent Variable:   Delta1 
Stiffness Sum of Squares df Mean Square F Sig. 
0 Contrast 546.544 4 136.636 24.918 .000 
Error 1853.414 338 5.483   
1 Contrast 449.610 4 112.402 20.498 .000 
Error 1853.414 338 5.483   
 
Each F tests the simple effects of Factor within each level combination of the other effects shown. 
These tests are based on the linearly independent pairwise comparisons among the estimated 
marginal means. 
 
 
Univariate Analysis of Variance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Between-Subjects Factors 
 N 
Stiffness 0 148 
1 141 
Factor 0 64 
1 57 
2 63 
3 60 
4 55 
Tests of Between-Subjects Effects 
Dependent Variable:   Delta2 
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 105.084a 9 11.676 2.768 .004 
Intercept 488.906 1 488.906 115.896 .000 
Stiffness .501 1 .501 .119 .731 
Factor 48.335 4 12.084 2.864 .023 
Stiffness * Factor 37.994 4 9.498 2.252 .063 
Error 1430.066 339 4.218   
Total 2010.312 349    
Corrected Total 1535.151 348    
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Estimated Marginal Means 
 
 
1. Stiffness * Factor 
 
Estimates 
Dependent Variable:   Delta2 
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .366 .257 -.139 .871 
1 1.643 .329 .996 2.290 
2 .991 .317 .368 1.615 
3 1.038 .347 .356 1.721 
4 2.467 .388 1.703 3.230 
1 0 1.403 .375 .665 2.140 
1 1.243 .484 .291 2.195 
2 .875 .448 -.007 1.756 
3 1.118 .306 .516 1.721 
4 1.463 .395 .686 2.241 
 
 
 
Pairwise Comparisons 
Dependent Variable:   Delta2 
Fact
or 
(I) 
Stiffnes
s 
(J) 
Stiffnes
s 
Mean 
Differenc
e (I-J) 
Std. 
Error Sig.b 
95% Confidence Interval 
for Differenceb 
Lower 
Bound 
Upper 
Bound 
0 0 1 -1.036* .454 .023 -1.930 -.142 
1 0 1.036* .454 .023 .142 1.930 
1 0 1 .400 .585 .495 -.752 1.551 
1 0 -.400 .585 .495 -1.551 .752 
2 0 1 .116 .549 .832 -.963 1.196 
1 0 -.116 .549 .832 -1.196 .963 
3 0 1 -.080 .463 .863 -.990 .831 
1 0 .080 .463 .863 -.831 .990 
4 0 1 1.004 .554 .071 -.086 2.093 
1 0 -1.004 .554 .071 -2.093 .086 
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Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
Univariate Tests 
Dependent Variable:   Delta2 
Factor Sum of Squares df Mean Square F Sig. 
0 Contrast 21.937 1 21.937 5.200 .023 
Error 1430.066 339 4.218   
1 Contrast 1.967 1 1.967 .466 .495 
Error 1430.066 339 4.218   
2 Contrast .190 1 .190 .045 .832 
Error 1430.066 339 4.218   
3 Contrast .126 1 .126 .030 .863 
Error 1430.066 339 4.218   
4 Contrast 13.845 1 13.845 3.282 .071 
Error 1430.066 339 4.218   
 
Each F tests the simple effects of Stiffness within each level combination of the other effects shown. 
These tests are based on the linearly independent pairwise comparisons among the estimated 
marginal means. 
 
2. Stiffness * Factor 
Estimates 
Dependent Variable:   Delta2 
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .366 .257 -.139 .871 
1 1.643 .329 .996 2.290 
2 .991 .317 .368 1.615 
3 1.038 .347 .356 1.721 
4 2.467 .388 1.703 3.230 
1 0 1.403 .375 .665 2.140 
1 1.243 .484 .291 2.195 
2 .875 .448 -.007 1.756 
3 1.118 .306 .516 1.721 
4 1.463 .395 .686 2.241 
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Pairwise Comparisons 
Dependent Variable:   Delta2 
Stiffness (I) Factor 
(J) 
Factor 
Mean 
Difference (I-
J) Std. Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
0 0 1 -1.276* .417 .024 -2.455 -.098 
2 -.625 .408 1.000 -1.777 .527 
3 -.672 .432 1.000 -1.892 .548 
4 -2.101* .465 .000 -3.416 -.786 
1 0 1.276* .417 .024 .098 2.455 
2 .651 .457 1.000 -.639 1.942 
3 .604 .478 1.000 -.747 1.955 
4 -.824 .509 1.000 -2.262 .613 
2 0 .625 .408 1.000 -.527 1.777 
1 -.651 .457 1.000 -1.942 .639 
3 -.047 .470 1.000 -1.375 1.281 
4 -1.476* .501 .035 -2.891 -.060 
3 0 .672 .432 1.000 -.548 1.892 
1 -.604 .478 1.000 -1.955 .747 
2 .047 .470 1.000 -1.281 1.375 
4 -1.428 .521 .064 -2.900 .043 
4 0 2.101* .465 .000 .786 3.416 
1 .824 .509 1.000 -.613 2.262 
2 1.476* .501 .035 .060 2.891 
3 1.428 .521 .064 -.043 2.900 
1 0 1 .160 .612 1.000 -1.571 1.890 
2 .528 .584 1.000 -1.123 2.179 
3 .284 .484 1.000 -1.084 1.652 
4 -.061 .545 1.000 -1.600 1.479 
1 0 -.160 .612 1.000 -1.890 1.571 
2 .368 .660 1.000 -1.496 2.232 
3 .125 .573 1.000 -1.494 1.743 
4 -.220 .625 1.000 -1.986 1.546 
2 0 -.528 .584 1.000 -2.179 1.123 
1 -.368 .660 1.000 -2.232 1.496 
3 -.244 .543 1.000 -1.777 1.290 
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4 -.588 .598 1.000 -2.277 1.100 
3 0 -.284 .484 1.000 -1.652 1.084 
1 -.125 .573 1.000 -1.743 1.494 
2 .244 .543 1.000 -1.290 1.777 
4 -.345 .500 1.000 -1.758 1.068 
4 0 .061 .545 1.000 -1.479 1.600 
1 .220 .625 1.000 -1.546 1.986 
2 .588 .598 1.000 -1.100 2.277 
3 .345 .500 1.000 -1.068 1.758 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
Univariate Tests 
Dependent Variable:   Delta2 
Stiffness Sum of Squares df Mean Square F Sig. 
0 Contrast 98.725 4 24.681 5.851 .000 
Error 1430.066 339 4.218   
1 Contrast 5.571 4 1.393 .330 .858 
Error 1430.066 339 4.218   
 
Each F tests the simple effects of Factor within each level combination of the other effects shown. 
These tests are based on the linearly independent pairwise comparisons among the estimated 
marginal means. 
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A1.2 TWITCH FORCE 
 
Between-Subjects Factors 
 N 
Stiffness 0 168 
1 170 
Factor 0 69 
1 69 
2 70 
3 66 
4 64 
 
 
Stffness Factor Mean Std. Deviation N 
0 
 
0 .027428568 .334036159 34 
1 1.355063523 .676761051 32 
2 -.214188235 .345381049 34 
3 .690377438 .560129429 33 
4 1.01427437 .804048889 30 
Total .51417974 .808348989 168 
1 
 
0 .292331741 1.85785923 35 
1 .712532796 .529729433 35 
2 -1.028741593 1.012925404 33 
3 1.22886219 1.058981894 33 
4 .94952217 1.043201413 33 
Total .480952935 1.388468168 170 
Total 0 .115729626 1.100678987 69 
1 1.083995873 .692687516 67 
2 -.496149013 .756509807 67 
3 .921156618 .846310096 66 
4 .986879208 .903752674 63 
Total .501357315 1.068016945 298 
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Tests of Between-Subjects Effects 
Dependent Variable:   Force 
Source 
Type III Sum of 
Squares df 
Mean 
Square F Sig. 
Partial Eta 
Squared 
Corrected Model 125.455a 9 13.939 18.819 .000 .370 
Intercept 68.925 1 68.925 93.054 .000 .244 
Stffness 1.408 1 1.408 1.900 .169 .007 
Factor 107.234 4 26.809 36.194 .000 .335 
Stffness * Factor 17.839 4 4.460 6.021 .000 .077 
Error 213.321 288 .741    
Total 413.681 298     
Corrected Total 338.776 297     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a. R Squared = .370 (Adjusted R Squared = .351) 
Pairwise Comparisons 
Estimates 
Dependent Variable:   Force 
Stffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .027 .117 -.203 .258 
1 1.355 .141 1.077 1.634 
2 -.214 .148 -.505 .076 
3 .690 .163 .370 1.011 
4 1.014 .157 .705 1.324 
1 0 .292 .166 -.034 .618 
1 .713 .166 .387 1.039 
2 -1.029 .203 -1.428 -.629 
3 1.229 .188 .859 1.599 
4 .950 .183 .588 1.311 
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Stiffness (I) Factor (J) Factor 
Mean Difference (I-
J) 
Std. 
Error Sig.
b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
0 
0 
1 1.328* 0.184 0 -1.847 -0.808 
2 0.242 0.188 1 -0.291 0.775 
3 -.663* 0.2 0.011 -1.23 -0.096 
4 -.987* 0.196 0 -1.541 -0.432 
1 
0 1.328* 0.184 0 0.808 1.847 
2 1.569* 0.204 0 0.991 2.148 
3 .665* 0.216 0.022 0.055 1.275 
4 0.341 0.211 1 -0.257 0.939 
2 
0 -0.242 0.188 1 -0.775 0.291 
1 -1.569* 0.204 0 -2.148 -0.991 
3 -.905* 0.22 0 -1.526 -0.283 
4 -1.228* 0.216 0 -1.838 -0.619 
3 
0 .663* 0.2 0.011 0.096 1.23 
1 -.665* 0.216 0.022 -1.275 -0.055 
2 .905* 0.22 0 0.283 1.526 
4 -0.324 0.226 1 -0.964 0.316 
4 
0 .987* 0.196 0 0.432 1.541 
1 -0.341 0.211 1 -0.939 0.257 
2 1.228* 0.216 0 0.619 1.838 
3 0.324 0.226 1 -0.316 0.964 
1 
0 
1 -0.42 0.234 0.739 -1.083 0.242 
2 1.321* 0.262 0 0.58 2.062 
3 -.937* 0.25 0.002 -1.645 -0.228 
4 -0.657 0.247 0.033 -1.356 0.042 
1 
0 0.42 0.234 0.739 -0.242 1.083 
2 1.741* 0.262 0 1 2.482 
3 -0.516 0.25 0.401 -1.225 0.192 
4 -0.237 0.247 1 -0.936 0.462 
2 
0 -1.321* 0.262 0 -2.062 -0.58 
1 -1.741* 0.262 0 -2.482 -1 
3 -2.258* 0.276 0 -3.04 -1.476 
4 -1.978* 0.274 0 -2.752 -1.204 
3 
0 .937* 0.25 0.002 0.228 1.645 
1 0.516 0.25 0.401 -0.192 1.225 
2 2.258* 0.276 0 1.476 3.04 
4 0.279 0.263 1 -0.463 1.022 
4 
0 0.657 0.247 0.033 -0.042 1.356 
1 0.237 0.247 1 -0.462 0.936 
2 1.978* 0.274 0 1.204 2.752 
3 -0.279 0.263 1 -1.022 0.463 
 
 
 
 
 
 
 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Dependent Variable:   Force 
Stffness Sum of Squares df Mean Square F Sig. Partial Eta Squared 
0 Contrast 65.366 4 16.342 22.062 .000 .235 
Error 213.321 288 .741    
1 Contrast 60.011 4 15.003 20.255 .000 .220 
Error 213.321 288 .741    
 
 
 
 
 
 
 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Each F tests the simple effects of Factor within each level combination of the other effects shown. These tests are 
based on the linearly independent pairwise comparisons among the estimated marginal means. 
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A1.3 Kinetics 
 
A1.3.1 Vmax Contraction 
 
 
Between-Subjects Factors 
 N 
Stiffness 0 168 
1 170 
Factor 0 69 
1 69 
2 70 
3 66 
4 64 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   day1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 112367.309a 9 12485.257 29.795 .000 
Intercept 1126362.432 1 1126362.432 2687.966 .000 
Stiffness 17872.975 1 17872.975 42.652 .000 
Factor 75252.106 4 18813.027 44.896 .000 
Stiffness * Factor 13186.976 4 3296.744 7.867 .000 
Error 137444.787 328 419.039   
Total 1496574.549 338    
Corrected Total 249812.096 337    
 
a. R Squared = .450 (Adjusted R Squared = .435) 
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Estimated Marginal Means 
 
 
1. Stiffness * Factor 
 
Estimates 
Dependent Variable:   day1   
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 48.846 4.015 40.948 56.744 
1 94.705 3.237 88.338 101.072 
2 43.079 3.619 35.960 50.198 
3 73.903 3.940 66.153 81.653 
4 76.650 3.122 70.509 82.792 
1 0 44.744 4.268 36.347 53.140 
1 57.267 2.924 51.514 63.020 
2 33.096 3.321 26.563 39.628 
3 58.220 3.278 51.772 64.669 
4 68.412 4.467 59.625 77.200 
 
Pairwise Comparisons 
Dependent Variable:   day1   
Facto
r 
(I) 
Stiffness 
(J) 
Stiffness 
Mean 
Difference (I-J) Std. Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
0 0 1 4.102 5.860 .484 -7.425 15.630 
1 0 -4.102 5.860 .484 -15.630 7.425 
1 0 1 37.438* 4.362 .000 28.857 46.019 
1 0 -37.438* 4.362 .000 -46.019 -28.857 
2 0 1 9.983* 4.911 .043 .322 19.645 
1 0 -9.983* 4.911 .043 -19.645 -.322 
3 0 1 15.683* 5.125 .002 5.601 25.765 
1 0 -15.683* 5.125 .002 -25.765 -5.601 
4 0 1 8.238 5.450 .132 -2.483 18.959 
1 0 -8.238 5.450 .132 -18.959 2.483 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Dependent Variable:   day1   
Factor Sum of Squares df Mean Square F Sig. 
0 Contrast 205.383 1 205.383 .490 .484 
Error 137444.787 328 419.039   
1 Contrast 30866.917 1 30866.917 73.661 .000 
Error 137444.787 328 419.039   
2 Contrast 1731.412 1 1731.412 4.132 .043 
Error 137444.787 328 419.039   
3 Contrast 3924.143 1 3924.143 9.365 .002 
Error 137444.787 328 419.039   
4 Contrast 957.542 1 957.542 2.285 .132 
Error 137444.787 328 419.039   
 
Each F tests the simple effects of Stiffness within each level combination of the other effects shown. 
These tests are based on the linearly independent pairwise comparisons among the estimated 
marginal means. 
 
 
2. Stiffness * Factor 
 
Estimates 
Dependent Variable:   day1   
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 48.846 4.015 40.948 56.744 
1 94.705 3.237 88.338 101.072 
2 43.079 3.619 35.960 50.198 
3 73.903 3.940 66.153 81.653 
4 76.650 3.122 70.509 82.792 
1 0 44.744 4.268 36.347 53.140 
1 57.267 2.924 51.514 63.020 
2 33.096 3.321 26.563 39.628 
3 58.220 3.278 51.772 64.669 
4 68.412 4.467 59.625 77.200 
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Pairwise Comparisons 
Dependent Variable:   day1   
Stiffne
ss (I) Factor (J) Factor 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower 
Bound Upper Bound 
0 0 1 -45.859* 5.157 .000 -60.433 -31.285 
2 5.767 5.405 1.000 -9.508 21.041 
3 -25.057* 5.625 .000 -40.954 -9.161 
4 -27.805* 5.085 .000 -42.177 -13.432 
1 0 45.859* 5.157 .000 31.285 60.433 
2 51.626* 4.855 .000 37.905 65.347 
3 20.802* 5.099 .001 6.392 35.211 
4 18.055* 4.497 .001 5.346 30.763 
2 0 -5.767 5.405 1.000 -21.041 9.508 
1 -51.626* 4.855 .000 -65.347 -37.905 
3 -30.824* 5.349 .000 -45.942 -15.706 
4 -33.571* 4.779 .000 -47.078 -20.065 
3 0 25.057* 5.625 .000 9.161 40.954 
1 -20.802* 5.099 .001 -35.211 -6.392 
2 30.824* 5.349 .000 15.706 45.942 
4 -2.747 5.026 1.000 -16.953 11.458 
4 0 27.805* 5.085 .000 13.432 42.177 
1 -18.055* 4.497 .001 -30.763 -5.346 
2 33.571* 4.779 .000 20.065 47.078 
3 2.747 5.026 1.000 -11.458 16.953 
1 0 1 -12.523 5.174 .160 -27.146 2.099 
2 11.648 5.408 .320 -3.636 26.932 
3 -13.477 5.382 .128 -28.686 1.733 
4 -23.669* 6.178 .002 -41.130 -6.208 
1 0 12.523 5.174 .160 -2.099 27.146 
2 24.171* 4.425 .000 11.666 36.676 
3 -.953 4.393 1.000 -13.368 11.461 
4 -11.145 5.339 .376 -26.235 3.944 
2 0 -11.648 5.408 .320 -26.932 3.636 
1 -24.171* 4.425 .000 -36.676 -11.666 
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3 -25.125* 4.666 .000 -38.311 -11.938 
4 -35.317* 5.566 .000 -51.047 -19.586 
3 0 13.477 5.382 .128 -1.733 28.686 
1 .953 4.393 1.000 -11.461 13.368 
2 25.125* 4.666 .000 11.938 38.311 
4 -10.192 5.541 .667 -25.851 5.467 
4 0 23.669* 6.178 .002 6.208 41.130 
1 11.145 5.339 .376 -3.944 26.235 
2 35.317* 5.566 .000 19.586 51.047 
3 10.192 5.541 .667 -5.467 25.851 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
 
 
Univariate Tests 
Dependent Variable:   day1   
Stiffness Sum of Squares df Mean Square F Sig. 
0 Contrast 61546.733 4 15386.683 36.719 .000 
Error 137444.787 328 419.039   
1 Contrast 23306.721 4 5826.680 13.905 .000 
Error 137444.787 328 419.039   
 
Each F tests the simple effects of Factor within each level combination of the other effects shown. These 
tests are based on the linearly independent pairwise comparisons among the estimated marginal means. 
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A1.3.2 Vmax 50% Relaxation 
 
Between-Subjects Factors 
 N 
Stiffness 0 168 
1 170 
Factor 0 69 
1 69 
2 70 
3 66 
4 64 
 
Tests of Between-Subjects Effects 
Dependent Variable:   Vmax1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model 151365.230a 9 16818.359 55.716 .000 
Intercept 1127392.979 1 1127392.979 3734.856 .000 
stiffness 79255.041 1 79255.041 262.558 .000 
factor 47705.083 4 11926.271 39.510 .000 
stiffness * factor 7682.070 4 1920.518 6.362 .000 
Error 147608.163 489 301.857   
Total 1713473.338 499    
Corrected Total 298973.392 498    
 
a. R Squared = .506 (Adjusted R Squared = .497) 
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Estimated Marginal Means 
 
 
1. stiffness * factor 
 
Estimates 
Dependent Variable:   Vmax1  day1 
stiffness factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 42.758 3.407 36.063 49.453 
1 80.828 2.896 75.139 86.518 
2 60.928 2.650 55.722 66.134 
3 70.599 3.344 64.029 77.168 
4 80.757 2.123 76.587 84.928 
1 0 33.841 3.623 26.723 40.959 
1 48.838 1.792 45.317 52.359 
2 23.816 2.590 18.727 28.905 
3 43.040 2.534 38.061 48.020 
4 45.556 1.821 41.977 49.134 
 
Pairwise Comparisons 
Dependent Variable:   Vmax1   
factor 
(I) 
stiffness 
(J) 
stiffness 
Mean Difference 
(I-J) 
Std. 
Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
0 0 1 8.917 4.973 .074 -.855 18.689 
1 0 -8.917 4.973 .074 -18.689 .855 
1 0 1 31.990* 3.405 .000 25.300 38.681 
1 0 -31.990* 3.405 .000 -38.681 -25.300 
2 0 1 37.112* 3.705 .000 29.832 44.392 
1 0 -37.112* 3.705 .000 -44.392 -29.832 
3 0 1 27.558* 4.196 .000 19.315 35.802 
1 0 -27.558* 4.196 .000 -35.802 -19.315 
4 0 1 35.201* 2.797 .000 29.706 40.696 
1 0 -35.201* 2.797 .000 -40.696 -29.706 
 
 
 
 
 
 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Dependent Variable:   Vmax1   
factor Sum of Squares df Mean Square F Sig. 
0 Contrast 970.425 1 970.425 3.215 .074 
Error 147608.163 489 301.857   
1 Contrast 26639.452 1 26639.452 88.252 .000 
Error 147608.163 489 301.857   
2 Contrast 30284.556 1 30284.556 100.327 .000 
Error 147608.163 489 301.857   
3 Contrast 13023.748 1 13023.748 43.145 .000 
Error 147608.163 489 301.857   
4 Contrast 47815.933 1 47815.933 158.406 .000 
Error 147608.163 489 301.857   
 
Each F tests the simple effects of stiffness within each level combination of the other effects 
shown. These tests are based on the linearly independent pairwise comparisons among the 
estimated marginal means. 
 
 
2. stiffness * factor 
 
Estimates 
Dependent Variable:   Vmax1   
stiffness factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 42.758 3.407 36.063 49.453 
1 80.828 2.896 75.139 86.518 
2 60.928 2.650 55.722 66.134 
3 70.599 3.344 64.029 77.168 
4 80.757 2.123 76.587 84.928 
1 0 33.841 3.623 26.723 40.959 
1 48.838 1.792 45.317 52.359 
2 23.816 2.590 18.727 28.905 
3 43.040 2.534 38.061 48.020 
4 45.556 1.821 41.977 49.134 
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Pairwise Comparisons 
Dependent Variable:   Vmax1   
stiffnes
s 
(I) 
factor 
(J) 
factor 
Mean 
Difference 
(I-J) Std. Error Sig.b 
95% Confidence Interval for 
Differenceb 
Lower Bound Upper Bound 
0 0 1 -38.070* 4.472 .000 -50.679 -25.461 
2 -18.170* 4.316 .000 -30.341 -5.999 
3 -27.841* 4.774 .000 -41.302 -14.379 
4 -37.999* 4.014 .000 -49.319 -26.679 
1 0 38.070* 4.472 .000 25.461 50.679 
2 19.900* 3.925 .000 8.833 30.968 
3 10.230 4.423 .212 -2.243 22.702 
4 .071 3.590 1.000 -10.053 10.195 
2 0 18.170* 4.316 .000 5.999 30.341 
1 -19.900* 3.925 .000 -30.968 -8.833 
3 -9.671 4.266 .238 -21.701 2.359 
4 -19.829* 3.395 .000 -29.402 -10.256 
3 0 27.841* 4.774 .000 14.379 41.302 
1 -10.230 4.423 .212 -22.702 2.243 
2 9.671 4.266 .238 -2.359 21.701 
4 -10.159 3.960 .106 -21.326 1.009 
4 0 37.999* 4.014 .000 26.679 49.319 
1 -.071 3.590 1.000 -10.195 10.053 
2 19.829* 3.395 .000 10.256 29.402 
3 10.159 3.960 .106 -1.009 21.326 
1 0 1 -14.997* 4.042 .002 -26.394 -3.600 
2 10.025 4.453 .248 -2.533 22.582 
3 -9.200 4.421 .380 -21.667 3.267 
4 -11.715* 4.055 .040 -23.149 -.281 
1 0 14.997* 4.042 .002 3.600 26.394 
2 25.022* 3.149 .000 16.141 33.903 
3 5.798 3.104 .624 -2.955 14.550 
4 3.282 2.555 1.000 -3.923 10.487 
2 0 -10.025 4.453 .248 -22.582 2.533 
1 -25.022* 3.149 .000 -33.903 -16.141 
3 -19.224* 3.624 .000 -29.442 -9.006 
4 -21.740* 3.166 .000 -30.668 -12.812 
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3 0 9.200 4.421 .380 -3.267 21.667 
1 -5.798 3.104 .624 -14.550 2.955 
2 19.224* 3.624 .000 9.006 29.442 
4 -2.516 3.121 1.000 -11.316 6.285 
4 0 11.715* 4.055 .040 .281 23.149 
1 -3.282 2.555 1.000 -10.487 3.923 
2 21.740* 3.166 .000 12.812 30.668 
3 2.516 3.121 1.000 -6.285 11.316 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Bonferroni. 
 
Univariate Tests 
Dependent Variable:   Vmax1   
stiffness Sum of Squares df Mean Square F Sig. 
0 Contrast 34814.196 4 8703.549 28.833 .000 
Error 147608.163 489 301.857   
1 Contrast 22007.173 4 5501.793 18.226 .000 
Error 147608.163 489 301.857   
 
Each F tests the simple effects of factor within each level combination of the other effects 
shown. These tests are based on the linearly independent pairwise comparisons among the 
estimated marginal means. 
 
 
A1.3.3 Time to Peak 
 
Between-Subjects Factors 
 N 
Stiffness 0 168 
1 170 
Factor 0 69 
1 69 
2 70 
3 66 
4 64 
 
 
153	
Tests of Between-Subjects Effects 
Dependent Variable:   timePeak1   
Source Type III Sum of Squares df Mean Square F Sig. 
Corrected Model .481a 8 .060 8.869 .000 
Intercept 15.879 1 15.879 2341.922 .000 
stiffness .044 1 .044 6.486 .011 
factor .226 4 .057 8.344 .000 
stiffness * factor .231 3 .077 11.359 .000 
Error 2.495 368 .007   
Total 29.083 377    
Corrected Total 2.976 376    
 
a. R Squared = .162 (Adjusted R Squared = .143) 
 
 
 
Estimated Marginal Means 
 
 
1. stiffness * factor 
 
Estimates 
Dependent Variable:   timePeak1   
stiffness factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .a . . . 
1 .255 .019 .217 .293 
2 .187 .018 .153 .222 
3 .223 .021 .181 .265 
4 .311 .012 .288 .335 
1 0 .256 .015 .228 .285 
1 .244 .009 .227 .261 
2 .245 .013 .219 .271 
3 .330 .013 .304 .355 
4 .266 .009 .247 .284 
 
a. This level combination of factors is not observed, thus the corresponding population marginal mean is not estimable. 
 
 
154	
Pairwise Comparisons 
Dependent Variable:   timePeak1   
factor 
(I) 
stiffness 
(J) 
stiffness 
Mean Difference 
(I-J) 
Std. 
Error Sig.d 
95% Confidence Interval for 
Differenced 
Lower 
Bound Upper Bound 
0 0 1 .a . . . . 
1 0 .c . . . . 
1 0 1 .011 .021 .598 -.031 .053 
1 0 -.011 .021 .598 -.053 .031 
2 0 1 -.058* .022 .008 -.101 -.015 
1 0 .058* .022 .008 .015 .101 
3 0 1 -.107* .025 .000 -.156 -.058 
1 0 .107* .025 .000 .058 .156 
4 0 1 .046* .015 .003 .016 .076 
1 0 -.046* .015 .003 -.076 -.016 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
a. The level combination of factors in (I) is not observed. 
c. The level combination of factors in (J) is not observed. 
d. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Dependent Variable:   timePeak1   
factor Sum of Squares df Mean Square F Sig. 
0 Contrast .000 0 . . . 
Error 2.495 368 .007   
1 Contrast .002 1 .002 .279 .598 
Error 2.495 368 .007   
2 Contrast .047 1 .047 7.003 .008 
Error 2.495 368 .007   
3 Contrast .124 1 .124 18.233 .000 
Error 2.495 368 .007   
4 Contrast .061 1 .061 9.032 .003 
Error 2.495 368 .007   
 
Each F tests the simple effects of stiffness within each level combination of the other effects shown. 
These tests are based on the estimable linearly independent pairwise comparisons among the 
estimated marginal means. 
 
 
2. stiffness * factor 
 
 
Estimates 
Dependent Variable:   timePeak1   
stiffness factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .a . . . 
1 .255 .019 .217 .293 
2 .187 .018 .153 .222 
3 .223 .021 .181 .265 
4 .311 .012 .288 .335 
1 0 .256 .015 .228 .285 
1 .244 .009 .227 .261 
2 .245 .013 .219 .271 
3 .330 .013 .304 .355 
4 .266 .009 .247 .284 
 
a. This level combination of factors is not observed, thus the corresponding population marginal 
mean is not estimable. 
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Pairwise Comparisons 
Dependent Variable:  timePeak1   
stiffness 
(I) 
factor (J) factor 
Mean 
Difference (I-
J) Std. Error Sig.d 
95% Confidence Interval for 
Differenced 
Lower Bound Upper Bound 
0 0 1 .a . . . . 
2 .a . . . . 
3 .a . . . . 
4 .a . . . . 
1 0 .b . . . . 
2 .068 .026 .057 -.001 .138 
3 .032 .029 1.000 -.044 .109 
4 -.056 .023 .086 -.117 .004 
2 0 .b . . . . 
1 -.068 .026 .057 -.138 .001 
3 -.036 .028 1.000 -.109 .037 
4 -.124* .021 .000 -.181 -.068 
3 0 .b . . . . 
1 -.032 .029 1.000 -.109 .044 
2 .036 .028 1.000 -.037 .109 
4 -.089* .024 .002 -.153 -.024 
4 0 .b . . . . 
1 .056 .023 .086 -.004 .117 
2 .124* .021 .000 .068 .181 
3 .089* .024 .002 .024 .153 
1 0 1 .012 .017 1.000 -.036 .060 
2 .011 .020 1.000 -.044 .067 
3 -.073* .020 .002 -.129 -.018 
4 -.009 .017 1.000 -.058 .040 
1 0 -.012 .017 1.000 -.060 .036 
2 -.001 .016 1.000 -.046 .044 
3 -.086* .016 .000 -.130 -.041 
4 -.022 .013 .941 -.058 .015 
2 0 -.011 .020 1.000 -.067 .044 
1 .001 .016 1.000 -.044 .046 
3 -.084* .019 .000 -.137 -.032 
4 -.020 .016 1.000 -.066 .025 
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3 0 .073* .020 .002 .018 .129 
1 .086* .016 .000 .041 .130 
2 .084* .019 .000 .032 .137 
4 .064* .016 .001 .018 .110 
4 0 .009 .017 1.000 -.040 .058 
1 .022 .013 .941 -.015 .058 
2 .020 .016 1.000 -.025 .066 
3 -.064* .016 .001 -.110 -.018 
 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
a. The level combination of factors in (I) is not observed. 
b. The level combination of factors in (J) is not observed. 
d. Adjustment for multiple comparisons: Bonferroni. 
 
 
Univariate Tests 
Dependent Variable:   timePeak1   
stiffness Sum of Squares df Mean Square F Sig. 
0 Contrast .262 3 .087 12.876 .000 
Error 2.495 368 .007   
1 Contrast .219 4 .055 8.068 .000 
Error 2.495 368 .007   
 
Each F tests the simple effects of factor within each level combination of the other effects 
shown. These tests are based on the estimable linearly independent pairwise comparisons 
among the estimated marginal means. 
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A1.3.4 Time to 50% Relaxation 
 
Between-Subjects Factors 
 N 
Stiffness 0 168 
1 170 
Factor 0 69 
1 69 
2 70 
3 66 
4 64 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   TimeR1   
Source 
Type III Sum of 
Squares df Mean Square F Sig. 
Corrected Model .306a 9 .034 1.542 .131 
Intercept 9.247 1 9.247 419.606 .000 
Stiffness .004 1 .004 .203 .653 
Factor .260 4 .065 2.952 .020 
Stiffness * Factor .077 4 .019 .878 .477 
Error 9.520 432 .022   
Total 23.038 442    
Corrected Total 9.826 441    
 
a. R Squared = .031 (Adjusted R Squared = .011) 
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Estimated Marginal Means 
 
 
1. Stiffness * Factor 
 
Estimates 
Dependent Variable:   TimeR1   
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .188 .028 .134 .242 
1 .204 .035 .135 .273 
2 .117 .030 .057 .176 
3 .133 .035 .065 .202 
4 .214 .021 .173 .255 
1 0 .148 .026 .097 .200 
1 .178 .016 .147 .208 
2 .135 .023 .090 .179 
3 .175 .020 .134 .215 
4 .184 .016 .152 .215 
 
Pairwise Comparisons 
Dependent Variable:   TimeR1   
Facto
r 
(I) 
Stiffness (J) Stiffness 
Mean 
Difference (I-
J) 
Std. 
Error Sig.a 
95% Confidence Interval 
for Differencea 
Lower Bound 
Upper 
Bound 
0 0 1 .040 .038 .297 -.035 .115 
1 0 -.040 .038 .297 -.115 .035 
1 0 1 .026 .038 .494 -.049 .102 
1 0 -.026 .038 .494 -.102 .049 
2 0 1 -.018 .038 .630 -.093 .056 
1 0 .018 .038 .630 -.056 .093 
3 0 1 -.041 .040 .310 -.121 .038 
1 0 .041 .040 .310 -.038 .121 
4 0 1 .030 .026 .252 -.022 .082 
1 0 -.030 .026 .252 -.082 .022 
 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
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Univariate Tests 
Dependent Variable:   TimeR1   
Factor Sum of Squares df Mean Square F Sig. 
0 Contrast .024 1 .024 1.092 .297 
Error 9.520 432 .022   
1 Contrast .010 1 .010 .468 .494 
Error 9.520 432 .022   
2 Contrast .005 1 .005 .232 .630 
Error 9.520 432 .022   
3 Contrast .023 1 .023 1.035 .310 
Error 9.520 432 .022   
4 Contrast .029 1 .029 1.314 .252 
Error 9.520 432 .022   
 
Each F tests the simple effects of Stiffness within each level combination of the other effects 
shown. These tests are based on the linearly independent pairwise comparisons among the 
estimated marginal means. 
 
 
2. Stiffness * Factor 
 
Estimates 
Dependent Variable:   TimeR1   
Stiffness Factor Mean Std. Error 
95% Confidence Interval 
Lower Bound Upper Bound 
0 0 .188 .028 .134 .242 
1 .204 .035 .135 .273 
2 .117 .030 .057 .176 
3 .133 .035 .065 .202 
4 .214 .021 .173 .255 
1 0 .148 .026 .097 .200 
1 .178 .016 .147 .208 
2 .135 .023 .090 .179 
3 .175 .020 .134 .215 
4 .184 .016 .152 .215 
 
 
161	
Pairwise Comparisons 
Dependent Variable:   TimeR1   
Stiffn
ess (I) Factor (J) Factor 
Mean 
Difference (I-J) Std. Error Sig.a 
95% Confidence Interval 
for Differencea 
Lower Bound 
Upper 
Bound 
0 0 1 -.016 .045 1.000 -.141 .110 
2 .072 .041 .814 -.044 .187 
3 .055 .045 1.000 -.071 .181 
4 -.026 .035 1.000 -.123 .072 
1 0 .016 .045 1.000 -.110 .141 
2 .087 .046 .606 -.044 .218 
3 .070 .049 1.000 -.069 .210 
4 -.010 .041 1.000 -.125 .105 
2 0 -.072 .041 .814 -.187 .044 
1 -.087 .046 .606 -.218 .044 
3 -.017 .046 1.000 -.147 .114 
4 -.097 .037 .086 -.201 .007 
3 0 -.055 .045 1.000 -.181 .071 
1 -.070 .049 1.000 -.210 .069 
2 .017 .046 1.000 -.114 .147 
4 -.080 .041 .489 -.195 .034 
4 0 .026 .035 1.000 -.072 .123 
1 .010 .041 1.000 -.105 .125 
2 .097 .037 .086 -.007 .201 
3 .080 .041 .489 -.034 .195 
1 0 1 -.029 .031 1.000 -.115 .057 
2 .014 .035 1.000 -.084 .111 
3 -.026 .033 1.000 -.120 .068 
4 -.035 .031 1.000 -.122 .052 
1 0 .029 .031 1.000 -.057 .115 
2 .043 .028 1.000 -.035 .120 
3 .003 .026 1.000 -.070 .076 
4 -.006 .023 1.000 -.070 .058 
2 0 -.014 .035 1.000 -.111 .084 
1 -.043 .028 1.000 -.120 .035 
3 -.040 .030 1.000 -.126 .046 
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4 -.049 .028 .813 -.127 .030 
3 0 .026 .033 1.000 -.068 .120 
1 -.003 .026 1.000 -.076 .070 
2 .040 .030 1.000 -.046 .126 
4 -.009 .026 1.000 -.082 .064 
4 0 .035 .031 1.000 -.052 .122 
1 .006 .023 1.000 -.058 .070 
2 .049 .028 .813 -.030 .127 
3 .009 .026 1.000 -.064 .082 
 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Bonferroni. 
 
 
 
Univariate Tests 
Dependent Variable:   TimeR1   
Stiffness Sum of Squares df Mean Square F Sig. 
0 Contrast .206 4 .051 2.332 .055 
Error 9.520 432 .022   
1 Contrast .089 4 .022 1.014 .400 
Error 9.520 432 .022   
 
Each F tests the simple effects of Factor within each level combination of the other effects 
shown. These tests are based on the linearly independent pairwise comparisons among the 
estimated marginal means. 
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A1.4 Cell Size 
 
Univariate Analysis of Variance 
 
Between-Subjects Factors 
 N 
Factor 0 46 
1 50 
2 46 
3 48 
4 48 
 
Descriptive Statistics 
Dependent Variable:   CellSize   
Factor Mean Std. Deviation N 
0 186.63361899 51.760458680 46 
1 226.67364519 41.91141073 50 
2 215.1709091 58.20572317 46 
3 247.0990000 37.38510411 48 
4 234.71367859 41.13840859 48 
Total 224.39003079 49.04103548 238 
 
 
Tests of Between-Subjects Effects 
Dependent Variable:   CellSize   
Source 
Type III Sum 
of Squares df Mean Square F Sig. 
Partial Eta 
Squared 
Corrected Model 49391.669a 4 12347.917 5.917 .000 .159 
Intercept 6265218.240 1 6265218.240 3002.236 .000 .960 
Factor 49391.669 4 12347.917 5.917 .000 .159 
Error 260856.319 125 2086.851    
Total 6855863.156 130     
Corrected Total 310247.988 129     
a. R Squared = .159 (Adjusted R Squared = .132) 
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CellSize 
 
Factor N 
Subset 
 
1 2 
Tukey HSDa,b,c 0 21 186.6336189  
2 22 215.1709091 215.1709091 
1 31  226.6736452 
4 28  234.7136786 
3 28  247.099000 
Sig.  .177 .099 
Means for groups in homogeneous subsets are displayed. 
 Based on observed means. 
 The error term is Mean Square(Error) = 2086.851. 
a. Uses Harmonic Mean Sample Size = 25.412. 
b. Th  group sizes are unequal. The harmonic mean of the group sizes is used. Type I 
error levels are not guaranteed. c. Alpha = .05. 
	
 
